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Abstract: 
The aim of this work is to study the in-vitro aerodynamic performance of a new inhaled 
theophylline formulation prepared by supercritical fluids technique.  
 
For the analysis of the output from the in-vitro tests  (and further in-vivo tests) a new, 
fast, sensitive high performance liquid chromatographic (HPLC) method was developed 
and validated for the determination of theophylline and other related derivatives in 
aqueous and urine samples using new packing materials (monolithic columns). These 
columns achieve efficient separation under lower backpressure and shorter time 
comparing to other traditionally or newly introduced C18 columns.  
 
Solution enhanced dispersion by supercritical fluid (SEDS) process has been applied for 
the production of anhydrous theophylline as pure crystals in the range 2-5 m to be used 
as new inhaled dry powder formulation for asthma. Fifteen theophylline samples have 
been prepared under different experimental conditions.  
 
The drug produced by this method has been subject to a number of solid-phase 
analytical procedures designed to establish the crystal structure [X-ray powder 
diffraction (XRPD)], the structure and conformation [(FTIR), Fourier-transform Raman 
spectroscopy (FT-Raman)], and the morphology and particle size [scanning electron 
microscope (SEM)]. While, thermal gravimetric analysis (TGA), and differential 
scanning calorimetry (DSC) have been used to monitor any phase transition or 
polymorphic changes after processing. All these analytical techniques gave a 
satisfactory indication of the solid-state chemistry of the processed particles and assess 
the development of new inhalation product. 
  
The performance of inhaled SEDS theophylline with or without a carrier was evaluated 
using the developed HPLC method. Three samples having different particle sizes were 
selected out of the prepared powders by SEDS technique to be tested. The dose 
sampling unit and the Anderson Cascade Impactor were used to determine the in-vitro 
emitted dose and the deposition profiles of SEDS samples, respectively. The effect of 
different inhalation flows was studied using two different flows 28.3, and 60 L min
-1
 
with 4 L inhalation volume. Different DPI devices were investigated in this study; 
Easyhaler
®
 and Spinhaler
®
. The particle size has an important effect on the aerodynamic 
behaviour and deposition profile of inhaled drug, the smaller the particles the greater the 
total lung deposition.  The presence of a carrier improves the respirable fraction for all 
the tested formulations. 
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1.1. Introduction 
Asthma is a chronic inflammatory pulmonary disorder that is characterized by 
reversible obstruction of the airways. Since the 1980s, there has been a worldwide 
increase in the prevalence of asthma in both children and adults [1]. This led to 
significant increases in morbidity and mortality because of the disease. Theophylline is 
one of the medications used for treatment of asthma; it belongs to a group of medicines 
known as xanthine-derivatives bronchodilators. Bronchodilators work by opening up 
the air passages in the lungs so that air can freely flow into the lungs. In doing so, they 
help to relieve symptoms such as coughing, wheezing and shortness of breath. 
Theophylline is a naturally occurring alkaloid found in many plant species and food 
products as tea, coffee.  
Current British Thoracic Society (BTS) guidelines [2] recommend the use of 
theophylline at step 3/4 in asthma management. However, treatment with theophylline 
has undergone a number of cycles of passion and disapproval over the past 50 years. 
The high incidence of side effects within the therapeutic range and the narrow 
therapeutic index as well as the availability of more potent and less toxic alternatives, 
accompanied with the broadcasting of clinical practice guidelines that list theophylline 
as a "not preferred" drug, all have resulted in recent less frequent prescribing of 
theophylline [3].  However, the request for this work originated from senior medics in 
hospital, who are still prescribing theophylline as a low cost efficient therapeutic option.  
Furthermore, theophylline has antiinflammatory, immunomodulatory, as well as 
bronchoprotective effects that potentially contribute to its efficacy as a prophylactic 
anti-asthma drug. [1, 3-6].  
Theophylline is currently available as sustained release tablet or capsule, intravenous 
injections and suppositories (Aminophylline). But modern asthma therapy has promoted 
the benefits of aerosol drug delivery to the lung. This inhaled route allows drug delivery 
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directly to its required site of action, and as a result only a small quantity is required for 
sufficient therapeutic response. Therefore, there is a low incidence of systemic side 
effects compared with the oral or intravenous administration. In addition, the onset of 
action for the inhaled drugs is generally faster than the oral administration. Thus 
administration of theophylline by inhalation may alleviate some of drawbacks of its 
available dosage forms. As such the purpose of this research program was to explore 
further a new formulation of theophylline, to particularly examine the possibility of an 
inhaled product, which could be tested at a later stage clinically.  
Pulmonary delivery using dry powder inhalers (DPIs) by virtue of their propellant free 
nature, high patient compliance and high dose carrying capacity have encouraged their 
rapid development. Traditionally DPIs are produced by drug crystallization followed by 
milling to micronize the drug particles (2-5 m) for respiratory delivery [7, 8]. However, 
these methods have various limitations such as poor control over the powder 
crystallinity, shape, size and size distribution [7-9]. Over the recent years methods 
utilising supercritical fluid (SCF) have been designed to produce respirable particles in 
a single step operation. Solution Enhanced Dispersion by Supercritical fluid (SEDS) 
process has been used in various pharmaceutical operations including crystallization and 
size reduction [10, 11]. The advantages of this technique include the production of 
particles with controllable physical and chemical properties with narrow size 
distribution. Although, it was reported that theophylline has been prepared by other SCF 
techniques [12-14] no studies were performed on the in-vitro lung deposition profiles of 
SEDS  produced particles. This program is the first stages of development of SEDS 
theophylline particles and in-vitro evaluation of their performance as inhaled dry 
powder formulation. 
One of the challenging and time consuming tasks in the in-vitro determination of the 
aerodynamic behaviour as well as the quality assurance of an inhaled drug is the 
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requirement of analysis of a large number of samples. Therefore an HPLC method with 
reduced total analysis time was needed. In recent years, to improve the method 
development speed, a number of new column packings have been introduced. The 
HPLC monolithic packing is one of these approaches. It has a different structure when 
compared with conventional silica based columns. They consist of a single piece of 
either an organic polymer or silica that possesses an interconnected skeleton and flow 
path through this skeleton. The column has a total porosity of over 80 % v/v, with fast 
mass transfer and low-pressure resistance, which enables rapid separation [15, 16]. 
Therefore in this thesis the performance of monolithic columns for separation of 
theophylline and other related compounds in comparison with different packed C18 
columns has been investigated.  
 
1. 2. Thesis Hypothesis 
Our hypothesis has been that an inhalable theophylline 
formulation with good aerodynamic performance may give a new approach to alleviate 
the side effects associated mainly with oral or parentral dosage forms. These new 
inhalable formulations will permit an efficient local delivery of theophylline to its site 
of action deeply in the human airways to relieve the bronchoconstriction in asthmatic 
patients. For effective drug deposition in the lung, a number of factors associated with 
theophylline particle size, shape and crystallinity as well as the inhaler type have to be 
investigated.  
 
1. 3. Aims and Objectives   
The aim of work is to produce different SEDS theophylline samples within the range of 
2-5 m. Then take the produced samples through quality assurance assessments using 
different analytical tools. This will be followed by in-vitro evaluation of the 
aerodynamic behaviour of these SEDS samples. Since there will be a large number of 
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samples collected after in-vitro dose emission or in-vitro inhalation of the theophylline 
development of a fast and efficient HPLC method is required for quantification of 
theophylline and its related compounds and for further in-vivo work.  
The objectives of this work are: 
1- Investigation of the performances of different stationary phases (focussing on 
recently introduced columns) regarding the total analysis time. 
2- Development of fast and efficient HPLC method for the determination of 
theophylline and related compounds in aqueous solutions and urine samples. 
3- Evaluation of the performance of monolithic C18 column in comparison with other 
traditionally or newly introduced particle- packed C18 columns. 
4- Crystallisation of theophylline using Solution enhanced dispersion with super 
critical fluids (SEDS) technique. 
5- Develop knowledge and understanding on how the SEDS process parameters 
influence and control the produced particle properties.  
6- Studying the solid-state chemistry of the SEDS samples using a number of 
analytical techniques. 
7- Evaluate the SEDS theophylline aerodynamic performances for potential benefit in 
inhaled formulated products using conditions that mimic the patient use.  
 
1. 4. Thesis structure 
This thesis consists of six chapters: 
Chapter 1 a general introduction with the aim and objectives of the work. 
Chapter 2 the literature review of the issues related to this research including: 
 Asthma and its management using various types of bronchodilators and 
corticosteroids.  
 Theophylline; its structure, mechanism of action, pharmacological effects and 
Chapter 1                                                                                        General introduction 
 6 
pharmacokinetics.  
 Analytical review containing some of the reported methods for theophylline 
analysis 
 HPLC stationary phases used in this study, including monolith and platinum 
columns. 
 SEDS technique; its principle and application  
 Different analytical techniques used for characterisation of SEDS products 
 Respiratory physiology-structure and function of respiratory system 
 Inhalation therapies, mechanism of particle deposition from dry powder inhaler, 
and drug delivery systems to lungs. 
Chapter 3 describes development and validation of a HPLC method for determination 
of theophylline in urine samples (with other related compounds) and in 
aqueous solution using different types of stationary phases. 
Chapter 4 includes crystallisation of theophylline by SEDS technique and the effect of 
different crystallisation parameters on the product properties.  
                  Characterisation of SEDS samples using different analytical techniques such 
as scanning electron microscopy (SEM), differential scanning calorimetry 
(DSC), thermal gravimetric analysis (TGA), x-ray powder diffraction,  
                   infrared spectroscopy (FT-IR), and Raman spectroscopy (FT-Raman). 
Chapter 5 focuses on in-vitro evaluation of the aerodynamic behaviour of SEDS 
theophylline either alone or blended with lactose. This chapter includes 
determination of the total emitted dose and the in-vtiro aerodynamic 
particle size distribution of SEDS theophylline at different inhalation flows 
using two dry powder inhaler devices; Easyhaler
®
 and Spinhaler
®
. 
Chapter 6     includes general conclusion for this study. 
  7 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
Literature review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 2                                                                                                 Literature review 
 8 
2.1. Asthma 
 
Asthma-like symptoms were first mentioned from 3500 years ago in an Egyptian 
manuscript called the Ebres Papyrus. Five hundred years later, the word “asthma” was 
first used by Hippocrates, to describe these symptoms; the word means” laboured 
breathing” in Greek [4]. Although the occurrence of asthma continues to increase in 
most countries, finding a universally harmonized and suitable definition for this 
condition remains problematic [6].  
Early definitions of asthma include the airways obstruction that could be relieved with 
treatment and the bronchial hyper-responsiveness (BHR) as the essential symptoms, 
which characterise asthma from other similar conditions, such as chronic bronchitis, and 
chronic obstructive pulmonary diseases (COPD). More recently, the definition of 
asthma has been improved by the recognition that the airway submucosa of asthmatic 
patients are chronically inflamed with a typical inflammatory infiltrate, and these 
inflammatory processes are important causes of the main asthma symptoms.  
Furthermore, the loss of reversibility of the airway obstruction is recognized as a long-
term effect of the chronic inflammation [5]. 
 
2.1.1. Epidemiology of Asthma [1]. 
 Asthma is most commonly found in children (10-15 %), with about half of all cases 
developing before the age of 10. However, up to 70 % of children with asthma go into 
remission by the age of 20.  
  Asthma affects approximately 5 – 10 % of adults. 
  There are about 150 million of people who suffer from asthma all over the world.  
 Asthma predominance is greater in industrialized countries.  
 Hospital admissions with asthma are increasing, especially in children. 
Chapter 2                                                                                                 Literature review 
 9 
 Prescribed therapy for asthma is increasing (especially inhaled 2- agonists). 
However until now, the real reasons for the worldwide increases in asthma morbidity 
and mortality are unknown. 
 
2.1.2. Pathophysiology and mechanism of asthma. 
Immunological mechanisms play an essential role in the asthmatic reaction and both 
immediate and delayed responses are involved. Inhalation of an appropriate antigen by 
asthmatic patients causes a rapid decline in the patient lung function associated with an 
immediate bronchoconstriction response (early-phase response). After this initial phase, 
the lung function returns toward the baseline within the first hour either spontaneously 
or by treatment [4].  However, a further apparently unprovoked reaction may occur 
hours later (late-phase response). This late response may be less severe than during first 
response but is more prolonged and lasting several hours [4, 6]. 
Many inflammatory cells are involved in the pathogenesis of asthma including the mast 
cells, T-lymphocytes, eosinophils,  and macrophages [6].  
The mast cells are responsible for the immediate reaction following exposure to an 
allergen. Cross linkage of IgE antibodies by allergens on the surface of the mast cells 
leads to cells degranulation and rapid release of the inflammatory mediators such as 
histamine, leukotrienes, prostaglandins, platelet activation factor (PAF) and a number of 
intracellular messengers called cytokines [17]. Also following the allergen stimulation 
T-lymphocytes become activated producing a number of interleukins [4]. Eosinophils 
play an important role in the asthmatic inflammation reaction as they are capable of 
causing severe damage to the bronchial epithelium [17]. The macrophages are 
considered as scavengers in the air ways and also release some mediators such as PAF 
and leukotrienes [4].  
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The release of these inflammatory mediators results in bronchoconstriction, mucus 
secretion, exudation of plasma and BHR. On the other hand, cytokines play an 
important role in coordination and persistence of the inflammatory process in chronic 
cases (Figure 2.1) [4]. Structural changes may occur with sub-epithelial fibrosis 
(basement membrane thickening), airway smooth muscle hyperplasia and new vessel 
formation if the inflammation and bronchoconstriction are left untreated causing 
irreversible airflow obstruction  (Figure 2.2.) [1, 6].  
There are different risk factors that increase the possibility of the development of 
asthma such as family history, sex, exercise and certain drugs. These factors play an 
important role in causing asthma or triggering the asthma symptoms [4, 6]. Figure 2.3 
shows a simplified diagram for the mechanism of the development of asthmatic 
symptoms.    
 
 
 
 
 
 
 
 
 
Figure 2. 1. Diagrammatic representation of the mechanism of asthma (copied from 
www8.georgetown.edu/dml/facs/graphics/gallery.htm)  
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Figure 2. 2.  What happen in asthma; (adapted from http://www.lunguk.org) 
 
    
  Figure 2. 3. Development of asthmatic symptoms [6]. 
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2.1.3. Types of asthma 
1- Extrinsic asthma 
This type of asthma is initiated by known external allergens. Patients with this type 
tends to be atopic, where they readily develop immunoglobulin E (IgE) antibodies 
against common materials present in the environment [18]. 
 
2- Intrinsic asthma 
It is also known as cryptogenic or late-onset asthma where the agents responsible for the 
attacks are unknown or sometimes poorly defined. Patients are not atopic and the 
condition is usually found in adulthood [18]. The distinction between the two types of 
asthma is however largely academic, because in clinical practice, many patients do not 
belong to either category but instead fall into a mixed group with features of each [4]. 
    
3- Occupational asthma 
This type of asthma is triggered only by factors inside the work place and it can occur in 
workers with or without previous history of asthma [6]. 
 
2.1.4. Clinical Features  
Asthma symptoms may vary in intensity and symptoms but the frequent symptoms seen 
in asthmatic patients are [1]. 
1- Wheezing; it is only heard during exercise or forced expiration. 
2- Cough; usually non-productive, but can be accompanied by the expectoration of 
mucoid sputum especially in children. 
3- Chest tightness 
4- Unpredicted symptoms may be observed before an attack; itching under the chin, 
and discomfort between shoulder blades.   
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2.1.5. Drug therapy of asthma.  
2.1.5.1. 2-agonists 
 
They are sympathomimetic bronchodilators produce their actions by direct stimulation 
of 2-adrenoceptors in airway smooth muscles. Short acting 2-agonists (Sulbutamol, 
Terbutaline) relax bronchial smooth muscle and cause a rapid increase in the airflow 
(within 3-5 min.). The long acting 2-agonists (Salmeterol, Formoterol) cause 
bronchodilation for at least 12 hours following a single-dose administration. 2-agonists 
are contraindicated in patients with hypertropic cardiomyopathy as well as diabetic 
patients because of their positive inotropic and hyperglycemic effects, respectively [4].  
 
2.1.5.2. Corticosteroids 
Corticosteroids provide an efficient anti-inflammatory effect in asthma. They have a 
highly complex mechanism of action. They inhibit the increase in the airways BHR, 
reverse β-receptor down-regulation, inhibit cytokines production, and reduce the mucus 
secretion as well as the airway oedema. In acute attacks of asthma the early use of 
systemic corticosteroids often terminates the evolution, which decreases the need for 
hospitalization, prevents relapse, and speeds recovery and they can be administered by 
oral, intravenous, and inhalation routes. Inhaled corticosteroids are now recommended 
as first-line therapy for patients with mild to severe asthma. The most widely used 
inhaled corticosteroids are Beclomethasone dipropionate, Budesonide, and Fluticasone 
propionate. Their local side effects include dysphonia and oral candidiasis, while the 
systemic effects which are dose related, include inhibition of the adrenal-pituitary axis, 
osteoporosis, cataracts, and skin atrophy [4]. 
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2.1.5.3. Methylxanthines 
Methylxanthines belong to the group of purine alkaloids. They are basic compounds 
present in many plant species and food products as tea, coffee grains, guarana fruit, 
cocoa, and cola nuts. Caffeine and theophylline are used to alleviate neonatal apnoea, to 
relieve bronchial spasm and in the therapy of asthma. In addition, they are components 
of the over-the-counter drug mixtures for pain, cold, and cough [19]. 
 As long ago as 1786 Withering recommended strong coffee as a therapy for asthma 
symptoms, and during the last century Salter, also stated that strong coffee on an empty 
stomach was the best treatment available for asthma [20]. Theophylline was first 
identified in extracts from tealeaves by Kossel in Berlin in 1888 and was first 
synthesized in 1900 by the Boehringer Ltd [21]. Macht and Ting [22] first demonstrated 
the bronchodilator action of theophylline on pig airways in 1921. In the following year 
Hirsh reported the beneficial effects of rectally administered theophylline in four 
asthmatic patients [21]. It was not until the 1930‟s that theophylline was widely used in 
the treatment of asthma. There was also a great interest in theophylline in 1980s when 
slow-release preparations were developed and assays for measuring plasma 
concentrations became available [4, 5]. 
 
2.1.5.4. Anticholinergics 
 
These drugs relax the bronchial smooth muscles through competitive inhibition of the 
muscarinic acetylcholine receptors. By blocking of these receptors, they inhibit the 
cholinergic reflex bronchoconstriction, reduce the vagal cholinergic tone leading to 
bronchodilation and decrease the mucus secretion. Inhaled anticholinergics have no 
value in the management of stable asthma however they may be useful in acute asthma 
if the patient not respond to short acting 2-agonists. Atropine, a naturally occurring 
compound, was the first anticholinergic drug to be used for treatment of asthma. 
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However, its side effects were too troublesome, and further development led to the 
introduction of less soluble quaternary compounds such as Ipratropium bromide. 
Tiotropium bromide is a newer long acting anticholinergic drug licensed for the 
treatment of COPD but not for asthma [1, 4].  
 
2.1.5.5. Mast cells stabilizers 
 
These compounds inhibit histamine release from mast cells, reduce airway 
hyperresponsiveness, and block the early and late responses to allergens. They are 
ineffective once symptoms have occurred. They are the safest of all antiasthmatic drugs 
but the least effective [1, 4-6]. 
 
2.1.5.6. Leukotriene receptor antagonists 
Leukotrienes are inflammatory mediators released by inflammatory cells such as mast 
cells, and neutrophils. Their mediated effects include airways oedema, smooth muscle 
contraction, and mucus secretion. Leukotriene receptor antagonists prevent leukotrienes 
from binding to cys-LT1 receptors found in human airways, and so hinder their 
physiological action. Both Montelukast and Zafirlukast are orally active leukotrienes 
receptor antagonists that bind with high affinity to the cys-LT1 receptors [4, 5].  
 
2.1.5.7. New therapies and future developments in asthma management [1, 4-6]. 
(1) Immunomodulators 
Improved recognition of asthma has led to the development of several new approaches 
of treatments. One of these approaches is Omalizumab (licensed in 2005), which is an 
anti-immunoglobulin E (IgE) used for the organization of atopic asthma. It is a 
monoclonal antibody that binds to circulating IgE, which is released upon exposure to 
an allergen, so prevents receptor binding on the effector cells and stops the release of 
inflammatory mediators including histamine, and leukotriene.   
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 (2) Selective phosphodiesterase (PDE) inhibitors 
 The cAMP is metabolised and inactivated by PDE enzymes. Therefore, selective 
inhibitors for PDE3 and PDE4, which are the major PDEs within the bronchial smooth 
muscles, increase cAMP levels leading to brochodilation.  
 
(3) Mediator antagonists 
Antagonism of the inflammatory mediators which are involved in pathogenesis of 
asthma is a new logical approach for treatments. They include antagonists/inhibitors of 
histamine, thromboxane, bradykinin, and tachykinins. However several of the mediator 
antagonists have been found to be ineffective in asthma. 
 
(4) Anti-tumour necrosis factor-alpha (TNF-) 
They are used to antagonize the inflammatory effect of the tumour necrosis factor, 
which is released in allergic responses from mast cells, and macrophages [23, 24]. TNF-
 antagonists such as Infliximab and Entanercept present a new approach in asthma 
therapy especially for patients with severe disease. 
 
(5) Anti-adhesion therapies 
Infiltration of blood-brone inflammatory cells into tissues is dependant on their 
adhesion to certain receptors located in the airway membranes before migration to the 
inflammatory sites. Agents (such as a monoclonal antibody ICAM-1) that block these 
adhesion receptors are able to be effective anti-inflammatory drugs [25].  
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2.2. Theophylline 
The use of theophylline to treat asthma has undergone a number of cycles of passion 
and disapproval over the last 50 years. The broadcasting of clinical practice guidelines 
that list theophylline as a "not preferred" alternative, the availability of newer agents, 
and concerns regarding the risk-benefit ratio of the drug have resulted in infrequent 
prescribing of theophylline [3].   
However, theophylline was selected as the object of these studies due to several 
advantages including its low cost compared with other long-term maintenance 
medications as well as its ability to control chronic asthma as a result of its modest 
degree of bronchodilator activity. Furthermore, theophylline has antiinflammatory, 
immunomodulatory, and bronchoprotective effects that potentially contribute to its 
efficacy as a prophylactic anti-asthma drug [1, 3-6]. 
 
 
 
 
 
 
 
 
                               Figure 2. 4 Chemical structure of theophylline 
 
Theophylline is a methylxanthine derivative, similar in structure to the common dietary 
xanthines; caffeine and theobromine (Figure 2.4.). Several substituted derivatives have 
been synthesized but none has any advantage over theophylline except the 3-propyl 
derivative, enprofylline, which is more potent and has less toxic effects [26, 27]. Many 
salts of theophylline have also been marketed, the most common being aminophylline. 
To increase solubility at neutral pH the ethylenediamine salt is used, so that the 
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intravenous administration is possible. Other salts, have been used such as choline 
theophylline, but they do not have any particular advantages while, others, such as 
aceifylline, are virtually inactive [21, 26]. 
 
2.2.1. Mechanism of action [4, 5]       
Although theophylline has been in clinical use for many years its full mechanism of 
action is still uncertain .There are several modes of action have been proposed including: 
 
 Inhibition of phosphodiesterase (PDE)  
Theophylline is thought to cause bronchodilation by interfering with the chemical 
mechanism by which the smooth muscle contracts. This occurs by inhibiting the action 
of PDE, which breaks down cyclic nucleotides in the cell producing an increase in the 
intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine 
monophosphate (cGMP). This leads to dilatation of the air ways smooth muscles. 
(Figure 2.5.) [4, 28]. 
          
        
 
 
 
 
 
 
          
Figure 2. 5. Inhibition of phosphopdiesterases (PDEs) by theophylline [1]  
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  Adenosine receptor antagonist 
Theophylline at the therapeutic concentrations prevents adenosine (a natural 
bronchoconstrictor) from binding to the smooth muscle cells by blocking adenosine 
receptors, which may account for its bronchodilator effect. Blocking of adenosine 
receptors could also responsible for some of side effects of theophylline, such as central 
nervous system stimulation, cardiac arrhythmias, and diuresis [29, 30].   
 
 Stimulation of catecholamine release 
Although, theophylline increases the secretion of adrenaline from the adrenal medulla, 
the increase in plasma concentration is small to account for any significant 
bronchodilator effect [31]. 
 
  Mediator inhibition 
Some in-vitro tests show that theophylline antagonizes the effect of some prostaglandins 
on vascular smooth muscle. It also inhibits the secretion and hinders the action of 
tumour necrosis factor that may be involved in asthmatic inflammation [22, 32].  
 
  Inhibition of intracellular calcium release 
There is also some evidence that theophylline may interfere with calcium mobilization 
in airway smooth muscles. As the elevation of the intracellular Ca
2+
 level plays an 
important role in the development and maintenance of the force in
 
the
 
airway smooth 
muscles [22]. It has been also reported that the increase in the influx of Ca
2+
, increases 
the contractile response to histamine in asthmatic patients [33].  
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2.2.2. Clinical effects of theophylline 
All the molecular mechanisms of action of theophylline produce the following clinical 
responses [1, 4-6] (Figure 2.6.); 
 Bronchodilation. 
 Improvement in diaphragmatic and respiratory muscles strength 
 Anti-inflammatory effects, and increased mucociliary clearance 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
            Figure 2.6. Cellular and clinical effects of theophylline 
                               (adapted from http://journals.prous.com.)  
 
2.2.3. Pharmacokinetics 
2.2.3.1. Theophylline serum level 
 
Theophylline has a narrow therapeutic index and its serum level must be monitored 
carefully in order to avoid the development of serious side effects. In adults low 
therapeutic effect is seen below 10 mg/l, while above 25 mg/l increasingly more serious 
side effects are likely and therefore the serum level of theophylline need to be 
maintained in the therapeutic range 10-20 mg/l [26, 34].  
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2.2.3.2. Metabolism of theophylline and other related methylxanthines 
 
Both theophylline (TP) and caffeine (CA) are extensively metabolised in the liver by 
cytochrome P450 enzymes, in particular CYP1A2. Therefore, less than 10 % of TP and 
less than 2 % of CA are excreted unchanged in the urine. CA in healthy human subjects 
is metabolised producing paraxanthine (80 %), theobromine (12 %), and TP (7 %).  The 
main metabolic pathway for TP is hydroxylation at position 8 to generate 1,3-
dimethyuric acid, which accounts for 45-55 % of its clearance. Other important steps in 
the metabolism of TP are N-demethylation to form 1-methylxanthine (20-25 %), and 3-
methylxanthine (13-16 %) [35, 36]. Figure 2.7 shows schematic diagram for the 
metabolism of methylxanthines in humans. 
There are various environmental factors, inter-individual variations, and concurrent 
administered drugs which may affect theophylline hepatic metabolism [37]. 
 Factors that increase the metabolism (reduced plasma level; dose increase is required) 
 Enzyme induction (rifampicin, phenobarbital, anticonvulsant) 
 Smoking (tobacco, marijuana), chronic alcoholism, and childhood 
 Barbecued meat, high protein, and low-carbohydrate diet 
 Factors that decrease metabolism (increased plasma level; dose reduction is required) 
 Bacterial infection (e.g. pneumonia), viral hepatitis, cirrhosis/liver disease, 
congestive heart failure, respiratory acidosis, and old age. 
 Enzyme inhibition (e.g. cimetidine, ciprofloxacine, contraceptives, allopurinol). 
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        Figure 2.7. Schematic diagram of the metabolism of methylxanthines in humans 
 
2. 2. 4. Routes of administration [1, 4-6]. 
 
Oral: Plain theophylline tablets are available but they are rapidly absorbed producing 
wide fluctuations in plasma levels and therefore are not recommended. However, 
several effective sustained release formulations are more convenient, that are absorbed 
at a relatively constant rate and provide steady plasma concentrations over 12-24h. 
 
Intravenous: Aminophylline is a mixture of theophylline with ethylenediamine, which 
is 20 times more soluble than theophylline alone, and is administered intravenously to 
patients with acute and severe asthma.    
 
Other routes: Aminophylline may be given as suppository, although rectal absorption is 
considered unreliable and proctitis may occur. On the other hand, intramuscular 
injections are also used for theophylline  
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2.3. Analytical review 
 
2.3.1 Chromatographic methods 
Several analytical methods have been reported for the analysis of theophylline, caffeine, 
and their metabolites in different biological samples, dietary supplements, and 
pharmaceutical dosage forms.  
 High Performance Liquid Chromatography (HPLC) seems to be the most popular 
method for the determination of these compounds (Table 2.1). Ultraviolet detection (UV) 
is widely used at 247-280 nm. Diode array and mass spectrometry have been also used 
for detection. In respect of HPLC columns, C18 silica gel reversed-phase columns with 
isocratic elution are commonly used in a number of reported methods. Gradient elution 
has been also used to resolve many interferences but it is more time consuming than 
isocratic methods.  
On the other hand, Gas chromatography (GC) and GC/MS have been used for the 
determination of TP, CA and other methylxanthines in biological fluids and 
pharmaceutical dosage forms [38 - 44]. 
Because a large number of samples can be run, in addition to the use of small quantities 
of solvents, thin layer chromatography (TLC) and HPTLC have been used for the 
assay of methylxanthines in plasma [45,46], and saliva [47] using UV-Vis 
spectrophotometer or a UV- densitometer for detection.  
Several methods have been reported for the assay of TP and related substances in 
pharmaceutical formulations and different body fluids using capillary electrophoresis 
(CE) coupled with UV or MS for detection [48-54].  
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     Table 2. 1. Published HPLC procedures for the determination of theophylline, different methylxanthines, and their metabolic products.   
Sample Detection Column Mobile phase Ref. 
TP, CA, and other drugs, in 
different dosage forms  
 
UV at 273 nm Hypersil ODS 
 
Methanol: phosphate buffer (pH 6)  [55] 
TP, CA, & metabolites in 
plasma and saliva 
UV at 274 nm  
 
 ODS 5µm 0.01M sodium acetate, Methanol (pH 4.75) (87.5:12.5 % v/v) [56] 
CA metabolites in plasma   
 
UV at 280 nm  Normal phase  
 
Dichloromethane containing 2.5% formate buffer in 1.2-2 % methanol  [57] 
CA, and TP in urine  
 
UV at 280 nm  Hypersil ODS  0-12.75% acetonitrile in 1% THF (pH 4.8)  [58] 
TP and its metabolites in 
urine 
 
UV at 276 nm Hypersil ODS (A) 1.28 g/L CH3COONa cont. 0.4% v/v conc. acetic acid (pH 4)  
(B) 20 % w/v acetonitrile and 0.5 v/v glacial acetic acid  
[59] 
TP in plasma and urine 
 
UV at 267nm  Sepralyte C18        0.05 M phosphate buffer : methanol (1:4 % v/v) [60] 
TP, CA in plasma 
 
UV at 273 nm C18 (Water)  Acetonitrile: THF: conc. acetic acid: water (50:30:5:915 % v/v) [61] 
TP and CA in plasma  DAD  ODS 3µm (A) 25% acetonitrile and 2% THF in 10 mM acetate buffer 
(B) 0.01% THF in 10 mM acetate buffer 
[62] 
Methylxanthines in human 
breast milk 
 
UV at 272 nm 
 
ODS 5µm       0-16% methanol in 10 mM sodium acetate and 5 mM TBA  [63] 
TP, CA and their metabolites 
in serum and saliva  
 
UV at 247 nm ODS 3µm 
 
Acetonitrile/methanol/buffer (pH 4.7) 0.05 M (4:7:89 % v/v)  
 
[64] 
TP, TB, and PA in rat brain  UV at 273 nm µBondapak  
 
THF / 10mM Na2HPO4  (pH 6.5)  (3:97 % v/v) [65] 
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          Cont. Table 2.1. 
Sample Detection Column Mobile phase Ref. 
CA, TP, TB, and PA UV at 274 nm ODS 5µm Methanol: 0.1 M phosphat buffer  (30:70 v/v% v/v)  [66] 
TP in blood.   DAD -UV  ODS 2 µm  Acetonitrile in phosphate buffer (pH 3.1) (10- 60 v/v %) 
 
[67] 
CA and TP in serum UV at 280 nm  Spheri-5µm  
 
Acetonitrile/ water (5:95 % v/v)  [68] 
TP metabolites in urine. UV at 280 nm ODS 5µm 10 mM Sodium acetate, acetonitrile, THF, and TBA 5mM  [69] 
TP in plasma and saliva  UV at 268 nm µBondapak  0.08 M Phosphate buffer (pH 2.5): methanol (75:35 % v/v)  [70] 
TP and its metabolites in 
urine and plasma  
UV at 273 nm ODS 5µm Methanol: 0.01 M acetate buffer (pH 4) (7:93 %v/v) for urine 
and (9:91 % v/v) for plasma  
 
[71] 
CA and TP in plasma UV at 273 nm ODS 5µm Acetonitrile: THF: conc. acetic acid: water (20:20:5:955 % v/v)  [72] 
Urinary CA metabolities  
 
UV at 280 nm Spherisorb S5  
 
Acetic acid: THF: acetonitrile: water (1:2.5:44:925.5 % v/v) [73] 
TP and CA in urine and 
plasma 
 
UV 254 nm Silicalite slurry  20 mM phosphate buffer pH 6.9:  acetonitrile from 80:20 % v/v [74] 
TP and CA in blood serum  UV at 273 nm ODS  0.2 mM sodium hydrogenphosphate solution (pH 4.7)    [75] 
(1-methyl-C
14
) CA and its 
metabolites in rat urine  
UV at 280 nm Lichrosphere 
RP-18  
(A) 10 mM sodium acetate buffer (pH 5.5): methanol: DMF 
(99:0.5:0.5 % v/v) (B) Methanol: A (50:50 % v/v) 
[76] 
TP in plasma UV at 280m LiChrospher  Acetonitrile: acidified distilled water (pH 4) (10/90 % v/v) [77] 
TP metabolites in plasma.  UV at 275 nm  ODS 5µm 20mM sodium acetate buffer (pH 4.8): acetonitrile: methanol  
 
[78] 
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Cont. Table 2. 1. 
Sample Detection  Column Mobile phase Ref. 
CA metabolites in biological 
samples  
UV at 275 nm Kromasil C4  Acetate buffer (pH 3): methanol (97:3 % v/v) changing to 
(80:20 % v/v)  
[79] 
Urinary CA metabolites  
 
UV -DAD  
at 270 nm  
Eclipse C18 (A) Water: acetic acid: THF (pH 3) (996.5: 1:2.5 % v/v)  
(B) Acetonitrile  
[80] 
Urinary CA metabolites  
 
Tandem MS 
 
ODS 5µm (A) Acetic acid  (B) Methanol: 2-propanol (C) Methanol [81] 
TP and other drugs in plasma 
 
Tandem MS  Monolith Acetonitrile/water/formic (90:10:1 %v/v)  [82] 
Methylxanthines in urine  DAD -UV  Supelcosil  Methanol: 5mM citric acid (pH 5) (20:80 %v/v)  [83] 
Methylxanthines in urine DAD -UV Lichrosorb RP-18 Gradient elution using 0.05% TFA and acetonitrile [19] 
TP, CA, & TB in plasma UV at 275 nm 5µm TSK gel ODS Methanol:0.01 M phosphate buffer (pH 3.5) (30: 70 % v/v) [84] 
TP& its metabolites in plasma MS YMC C18 Methanol: aq. 0.5 ml/L acetic acid [85] 
Methylxanthines and turine in 
dietary supplements  
MS  Luna-C18  Water/methanol/acetic acid (75:20:5 % v/v)  [86] 
Urinary CA metabolites  Tandem MS YMC-Pack C30 (A) 0.5% acetic acid (B) 100% Acetonitrile 
[87] 
CA and TP in serum UV at 272 nm Kromasil C18 50 mM SDS/propanol/10mM phosphate buffer (pH 7) [88] 
TP, CA, in green tea UV at 271 nm Imprinted monolith Dichloromethane /Methanol and acetic acid (20:1 %v/v) [89] 
TP and etofylline in plasma UV at 272 Intersil C18 10 mM acetate buffer: methanol: acetonitrile (86:7:7 %v/v) [90] 
TB, TP and CA in coca  UV-DAD  Novapack C18 20 % methanol in water  [91] 
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2.3.2. Spectrophotometric techniques 
Different spectrophotometric methods were used for the determination of theophylline 
in combined pharmaceutical tablets forms with ephedrine [92, 93]. A novel-coupling 
reagent (3-methyl 2-benzo thiazolinone hydrazone hydrochloride) and diazotized p-
nitroaniline have been to assay of TP and CA in pure form or in pharmaceutical 
formulations [94, 95]. Derivative UV-spectrophotometric techniques were used for 
determination of TP, TB, and CA in various food products. [96, 97]. Double wavelength 
and multi-wavelength spectrophotometric methods have been used for the determination 
of theophylline in serum and in pharmaceutical dosage forms without interference from 
TB, CA or phenobarbital (a common co-drug component in oral theophylline 
preparations) [98-102].  
 
2.3.3. Electrochemical methods 
Theophylline and different methylxanthines were determined by voltammetric [103] 
and amperometric techniques, using different types of electrodes [104, 105]. 
 
2.3.4. Immunoassay 
Different methods were reported for measuring TP level in biological fluids using 
fluorescence polarization immunoassay (FPIA) [106, 107], immunoaffinity solid-phase 
microextraction (SPME) [108], or  liposome-based flow injection immunoassay (FIIA) 
system [109]. In addition, a fluoroimmunosensor was developed for the assay of TP in 
human serum using immobilised antibody [110] 
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2.4. Production of inhaled particles 
 
The inhaled route has a number of well-recognized advantages over other routes for 
administration of drugs. As the drug is delivered directly to its required site of action, 
only a small quantity is required for a sufficient therapeutic response. Accordingly, 
there is a low incidence of systemic side effects compared with oral or intravenous 
administration. In addition, the onset of action of inhaled drugs is generally faster than 
that achieved by oral administration. There are expanding markets for different drugs 
used for asthma and chronic obstructive pulmonary diseases (COPD), and promising 
new drugs (e.g. for diabetes, osteoporosis, pain) with new targets and absorption 
mechanisms requiring new delivery approaches. Inhalation technology gives new 
opportunities to recognize the full potential of many existing drug substances [7]. The 
technology has primarily focused on two principals; engineering of efficient inhaler 
devices, and improvement of the drug formulation technology. Therefore, the goal was 
to prepare theophylline of physical and chemical characteristics suitable to be used as 
inhalable drug, that may alleviate some of its drawbacks when administered by different 
routes [7, 8].  
Different reported studies [111, 112] highlighted the influences of the particle size on 
the distribution and site of deposition of the inhaled drug within the airways. 
Randomised, double placebo-controlled study was carried out by Usami et al [113] in 
twelve subjects with asthma. The subjects inhaled technetium-99m-labeled 
monodisperse Albuterol aerosols of 1.5, 3, and 6 m mass median aerodynamic 
diameter. The results showed that the smaller particles achieved greater total lung 
deposition while a greater oropharyngeal deposition for lager particles with less 
bronchodilation effect. On the other hand, the micrometer-sized particles can exhibit 
really different physicochemical properties depending on the manufacturing conditions, 
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the quality and the uniformity of the powder produced [8]. Therefore, the production of 
ultra fine particles  (micrometer or sub micrometer) with narrow particle size 
distribution (PSD) and desired propertied for efficient respiratory delivery, still 
represents a significant challenge to the pharmaceutical industry [7]. 
Many conventional processes for particle production have a number of limitations in 
producing a desirable end product. Milling often results in 10-50 m particles with large 
PSD, and the process can generate a high local temperature that is likely to modify or 
even damage the product. In contrast, spray drying yields particles of suitable size, but 
exposes the product to locally high temperature [8].  
Lyophilization produces particles with very broad PSD. A final method is precipitation 
from solution by adding an organic antisolvent but this does not allow precise control of 
the particle size and result in a high content of residual organic solvent, which needs to 
be removed later. These techniques therefore, fail to yield particles of suitable size or 
size distribution. In addition, some of these methods subject liable molecules to high 
thermal stress. Thus, the need to find alternative approaches to produce small and 
consistent particles was an important driving force in the development of SCF 
technology [8, 9].  
As an alternative, particle formation using the SCF technique can efficiently produce 
particles reproducibly over a broad range of physicochemical characteristics that may 
alleviate issues and associated effects of conventional crystallisation and micronisation 
used to form inhalable particles [7-9].  
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2.4.1. Supercritical fluids (SCFs) 
This technique is based on gases and liquids at temperatures and pressures above their 
critical points (Tc- critical temperature; Pc critical pressure) [114]. As shown in Figure 
2.8 the critical point is located at the upper end of the liquid: gas-vapour pressure curve 
and the phase area in excess of this point is the SCF region.  
 
                                                                
            
                                     
Figure 2.8. Phase diagram of a pure substance 
                    (adapted   from www.le.ac.uk/supercritical_fluids.html) 
 
2.4.1.1. History 
 
SCFs were discovered as early as 1822, when Cagniard de la Tour first reported that the 
critical point of substances can be observed when a liquid in a sealed glass vessel was 
heated till the meniscus between the liquid and vapour disappeared and the substances 
became a fluid [115]. Later, Hanny and Hogarth [116] reported an experiment in which 
the dissolved solute precipitated as a snow in the SCF by reducing the pressure. This 
was the first reported use of supercritical fluid to form particles. However, commercial 
interest in SCFs techniques has taken place only over the past 30 years. This was 
Chapter 2                                                                                                 Literature review 
 31 
initiated in the 1970s by increased concern over energy costs as the SCF techniques 
might provide cost saving alternatives to liquid extraction and distillation. More 
recently, SCF techniques have been used in different commercial applications include 
extraction processes [115] particularly the decaffeination of coffee and tea as well as 
extraction of essential oils and flavours from natural products. In 1980s other SCF 
industrial applications were studied as purification of surfactants and pharmaceuticals, 
fractionation of polymeric materials, and polymerization. In the same period, interest in 
using SCFs for precipitation and crystallisation processes was developed for 
pharmaceutical materials. This has steadily increased in recent years with the aim to 
prepare powdered pharmaceuticals with discrete and targeted properties such as particle 
size distribution [7-9].  
 
2.4.1.2. Choice of SCF 
 
All gases can form SCFs above specific sets of critical conditions although extremely 
high temperatures and/or pressure may be required. Several SCFs with corresponding Tc 
and Pc values have been used for particle formation in several industrial sectors. Critical 
temperatures and pressures for a number of pure substances used as SCF are shown in 
Table 2.2. For pharmaceutical applications the most widely used SCF is carbon dioxide 
(CO2) (Tc; 31.1C, Pc 73.8 bar) because it has many advantages over other SCFs. These 
include [115]; 
 Low critical temperature (31.1 C), so it is suitable for heat sensitive materials. 
 Non-flammable   
 Non-toxic, so it is selective and acceptable in the food and pharmaceutical industries 
 Non-oxidizing, so chemical degradation of the compounds is less likely. 
 Inexpensive. 
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Table 2. 2. Critical temperature (Tc), and pressure (Pc), of some selected SCFs [115]. 
 
Solvent Tc (C) Pc (bar) 
Carbon dioxide 31.1 73.8 
Ethane 32.2 48.8 
Ethylene 9.3 50.4 
Propane 96.7 42.5 
Propylene 31.9 46.2 
Cyclohexane 280.3 40.7 
Isopropanol 235.2 47.6 
Trichlorofluoromethane 198.1 44.1 
Ammonia 132.5 112.8 
Water 374.2 220.5 
   
 
2.4.1.3. Properties of supercritical fluids  
 
SCFs have interesting physical characteristics that can be directed between liquid-like 
and gas-like properties. SCFs have density values that permit considerable solvation 
power, whilst the viscosity of solutes in SCFs is lower than in liquids and so the solute 
diffusivity is higher, which facilitates high mass transfer [8]. SCFs are highly 
compressible particularly near the critical point which allows their density and thus the 
solvation power to be carefully controlled by small changes in temperature and/or 
pressure [9]. They also exhibit very low surface tensions allow better penetration into 
microporous solids, which conventional liquids may not be able to penetrate.  Table 2.3 
shows a comparison of the density, viscosity, compressibility, and diffusivity of gases, 
liquids and SCFs [117]. 
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Table 2. 3. Comparisons of some physical properties of gases, liquids and SCFs [117]  
 
State Density 
(kg cm
-3
) 
Mass Diffusivity 
(m
2
. s) 
Viscosity 
(Pa.s) 
Compressibility 
(Mpa
-1
) 
Gas (0.5-2.0)  10-3 (1.0-3.0)  10-5 (1-4) 10-5 1.0-10 
Liquid 0.6 -1.6 (0.2-2.0)  10-9 (0.2-3.0)  10-3 (1.0-5.0)  10-3 
SCF 0.2 - 1.0 (1.0-7.0)  10-8 (1.0-9.0)  10-5 0.1  
 
2.4.1.4. Mechanisms of particle formation using SCF methods 
 
Several reviews have considered with SCF particle formation processes [118-120], 
which can be divided into three broad groups; 
 
(1) Precipitation from supercritical solutions composed of SCF and the solute  
Rapid expansion of supercritical solutions (RESS) exemplifies this first group. The 
principle of this method is described in Figure 2.9. The solid is packed into the 
extraction vessel at a controlled temperature and pressure. Then the SCF extracts the 
solid and the resultant solution is then sprayed through a nozzle into a precipitating 
column held at ambient or reduced temperature, which causes rapid expansion, leading 
to a high supersaturation level, and precipitation of the product. A wide range of 
materials and pharmaceutical products has been processed by RESS and it is also used 
for encapsulation processes [7-9]. RESS is thus a simple process usable with molecules 
having good or fair SCF-solubility.  However, for compounds with limited solubility in 
SCF a low output will result making the process economically unfavourable. Other 
challenges includes the high consumption of SCFs and high pressure required at large 
scale [8].  
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                       Figure 2. 9. Schematic diagram of RESS process [121] 
 
(2) Precipitation from gas saturated solutions (PGSS) 
This process involves dissolving a SCF in molten solute, then the resulting solution is 
fed via an orifice leading to a rapid expansion under ambient conditions [122]. PGSS 
has the same principle as RESS, but it has the benefits of using significantly less SCF 
and lower pressure during the process (Figure 2.10.). Although polymers, different 
kinds of lipids and two pharmaceuticals (nifedipine and felodipine) have been 
successfully micronized with the PGSS process, the high temperatures and high stability 
of solute in molten form limit this application for most pharmaceuticals, biologicals and 
any thermal liable materials [7-9].   
 
Figure 2. 10.  Schematic diagram of PGSS process [122] 
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(3) Precipitation from saturated solutions using SCF as antisolvent 
 Solids that are insoluble in SCFs or compressed gas can be prepared as fine particles by 
mean of this method. This technique utilizes the same basic principle to the use of 
antisolvent-based crystallization processes. With high solubilities of SCFs in organic 
solvents a volume expansion occurs when the two fluids make contact which leads to a 
reduction in solvent density and a fall in the solvent capacity. Such reductions cause 
increased levels of supersaturation, solute nucleation, and particle formation. 
Precipitation with compressed fluid antisolvent (PCA), gas antisolvent (GAS), 
supercritical antisolvent (SAS), aerosol solvent extraction system (ASES), and solution-
enhanced dispersion by supersaturation (SEDS) are the designations proposed for 
techniques relevant to this group [121, 122]. 
 
3.a. Gas antisolvent process (GAS)  
Gallager et al. [123] first proposed the GAS technique to overcome the limitations of 
RESS. This technique was first tested to prepare particles of explosives [121, 122]. The 
GAS process is a batch technique, which includes the gradual introduction of a 
compressed gas into a liquid solution of the solute of interest in an organic solvent. Due 
to the dissolution of the compressed gas, there is a rapid increase in the volume 
followed by a drop in the solvent strength, and then solid precipitation (Figure 2.11.).  
               
          Figure 2. 11.  Schematic diagram of GAS process [122]. 
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 3.b. Precipitation with compressed gas fluid anti-solvent (PCA), supercritical anti-
solvent (SAS), and aerosol solvent extraction system (ASES) processes 
Many pharmaceuticals have been processed by means of these three precipitation 
processes such as antibiotics, proteins, and drug substances such as sulbutamol [7-9]. 
These processes are modified from the GAS method in that the organic solvent drug 
solution is sprayed through a capillary or a nozzle into a continuous flowing stream of 
SCF as antisolvent (Figure 2.12.). This is to maximize the exposure of small amounts of 
solution to large quantities of SCF antisolvent, to accelerate the solubilization of the 
organic solvent in the SCF leading to precipitation of dry particles, therefore avoiding 
the drying stage in the GAS process.  
           
           
 
 
 
 
 
        
Figure 2. 12. Schematic diagram of PCA, SAS, and ASES processes [121] 
 
3.c Solution enhanced dispersion by supercritical fluids (SEDS) process 
The SEDS process was first developed and patented by Bradford Particle Design [10, 
11]. The general principle is the same as that for SAS process; supercritical CO2 and the 
organic solution are introduced concurrently in mixing chamber, followed by 
precipitation of the solid is due to anti-solvent effect. The essential difference is related 
to the way of introducing the different phases; in SEDS, a coaxial nozzle design with a 
mixing chamber is used. This arrangement provides a means whereby the drug in the 
organic solvent solution interacts and mixes with the SCF in the mixing chamber of the 
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nozzle before prior to dispersion, and then flows into a particle-formation vessel 
through a restricted orifice. Thus high mass transfer rates are achieved with a high ratio 
of SCF to solvent, and the high velocities of the SCF accelerate the break up of solution 
feed [9]. Over recent years this process has been used for several drugs and drug 
formulation application, with evidence of successful scale-up. This process has been 
further developed to process water-soluble materials, including carbohydrates and 
biological samples using three component-axial nozzle [124]. 
 
2.4.1.5. Summary of the advantages of SCF techniques over conventional    
             crystallisation and particle size reduction methods.  
 Minimal or no residual solvents in the material without further drying have been 
demonstrated with SCF. 
 Sensitive compounds and heat liable compounds can be processed such as explosives.  
 Reduced static in materials compared to fluid energy milling such as micronization.  
 Small particles with narrow size distribution have been reported in many papers.  
 Control over crystallinity and the ability to condition less crystalline material. 
SCF yield requires no further processing and can be used directly in pharmaceutical 
applications. 
 Reproducibility and repeatability have been demonstrated at several process scales. 
 Fewer processing steps that led to higher overall process yield within lower cost 
compared to other techniques. 
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2.4.2. Product Characterization 
A range of analytical methods can be used to establish the quality and properties of the 
drug particles produced by SCF techniques.  
 
2.4.2.1. Scanning electron microscope (SEM) 
SEM is an instrument that produces largely magnified images by using electrons instead 
of light to form an image.  A beam of electrons is produced at the top of the microscope 
by an electron gun.  The electron beam follows a vertical path through the microscope, 
which is held within a vacuum. Once the beam hits the sample, electrons and X-rays are 
ejected from the sample. Detectors collect these X-rays, backscattered electrons, and 
secondary electrons and convert them into a signal that is sent to a screen similar to a 
television screen producing the final image (Figure 2.13). It allows direct measurements 
of the particle size and provides full details about the particle shape and texture [7].  
 
 
 
 
 
 
 
 
 
 
 
                        Figure 2.13. Schematic diagram of SEM  
                                            (adapted from www.purdue.edu/REM/rs/sem.htm) 
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2.4.2.2. Thermal Methods of analysis 
Thermal analysis generally refers to any method involving heating of the sample and 
measuring the changes in some physical properties. The most important thermal 
methods for the study of solid-state chemistry are thermogravimetric analysis (TGA) 
and differential scanning calorimetry (DSC). TGA involves the measurement of the 
change in mass with temperature and is often used to study the loss of solvent of 
crystallisation or other solid /gas reactions. TGA is commonly used in research to 
determine the degradation temperatures, the absorbed moisture content of materials, the 
level of inorganic and organic components in materials, the decomposition points and 
the solvent residues. DSC is a technique for measuring the energy necessary to establish 
a nearly zero temperature difference between a tested substance and an inert reference 
material, as the two specimens are subjected to identical temperature regimes in an 
environment heated or cooled at a controlled temperature. DSC used to monitor any 
phase transition and changes in polymorphic form after processing or storage of the 
samples [128].   
 
2.4.2.3. X-ray powder diffraction (XRPD) 
XRPD is a powerful tool for the investigation of crystalline solids. Experimental results 
can lead to a complete determination of the solid structure and the packing relationship 
between individual molecules. This knowledge is often helpful in understanding the 
solid-state chemistry of the drug. XRPD gives a clear image about any changes in the 
crystallinity or the polymorphic forms of the tested substance [128]. 
 
2.4.2.4. Fourier Transform Infrared spectroscopy (FT-IR) 
IR spectroscopy is a useful method for the analysis of solids. IR spectroscopy is 
extremely sensitive to the structure and conformation of the compound of interest. This 
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technique is used to assess the polymorphic changes by detecting any change in the 
molecular vibration in samples. The relative position of the molecules alter in different 
polymorphs and these changes affect the molecular vibrations which are shown by 
corresponding shifts in IR banding of the spectra [129].  
 
2.4.2.5. Fourier Transform Raman Spectroscopy (FT-Raman) 
This technique is a complementary vibrational spectroscopic method to IR. The Raman 
effect is not an absorption effect as in infrared spectroscopy, but is depending on the 
polarizability of a vibrating group and on its ability to interact and couple with exciting 
radiation. The advantages of Raman includes its increased sensitivity, the ease of 
sample preparation and the fact that water, frequently present at low concentrations in 
many materials, has very low absorbance (at 3654 cm
-1
) and so gives minimal 
interference, unlike FTIR [130]. 
 
2.4.2.6. High Performance Liquid Chromatography (HPLC) 
HPLC is a dominant separation tool in all of the analytical areas such as for 
pharmaceuticals, chemicals, food industries, and environmental laboratories. The 
stationary phase is the heart of the HPLC system, and silica based packing materials are 
the most widely applied reversed-phase in the pharmaceutical industry. The 
hydrophobic surfaces of these packings are made by covalent bonding of 
monofunctional alkyldimethylchlorosilanes (RMe2SiCl) on to a silica surface. 
Octadecylsilane (C18) was the first commercially available silica-based bonded phase. 
Also alkyl-type ligands of different number of carbon atoms (C8, C4) as well as phases 
with phenyl or cyano- function groups have been used [131]. These phases are familiar 
to most chromatographers, with a large number of published applications [131-133]. 
Polar-endcapped, and polar embedded phases have been recently introduced providing 
an opportunity for potential modification of the chromatographic selectivity. A number 
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of these stationary phases have enhanced the retention of polar analytes [132].  
Although the silica based phases are the most widely applied reversed phases there are 
still some limitations for which selectivity, reproducibility, or repeatability is not 
obtained easily. These limitations include [131-133]; 
 At low pH the silica-based phases are subject to chemical attack, also the basic 
instability of bonded silica causes retention drift, short column life, and frequent 
replacement of the column and re-qualification of HPLC system. This is expensive in 
both terms of actual expenditure, and low productivity in the pharmaceutical  process.  
 Many silica-based bonding chemistries are not stable at high temperatures (> 40  C). 
On the other hand hydrolysis of the siloxane bond may occur at lower temperatures 
leading to stationary phase bleed resulting in retention time irreproducibility and high 
background noise for many applications as LC/MS.  
 Additionally, these stationary phases exhibit decreased and poorly reproducible 
retention under high portion of aqueous conditions. Unusual chromatographic 
behaviour and unfavourable results may be generated when these phases are used 
under such conditions [133].  
 In bonded phase silica, the partition mechanism responsible for retention in RP-HPLC 
often does not provide adequate chemical selectivity for chiral or structurally similar 
compounds.  
Nowadays the trend in the liquid chromatography is toward the development of new 
sorbents, which are able to separate efficiently complicated substances. Such sorbents 
should be able to work in a wide pH range and enable rapid analysis while sufficient 
separation; method sensitivity and selectivity remain unaffected.  One of these novel 
types of sorbents is a monolithic column [131].  
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2.4.2.6.1. Monolithic packing material 
Researchers working in the pharmaceutical field are looking for improved methods and 
tools which can attain a high resolution and separation in short experimental periods.  
When using HPLC columns packed with particulate materials, high pressures 
(sometimes up to 250 bar) have to be used to produce an acceptable flow rate and 
separations with more than 30 minutes for each run. Also, the high pressure used creates 
high backpressure on the instrumentation, which reduces the life of the pumps and seals. 
Moreover, in between runs these columns require a lengthy flushing or equilibration 
period before the next sample injection can take place. All these limitations of the 
particulate silica columns, have led to the development of novel and innovative new 
forms of HPLC stationary phases such as the monolithic columns which can provide 
practical solutions for all these difficulties [16, 134].   
Monolith packing is one of the new developments used to achieve a high-speed 
separation without loss of column efficiency. The monolithic phase is an example of the 
fourth generation support for HPLC. As Guiochon claimed  “ The invention and 
development of monolith columns is a major technological change in column 
technology, indeed the first original breakthrough to have occurred in this area since 
Tswett invented chromatography a century ago” [135]. A large number of experiments 
have been done so far using these columns [136-138]. The commercial availability of 
various monolithic columns provides great potential for these new continuous 
separation media. 
The first continuous separation media was produced from open-pore polyurethane 
foams and highly swollen polymer gels developed during the late 1960s and early 1970s 
[139, 140]. However, these attempts were less successful because the materials lacked 
sufficient permeability or solvent stability and could only be applied under low 
operational pressure. However, Hjerten et al. [141] developed another swollen, 
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compressed soft gel called a continuous „polymer bed‟ in 1989 but these beds were 
unable to work under higher backpressures, and therefore, limited the application for 
fast analyses. In 1992, Svec and Freschet [142] created a rigid, polymer monolith for 
capillary electro-chromatography (CEC) to overcome the drawbacks mentioned above. 
Because the porous inorganic materials are popular supports, Nakanishi, and Soga 
developed a technique to produce a porous silica monolith [143-146]. However, it was 
not until 2000, that silica-based monolithic HPLC columns were commercially available 
from Merck KgaA in Germany [15]. 
 Monolithic columns are characterized by having a different structure when compared 
with conventional packed columns. The column packings consist of one piece of either 
an organic polymer or silica with a continuous homogenous phase instead of a packed 
bed with individual particles. This column is usually made by sol-gel technology, with 
two types of pores (macropores and mesopores) in its structure (Figure 2.14) [147]. The 
column has a total porosity of over 80 % v/v, providing fast mass transfer and low-
pressure resistance, which allow rapid separation. The large pores (typically 2 m) are 
responsible for a low flow resistance and therefore permit the application of high eluent 
flow rates, while the small pores (about 13 nm) verify sufficient surface area for 
separation efficiency. Due to these facts, relatively higher flow rates (up to 9.9 ml min
-1
) 
can be used as the resolution of the silica rod column is less affected in comparison to 
particulate materials from increasing the flow rate and the column backpressure is still 
generally low. This makes the monolithic columns attractive for high throughput 
applications [15, 16, 134, 147].  
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      Figure 2.14. SEM picture of a cross section from a silica monolith 
                            (adapted from http://www.vwrsp.com) 
 
In addition, as the mass transport properties of these phases seem to be determined by 
convection rather than by diffusion, higher molecular weight molecules such as proteins, 
and peptides can be separated more efficiently with a monolith than with packed 
capillary phases [148, 149].  Another practical advantage is a short time needed for 
column equilibration when a mobile phase gradient is used. It is also possible to apply a 
gradient flow rate as well. However, it is interesting to note that the practical use of 
monolithic columns has not been as wide as one should expect, in spite of all their 
advantages. Whilst, there are a number of papers concerning monolithic columns, most 
of them consider mainly the preparation and testing of monolithic columns. A relatively 
small numbers of articles have been published which demonstrate their applications in a 
variety of chromatographic modes and these include GC, HPLC, and CEC [15, 150-
156]. The less common functions of monolithic materials include supports for solid-
phase and combinatorial synthesis , scavenger carriers for immobilization of enzymes, 
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immuno-adsorption using monolithic discs as well as solid-phase extractors and pre-
concentrators [156]. The comparison between a silica monolith and conventional 
columns packed with 3- to 5-m particles has shown that they have equivalent 
efficiency and sample capacity [157-160]. However, the monolith offers three- to five-
times lower flow resistance and better permeability to allow higher flow rates and 
higher productivity.  
Although the monolithic columns are relative new formats of stationary phases for 
HPLC and much remains to be investigated, their unique properties, in particular the 
ease of preparation, tolerance to high flow rate, and rapid speed that can be achieved at 
acceptable back pressures, make these packings equal or superior to the more 
conventional packed columns. It is just a matter of time until the range covered by 
monolithic technology will be extended and it will successfully compete with all of 
other well-established separation technique.  
 
2.4.2.6.2. Platinum
 TM
 columns 
Polar drugs have always been problematic in HPLC and during its continual 
development much research has been applied to assessing in, particularly for basic 
drugs. The major problems have been associated with the interaction between the polar 
drugs and C18 phases. One suggested solution has been to use shorter alkyl based phases 
but very short chain materials (<C4) suffer stability problems at low (< 2) and high (> 8) 
pHs. Polar embedded phases (such as carbamate and amide) have been also introduced 
to provide improved polar retention and are reported to give high stability in 100% 
aqueous mobile phases [161].  
Recently, a novel approach was taken by Grace Davison Discovery Sciences
®
 with the 
introduction of their Platinum™ columns. In these columns instead of thoroughly 
covering the silica with bonded phase (as traditional C18 columns), the exposure of the 
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silica is controlled to provide a dual-mode separation with both polar and non-polar 
sites [161, 162]. Therefore, platinum phases have enhanced polar selectivity in addition 
to reversed phase retention. In operation, it is proposed that the hydrophobic compounds 
are retained by the bonded phase (alkyl C18) while the polar compounds are retained by 
the inert silanol groups. Because of the claimed highly pure nature of the surface and the 
uniform covering of inert vicinal silanol groups, peak shape is generally considered to 
be very good. The columns are available in two types, which offer different levels of 
silica exposure. The standard column has a moderate silica exposure and is best used for 
neutral and moderately polar compounds. The other column platinum EPS (Extended 
Polar Selectivity) has a high level of silica exposure and can be used for highly polar 
analytes [161]. 
 
2.5. The basic factors affecting deposition of inhaled particles  
Over the past decades inhalation therapy has established itself as a valuable tool in the 
local therapy of pulmonary diseases, such as asthma or chronic obstructive pulmonary 
diseases (COPD). When an aerosolized drug product is orally inhaled, there are many 
factors that may influence the effectiveness of the drug deposition in the lung including 
respiratory tract anatomy, particle size and the type of the inhaler. [7]. To investigate the 
performance of theophylline as inhaled drug all these factors will be discussed. 
 
2.5.1. Anatomy of the respiratory tract 
The anatomy of the respiratory tract and the individual differences have an important 
effect on the particle deposition within lungs [163]. The respiratory tract represents a 
unique organ system in the body; its structure allows air to come into close contact with 
the blood. This fact makes the respiratory tract a useful route of administration of the 
drugs in the inhaled or aerosol form.  The respiratory tract consists of branching airways 
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that progressively decrease in diameter but increase in number and in total surface area 
(Figure 2.15). Because, their overall shape looks like a tree, the airways are often 
described as the pulmonary tree. The tree trunk is related to the trachea of the airways 
that divided into the two main bronchi. These are subdivided to form smaller bronchi 
that enter the left and right lobes of the lung. The bronchi undergo additional division to 
form the bronchioles. This process continues through the terminal bronchioles, the 
respiratory bronchioles, alveolar ducts and ends with the alveolar sacs [164].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 15.  Anatomy of the respiratory tract (adapted from 
                      http://webschoolsolutions.com/patts/systems/lungs.htm)  
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The most widely used morphological model for the description of the airways structures, 
was primarily introduced by Weibl [165]. The model proposed the existence of 24 
airway generations in total, with the trachea being generation 0 and the alveolar sacs 
being generation 23 (Table 2.4). The summed cross sectional area from the mouth to the 
alveolar sacs rapidly increases and results in trumpet shaped lung model, with a total 
absorptive surface area of up to 100 m
2
 [164].  
The first region in the respiratory tract includes nose, mouth, and the pharynx. The main 
function of this region is heating and moistening air as well as acting as a filter. The 
various levels of the airways may be categorized functionally as being either conducting 
or respiratory airways. Those airways, which are not involved in gas exchange, 
constitute the conducting zone of the airway and extend from the trachea to the terminal 
bronchioles, while, the respiratory zone includes airways involved in gas exchange and 
consists of respiratory bronchioles, alveolar ducts, and alveolar sacs.  
The luminal surface of the airways is lined with a continuous sheet of the epithelial cells. 
This surface is exposed to the inhaled substances such as gases, particulates or aerosols. 
It has an important function of limiting access of inhaled substances to the internal 
environment of the body (subepithelial structure).  The epithelial cells are separated 
from smooth muscle cells by lamina propria, a region of connective tissues containing 
nerves and blood vessels. The cilia on the surface of epithelia out side the alveolar 
region and the presence of mucus influence the efficient drug delivery via the lung. 
Contraction or relaxation of the smooth muscles has a direct effect on the airway 
branches and also on the airflow in the respiratory tract. Therefore, for efficient 
deposition and absorption of the inhaled drugs, it is essential to consider firstly the 
anatomy and air velocities within the respiratory tract [7, 164].  
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Table 2. 4. A schematic model of the airways branching according to Weibel [165] 
 
2.5.2. Particle size 
The most important physicochemical determinant for the deposition of aerosols in the 
lung is the particle size, which is generally characterized by aerodynamic diameter. The 
aerodynamic diameter is the most relevant to the lung delivery and ultimately to the 
therapeutic effect [112]. Since it relates to the particle dynamic behaviour and describes 
the main mechanisms of aerosol deposition (inertial impaction and sedimentation). The 
aerodynamic diameter is defined as the diameter of a unit density sphere having the 
same settling velocity (generally in air) as the particle regardless of the shape and 
density [7]. This is then generally referred to as the mass median aerodynamic diameter 
(MMAD). The MMAD is the particle diameter that has 50 % of the aerosol mass 
residing above and 50 % below it. While, the geometric standard deviation (GSD) is a 
measure of the variation of the particles diameters within the aerosol [7, 166].  
To reach the peripheral airways where the drug is most efficiently absorbed particles 
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need to be in the 2-5 m aerodynamic range. Larger particles deposit in the oral cavity 
or pharynx producing no therapeutic effects. Particles smaller than 2 m are thought to 
be exhaled or deposited in alveolar region [111]. The amount of an aerosol contained in 
particles having an aerodynamic diameter approximately within 2-5 m, is generally 
referred to the fine particle dose (FPD) [7]. This parameter is expressed with respect to 
the emitted or nominal dose and is defined as fine particle fraction (FPF). 
 
2.5.3. Mechanisms of deposition of aerosol particles 
After inhalation, particles have the potential to be deposited at different regions in the 
respiratory tract depending on their size and velocity. Different physical mechanisms 
drive the inhaled particles and move them in the airflow to the respiratory tract walls 
[167, 168]. These mechanisms are; inertial impaction, sedimentation, diffusion, 
interception, and electrostatic (Figure 2.16). 
 
 
 
 
 
 
 
Figure 2. 16. Schematic diagrams of the three main mechanisms of aerosol particle 
                     deposition (adapted from http://ocw.jhsph.edu/imageLibrary/index) 
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2.5.3.1. Inertial impaction 
Inertial impaction is an important mechanism of deposition of fast travelling large 
particles [169]. Inertial impaction is caused by the affinity of the particles and droplets 
to move in a straight direction instead of following the gas streamlines. Impaction may 
thus take place against the airways walls and is usually occurring within the first 
generation of the lung where the air velocity is high. The air flow velocity in the main 
bronchi is estimated to be 100 fold higher than in the terminal bronchioles, and 1000 
fold higher than in the alveolar region. Inertial impaction is dependent on the mass, and 
velocity of the inhaled particles, therefore the greater the particle mass and velocity, and 
the higher the chances of hitting the airways walls. Particles above 5 m are deposited 
in the oropharynx by this mechanism. After impaction in the oropharengeal region large 
particles are subsequently swallowed and may produce some systematic effects, while, 
particles less than 5 m will be carried by the air streams into deeper airways [168-170].  
  
2.5.3.2. Sedimentation 
Sedimentation is the main method of deposition of smaller particles (2- 5 m). It tends 
to occur in the small airways and alveoli, where air velocity is negligible [169]. At this 
point the particles traveling in the air streams tend to settle out under the force of gravity. 
To enhance this settling it is important that there is a breath-hold during each inhalation. 
Therefore, the rate of settling is not only proportional to the density and size of the 
inhaled particles but on the time spend in the airways [7, 169]. 
 
2.5.3.3. Diffusion  
When the particles become sufficiently small, deposition by diffusion becomes a 
significant mechanism. It results from the constant random collision of gas molecules 
with the particles, thus pushing them in an irregular fashion called Brownian motion 
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leading to deposition of the submicron molecules in the airways walls. In contrast to 
impaction and sedimentation, diffusional deposition increases with decreasing the size 
of particles regardless the particle density.  It is similar to sedimentation in that it occurs 
in the smaller airways and is enhanced by breath holding after inhalation [170]. 
 
2.5.3.4. Interception 
Unlike inertial impaction, interception occurs when particles impact on the airway 
surface because of their size rather than their inertia. The deposition occurs when the 
centre of gravity of the particle is within the streamlines of the gas phase but a distal end 
of the particle is already touching a solid or liquid surface. It is an important mechanism 
for deposition of elongated particles in lower airways [168].  
 
2.5.3.5. Electrostatic precipitation 
In the initial stages of generation of the aerosols significant electrostatic charges may be 
produced on the particles. The charged particles can induce an opposite charge on the 
walls of the airways leading to electrostatic attraction between them and so deposition 
occurs. There is no strong evidence that such a mechanism can led to major increases in 
the deposition of aerosols in human respiratory tract [170, 171]. 
 
2.5.4. Methods used for assessing the drug deposition 
Both in-vitro and in-vivo methods have been used to study the deposition of inhaled 
drugs within the lung. In-vivo studies reflect the real situation and are subjected to more 
intra- and inter-subject variations than in-vitro studies but they are more expensive and 
time consuming compared with in-vitro methods. 
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2.5.4.1. In-vitro methods 
 
A variety of analytical techniques have been used for in-vitro evaluation of the 
performance of inhaled formulations. They can test the dose uniformity, the emitted 
dose, and the particle size distribution. The in-vitro methods give an estimation of the 
in-vivo deposition. One of the most widely used techniques is the inertial impaction 
method. Different apparatus can be used all of them mimic the anatomy of the 
respiratory tract to give predictions of lung deposition. On the other hand, microscopic 
and laser diffraction techniques have been also used [7].     
 
2.5.4.1.1. Inertial Impaction 
 
Inertial impaction methods have been widely used for determination of the aerodynamic 
characteristics of the emitted dose from aerosols [172-174] many years ago. The 
original devices were designed to test the atmospheric air for pollutants, followed by 
their use in pharmaceutical applications [175, 176]. The applications of these methods 
for the assessment of the medical aerosols have been widely reviewed, showing 
different types of the impactors and their abilities or drawbacks in the determination of 
the performance of different inhaler devices [177].  The inertial impactors used mimic 
the dimensions of the airways and are based on the aerodynamic behaviour of the 
aerosol particles (Figure 2.17). The cascade impactor consists of several stages each 
with collecting plates. The air stream directs the inhaled particles towards the surface of 
the collection plates for that particulate stage. At each stage the airflow turns rapidly to 
run parallel to the collection plates. Particles in the air stream with high inertial mass 
will not be retained in the airflow and will be deposited on the plates, while the smaller 
particles with inadequate inertia will be held in the air-stream to the next stage where 
the process is repeated. The stages of the impactor are fixed in a stack, in order of 
decreasing particle size. As the air stream becomes smaller the air velocity increases and 
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finer particles are collected. Any remaining particles in the air stream after the final 
collector plate will be collected on a filter [178]. Finally, the amount of the deposited 
particles on each plate is determined by different analytical methods, mainly HPLC, 
after recovering of the drug particles using a suitable solvent.  Then all the aerodynamic 
features of the aerosol including FPD, FPF, MMAD, and GSD can be calculated. 
 
 
 
 
 
 
 
Figure 2. 17. Schematic representation of the principle of operation of cascade   
                      impactors  [178]. 
 
The United States (USP) and European (EP) Pharmacopoeia, list no less than five 
different cascade impactors/ impingers suitable for the aerodynamic assessment of fine 
particles. Selection of a certain impactor will mainly depend on the product to be tested, 
the data that is required, the geographical location where the product is to be marketed. 
The EP [173] specifies four impactors for the aerodynamic assessment of fine particles 
in both dry powder inhalers (DPI) and metered dose inhalers (MDIs) which are; single-
stage glass impinger (SSGI), multi-stage liquid impinger (MSLI), Andersen cascade 
impactor (ACI), and next generation impactor (NGI).  
 
The USP [174] specifies six impactors suitable for aerodynamic size distribution; ACI 
(with and without preseparator), Marple Miller impactor (MMI), MSLI and NGI (with 
or without separator). Nowadays, a discussion has taken place to harmonize the 
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different systems with DPI‟s and MDI‟s and only three impactors appear in the Ph.Eur., 
and USP which are; MSLI, ACI, and NGI. 
 
(1) Glass impinger 
The glass impinger (GI) comprises of a jet or nozzle plate containing one or more 
circular or slot-shaped orifices placed a fixed distances from a flat collection surface 
that is usually horizontal (Figure 2.18). Its usage is restricted to the assessment of MDIs 
and DPIs at airflow of 60  5 L min-1. It is based on the principle of liquid impingement 
to divide the emitted dose from the inhaler into respirable dose and non-respirable 
portion. At the beginning the impinger chambers are filled with specified amounts of 
solvent, and then at the end of the test, the drug collected in the lower chamber can be 
assayed and expressed as a respirable fraction (or percentage) of the delivered dose. As 
the GI uses only two stages, it is not possible to determine the MMAD of particles 
under testing. At a flow rate of 60 L min
-1
, the mean aerodynamic particle cut-off size of 
the lower stage is 6.4 m [173, 178]. 
 
 
 
 
 
 
                                        
                                      Figure 2. 18. Single stage impinger [178]. 
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(2) Multistage Liquid Impinger   
The Multi-Stage Liquid Impinger (MSLI) consists of a metal throat, five impaction 
stages, and final filter.  It is suitable for use within the airflow range 30 - 100 L min
-1
. 
Its collection stages are kept moist, which helps to reduce the problem of re-entrainment 
of powder. At a flow rate of 60 L min
-1
, the cut-off diameters of stages 1, 2, 3 and 4 are 
13, 6.8, 3.1 and 1.7 m respectively [173, 174, 178], while stage 5 is a filter, for 
collection of the smaller particles (Figure 2.19). 
 
 
 
 
 
 
 
                                              
                                Figure 2.19. Multistage Liquid impinger [178] 
 
 
(3) Andersen Cascade Impactor (ACI)  
It consists of a stack of eight plates, each containing a series of precision drilled holes, 
and a final filter stage [173, 174]. The diameter of the holes decreases progressively for 
each succeeding stage; therefore the jet velocity increases as the particles travel through 
the impactor. When sampling particles larger than 10 m, a preseparator is used to 
prevent the particle bouncing and re-entrainment errors. The eight stages correspond 
approximately to the various parts of the human respiratory system (Figure 2.20).  
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Figure 2.20. Diagram shows the ACI stages corresponding to the human respiratory 
                     system [178]. 
 
The standard ACI is designed for use at 28.3 L min
-1
. However, it is important to 
consider the change in effective cut-diameter (ECD) that will occur for each stage upon 
changing the airflow over the range of 28.3 - 100 L min
-1 
using Van Oort equation 
[179];  
ECD
*
 = ECD

(28.3/Q)
 0.5 
where; ECD
*
 is the stage ECD at sampling flow rate Q (L min
-1
) 
            ECD

 is the stage ECD at sampling flow rate 28.3 L min
-1 
When operated at 60 L/min stages 0 and 7 are removed and replaced with two 
additional stages, -0 and -1. Similarly, at 90 L min
-1
, stages 0, 6 and 7 are removed and 
replaced with three additional stages, -0, -1 and –2 [178].  
By determination of the amount of the drug deposited on the collection plates, it is 
possible to calculate FPD, FPF and all other aerodynamic features of the studied aerosol.  
Many studies have been carried out to evaluate cascade impactors [180, 181]. It was 
found that FPD recovery was lower when using a glass and metal impinger as compared 
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to values from the MSLI or ACI. It has also been reported that large differences in 
results between different ACIs, could result in variability in size distribution 
measurements. Therefore the same impactor should be used throughout a study [182]. 
 
(5) Next Generation Impactor (NGI) 
The NGI is a high performance, precision, particle classifying, cascade impactor with 
friendly design for the ease testing of MDIs, DPIs and similar devices. The NGI has 
seven stages plus a Micro-Orifice Collector (MOC) that eliminates the need for a final 
paper filter (Figure 2.21). At an airflow of 60 L min
-1
, the cut-off points for stages range 
from 8.06-0.34 m. The airflow passes through the impactor in a saw-tooth pattern. 
Particle separation and sizing is achieved by successively increasing the velocity of the 
air stream as it passes through each stage by directing it through a series of nozzles 
containing reducing jet sizes [173, 174, 178]. The NGI has several features to enhance 
its utility for inhaler testing including [178]; 
 Particles deposited on collection cups, which are held in a tray from the impactor as a 
single unit, facilitating quick turn around times if multiple trays are used. 
 The user can add up to 40 ml of any appropriate solvent directly to the cups for more 
efficient drug recovery.  
 MOC can capture very fine particles normally collected on the final filter. 
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                     Figure 2.21. Next Generation Impactor [178]. 
 
There are however, in general number problems associated with the impaction 
techniques. These include;  
1- Loss of the sample via impaction to the walls of the stages but this problem is 
reduced with modern impactors [183]. 
2- Re-entrainment errors can occur when the plates are overloaded with the sample 
upon using large doses. 
3- Particle bouncing, although this can be alleviated by using glass filters instead of the 
metal plates, spraying the collecting plates with a small amount of silicone oil, or 
dipping the plates in oil that has been diluted with a solvent [184]. 
4- Data from impaction techniques do not give an actual prediction for the in-vivo 
deposition. This may be attributed to the highly complex anatomy of the respiratory 
tract along with the effects of temperature, humidity, and pathological changes. 
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2.5.4.1.2. Microscopy techniques 
(1) Optical microscope 
Microscopy is an important tool for particle sizing using manual, semi-manual 
technique or automatic techniques. It is versatile, user-friendly, and relatively 
inexpensive. The microscope usually consists of an eyepiece, objective, stage, 
condenser and a telescoping drawtube for adjusting of the distance of the eyepiece to the 
objective and provides a direct examination of the particles usually by means of a linear 
scale or globe-and circle graticules. The inability to provide a sharp image of two 
objects located at different distances and the appearance of point objects as fuzzy discs 
surrounded by diffraction rings at high magnifications are considered as the main 
limitations of the optical microscope [185, 186]. 
 
(2) Scanning electron microscope (SEM) 
This was discussed in detail in section 2.4.2.1. 
 
 
(3) Image analysis 
This technique includes taking digital images of particle samples, converting them to 
binary data, designating the key dimension, and deriving particle-size data. Image 
analysis has the potential to account for the particles shape, though the images are only 
2-dimensional representations of three dimension particles. Another limitation of this 
approach is low capacity, since individual particles are imaged so a long time may be 
required. The image analysis technique is illustrated schematically in Figure 2.22 [185, 
186].  
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  Figure 2.22. Schematic diagram represents the digital image analysis [185].  
 
2.5.4.1.3. Laser diffraction technique 
This method is considered as one of the most important, and reproducible, techniques 
used for the particle size determination [185].  The technique is based on the fact that 
the particles passing through a laser beam will scatter light at an angle that is directly 
related to their size (Figure 2.23). As particle size decreases, the observed scattering 
angle increases logarithmically. In laser diffraction, particle size distributions are 
calculated by comparing a sample‟s scattering pattern with a suitable optical model, 
which assumes that the particles being measured are spherical [185]. However, laser 
diffraction has some practical limitations such as measurements with non-spherical 
particles which tend to be oversized and have exaggerated size distribution due to 
deviation from the spherical models used in the data processing. In addition, a poor 
particle size distribution may be observed for dry powders with agglomerated particles 
[185, 186].  
 
 
 
 
 
Figure 2.23. Schematic diagram represents particle sizing via laser diffraction [185].  
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2.5.4.2. In-vivo methods  
2.5.4.2.1. Pharmacokinetic methods 
 
Many pharmacokinetic methods have been developed to identify the amount of the drug 
delivered to the lungs following an inhalation. The pharmacokinetic evaluation can be 
done by a variety of direct approaches, including the determination of drug levels in the 
lung itself. Such studies have been performed in lung cancer patients who inhaled the 
drug before resectomy of sections of the lung. Determination of drug levels in a variety 
of patients at different time points enables the assessment of pulmonary kinetics. Such 
studies, however, show high variability and can be affected by pathological changes in 
the lungs of the cancer patients [187]. Other approaches determined the pulmonary fate 
of drugs by analyzing drug concentrations in the bronchopulmonary lavage fluid, 
however this methodology has not been frequently used as it is tedious, and difficult to 
standardize. Alternative methods such as the use of microdialysis offers a 
complementary procedure to these methods [186].  
The more established way of assessing the fate of a drug after inhalation has been 
achieved by standard pharmacokinetic approaches using plasma–concentration time 
profiles. It was reported [188, 189] that following inhalation up to 20 % of the dose is 
delivered to the lungs whilst the majority is swallowed. The proportion of the dose 
delivered to the lungs, will be cleared either by the mucociliary clearance or by 
absorption through the airway wall into the systemic circulation (Figure 2.24). The 
plasma concentration–time profiles obtained after drug inhalation might therefore 
include contributions from both pulmonary and gastrointestinal absorption and thus 
provide valuable data which predict the extra-pulmonary side effects [188]. To identify 
the effective lung dose, methods which differentiate between drug delivered to the 
systemic circulation via the oral and inhaled routes, are needed particularly for the drugs 
with high oral bioavailability.  
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The oral charcoal block technique or sampling during the lag time of the absorption 
phase has been used for this purpose [188, 189]. These approaches are not necessary for 
the drugs with poor oral absorption (e.g. sodium cromoglycate) or when the first pass 
effect is substantial (e.g. fluticasone) because the drugs can only enter the circulation 
via the lungs [186, 189]. The total systemic delivery can also be assessed using urinary 
excretion, especially if the molecules are polar and basic. Both physicochemical 
properties prevent the passive tubular reabsorption within the kidney so the urine pH 
does not have to be controlled [188]. 
 
 
Figure 2. 24. Diagram represents the pharmacokinetic fate of a drug following 
                          inhalation [189]. 
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(1) The charcoal block technique 
In order to recognize the lung deposition of an inhaled drug accurately, the 
gastrointestinal absorption of the orally swallowed fraction of the inhaled product can 
be blocked by giving the patient concomitant doses of charcoal to adsorb this drug 
fraction. In this technique, the mouth is thoroughly rinsed with charcoal slurry, which is 
swallowed immediately before drug inhalation. Charcoal administration is repeated 5 
min, 1h and 2h after drug inhalation [190]. Great care must be taken to ensure that for a 
given drug under the specific conditions of the clinical trial, a complete block of the oral 
absorption is actually observed. This approach has been used for determination of 
different drugs such as budesonide [190] and other glucocorticoids. Urinary excretion of 
drug following the oral administration of charcoal has also been reported to identify the 
total effective lung dose [191].  
 
(B) Utilizing the absorption lag times 
 It is an important method that can be also used to determine the pulmonary absorption 
of inhaled drugs [192, 193]. For example, after oral administration of salbutamol, the 
maximum urinary excretion rate is reached after 2 h; by contrast, for a lung-deposited 
drug, the maximum rate is reached after 30 min. Therefore, urine sampling up to 30 min 
after inhalation of salbutamol gives an indication of the fraction of the dose deposited in 
lung and can therefore be used to assess the pulmonary absorption of the drug. However, 
these methods are less reliable because variability in absorption rates will significantly 
affect the results [194]. The oral charcoal block technique or sampling during the lag 
time of the absorption phase are considered as a guide for determination of the relative 
amount of the inhaled dose, which has the potential to produce a clinical effect within 
the airways. Therefore, these approaches are useful to investigate the concordance 
between two inhaled products or differences between inhalation techniques.  
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2.5.4.2.2. Imaging techniques to assess pulmonary drug deposition 
(1) Gamma scintigraphy 
This method is a helpful technique in determining drug pulmonary deposition. It was 
first used during diagnostic testing and then extended to pharmaceuticals in the 1970s. 
Originally, radio-labeled Teflon particles [195] were used. Recently, versions of this 
techniques have been developed to attach the gamma emitting radionuclide 
99m
Tc (99 m 
technetium) to either a component of the formulation or the drug molecule [196]. 
Immediately following inhalation of the radiolabeled aerosol, images of the lung are 
recorded by a gamma camera. These images provide an immediate idea of where the 
drug is deposited, depending on the fact that the radioactive label follows the drug with 
high reliability. However conventional planar gamma cameras can only produce a two-
dimensional pictures and it cannot differentiate between the conducting airways and 
alveolated parts of the lung or between certain overlying structures. Three-dimensional 
imaging methods (SPECT and PET) have recently been introduced which overcome all 
these problems [195, 196]. 
 
(2) Single photon-emission computed tomography (SPECT) and positron-emission 
tomography (PET) 
SPECT and PET have been used to examine the fate of inhaled drugs [197-199]. An 
advantage of these methods is that they can be used to construct three-dimensional 
images. Compared with planar gamma scintigraphy, these techniques allow the 
determination of the pulmonary deposition with a higher degree of resolution and 
differentiate between the central and peripheral lung deposition as well as the 
pulmonary and gastrointestinal deposition. On the other hand, PET permits the drug to 
be labeled itself without changing its chemical structure and in that way it can overcome 
some of the drawbacks of scintigraphy. The positron emitters used in PET include 
11
C, 
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13
N, 
15
O and 
19
F. This technique has recently been used to study the deposition of 
fluticasone [200]. The main disadvantages of this method are that the positron emitters 
used so far have short half-lives and the method is very expensive. 
 
2.6. Inhaler devices 
Since 1930 various types of inhaler devices have been used to deliver the medical 
aerosol particles in the required size range for lung deposition. Three basic types of 
commercial drug delivery systems are available. These are nebulizers, pressurized 
metered dose inhalers (p-MDIs), and dry powder inhalers (DPI). p-MDIs are the most 
frequently used as they have demonstrated value in therapy. In Europe, especially 
Scandinavian countries DPIs, are frequently prescribed [7]. 
 
2.6.1. Nebulizers 
Nebulizers have been used in inhalation therapy since early 20
th
 century [201]. 
Nebulizers are used for both drug solutions and suspensions. They are commonly used 
for the treatment of hospitalized or disabled patients as well as for children and infants 
[202]. In a few cases, nebulizers may be used for local drug delivery to the trachea [202]. 
There are two general types of nebulizers available.  
 
(1) Ultrasonic nebulizer  
Ultrasound waves are produced in an ultrasonic nebulizer chamber by a ceramic 
piezoelectronic crystal that vibrates when electrically excited. These set up high-energy 
waves in the solution within the device chamber of precise frequency leading to creation 
of an aerosol cloud at the solution surface [7]. 
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(2) Air-jet nebulizer  
In this nebulizer the compressed air is forced through an orifice, and an area of low 
pressure is formed where the air-jet exits. A liquid is withdrawn from the perpendicular 
nozzle (the Berboulli effect) to mix with the air-jet to form droplets (Figure 2.25). Only 
the smallest droplets in the desired range are able to follow the streamlines of air and 
pass the baffle, which facilitates the formation of the aerosol cloud. Larger droplets 
impact on the baffle and return to the liquid reservoir [7, 202].  
The main disadvantages of nebulizers are their poor lung deposition, the long inhalation 
time, the high residual amount of the drug, and the need of a power supply. However 
recent generations of the nebulizers have improved technology and examples include 
the AeronebGO, e-flow, and Micro Air [7]. 
 
                 
 
                 
 
                
 
     
                
              Figure 2. 25. Schematic diagram of air jet nebulizer  
                                    (adapted from  www. img.medscape.com) 
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2.6.2. Pressurized metered dose inhalers 
Pressurized metered dose inhalers (p-MDIs) are based on a spray-can principle, such as 
used for hair sprays [7]. The p-MDI consists of four basic parts; container, metering 
valve, actuator, and mouthpiece (Figure 2.26). There are two types of p-MDI 
formulation; suspension and solution. The propellant used in p-MDI formulation has a 
dual function. Firstly, it works as a dispersion medium for the drug and the excipients. 
Secondly, it serves as an energy source to eject the formulation from the valve as 
droplets [7] which evaporates as soon as it leaves the device. One of the main 
disadvantages of the p-MDI is the required co-ordination of the dose release with the 
breath inspiration. This has been shown to be difficult with large numbers of asthmatic 
patients including children and elderly people [203] but the development of spacers 
makes the p-MDI easier to use [204], as they increase the amount of the drug available 
to the lung by decreasing the impaction of the drug with the oropharynx. There are still 
inherent problems in the basic design of a p-MDI involving propellant, surfactants, and 
lubricants used in the formulation. Some lubricants and surfactants can produce an 
irritant effect. Chlorofluorocarbons (CFC‟s) were the most commonly used propellant in 
p-MDI but their harmful effect became clear when the ozone hole was discovered over 
Antarctica. As a result CFC consumption was reduced and different p-MDIs have been 
redeveloped using alternative propellants based on hydrofluoroalkanes [205].  
 
Figure 2. 26. Pressurized metered dose inhaler (adapted from 
http://www.asthma.ca/adults/treatment/meteredDoseInhaler) 
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2.6.3. Dry powder inhalers 
The main alternative to the p-MDI is the breath-actuated dry powder inhaler (DPI). 
DPIs are typically designed to produce a metered quantity of powder in a stream of air 
drawn through a device by the patient own inspiration. The DPI was first introduced in 
1939, in a US patent by Stuart [206], who gave a  description of what is called the first 
DPI. The patent describes a device, which had been designed to aid the inhalation of 
aluminum dust for the chelation of inhaled silica. However, the device was never 
commercialized. In 1949 a patent by Fields, described the first DPI for the 
administration of pharmaceuticals, the so-called Aerohaler. It was the first commercially 
available DPI for the delivery of isoprenaline sulphate [206]. There was then 
considerable interest in these devices especially when the harmful effects of CFC, as 
propellant in p-MDI on the environment were observed. However, although these 
devices do overcome the need for coordination of actuation and inspiration because they 
are breath actuated, this operation is also considered one of their disadvantages. They 
are classified into two types; single dose devices (e.g Spinhaler, Rotahaler) and 
multidose DPI. Multidose DPI are divided into two different types of designs; the 
reservoir systems (Turbohaler
®
, Ultrahaler
®
, Clickhaler
®
, Easyhaler
®
) and the multiple 
unit-dose inhalers (Diskhaler
®
, Diskus
®
) (Table 2.5) [207, 208].  
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                 Table 2. 5. Dry powder inhalers currently available in the market 
Device Company (Country) 
 
Single dose factory-metered 
 
Spinhaler
®  
Rotahaler
®
  
Cyclohaler  
Aerolizer  
Aerohaler 
 
 
Fisons (UK) 
GlaxoWellcome (UK) 
Pharmachemie (NDL) 
Novartis (Switzerland) 
Boehringer-Ingelheim (Germany) 
 
Multidose factory-metered 
 
Diskhaler
®
  
Diskus
®
  
 
 
GlaxoWellcome (UK) 
GlaxoWellcome, (UK) 
 
Multidose patient/device-metered 
 
Turbohaler  
Ultrahaler
®  
Clickhaler
®
  
Easyhaler
®
  
Pulvinal  
 
 
AstraZeneca (Sweden) 
Rhone-Poulenc Rorer (France) 
ML Laboratries (UK)  
Orion Pharma (Finland) 
Chiesi (Italy) 
 
2.6.3.1. Single dose inhalers 
The concept of the first single-dose DPI, the Spinhaler
® 
(Fisons, Loughborough, UK) 
was described in early 1970s by Bell et al [209]. This device was developed for the 
administration of powdered sodium cromoglycate, which is used as a topical, non-
steroid preventer for allergic asthma. A mixture of the drug and a bulk carrier is pre-
filled into a hard gelatine capsule and then loaded into the device. Following activation, 
where the capsule is pierced, the patient inhales the dose by the inspired air (Figure 
2.27).  
 
 
 
 
 
      Figure 2. 27. Diagram represents Spinhaler
®
 (Fisons, Loughborough, UK) 
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This device was suitable in the treatment of children and elderly patients, as it avoided 
the problems of coordination by utilizing the patient‟s inspiratory flow for the energy 
required to dispense the particles from a pierced capsule [207, 208] 
The preference of using single dose DPI was expanded with the introduction of devices 
that were easier to manipulate such as the Rotahaler
®
 (GlaxoWellcome, Ware, UK) 
[210]. The Rotahaler
®
 has been developed for the delivery of salbutamol, and 
beclomethasone dipropionate powders. Here, the drug mixture is again filled into a hard 
gelatin capsule and the capsule is inserted into the device where it is broken open and 
the powder inhaled through a screened tube [211]. Over the last few years several new 
single-dose DPIs have been developed having similar designs such as; Foradil Aerolizer 
(Novartis/Schering-Plough) and Spiriva HandiHaler (Boehringer Ingelheim/Pfizer).The 
main disadvantage of single dose DPIs is the difficulty of loading the capsule, 
especially for elderly patients and those undergoing an asthma attack who require 
immediate delivery of the drug this led to the innovation of multidose DPIs [212].  
 
2.6.3.2. Multidose inhalers 
The development of multidose DPIs has been pioneered by Darco in 1988 who 
produced the Turbuhaler
®
 (Astrazeneca, Lund, Sweden) [213] which was really the first 
true metered-dose drug powder delivery system. This inhaler includes up to 200 doses 
in the drug powder reservoir, which can be dispensed in the dosing chamber by a simple 
back-and- forth twisting on the base unit. The Turbuhaler
®
 has been used to deliver 
carrier free particles of the - agonist, terbutaline sulphate as well as the steroid 
budesonide [214]. The main drawbacks for the Turbuhaler
®
, is its variable delivery at 
different flow rates and its high internal resistance. The optimum aerosol dispersion 
threshold for the Turbohaler
®
 occurs at a peak inhalation flow rate of at least 60 L min
-1
 
[211]. Studies have shown that young children and patients with COPD [215, 216] have 
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problems  in achieving the minimum required inhalation rate through a Turbohaler
®
. It 
has been reported that newer multiple dose reservoir devices such as the Easyhaler
®
 
(Orion Pharma, Kuopio, Finland) demonstrate a more consistent and flow rate-
independent delivery system than the Turbohaler
®
 when tested in-vitro [217, 218].  
 
Easyhaler
®
 (Orion Pharma, Kuopio, Finland) is a multiple dose reservoir DPI. It was 
designed to deliver at least 200 preloaded doses of sulbutamol or beclomethasone 
dipropionate. Shaking aids a dose (drug and carrier) being deposited from the powder 
reservoir to the dosing cup. The device actuation rotates the filled dosing cup into the 
inhalation channels where turbulent airflow breaks the drug mixture up into a fine 
particle dose, which is then deposited into the patients lung during the inhalation 
(Figure 2.28). A dose counting mechanism is provided by the dose counter which 
allows patients to see if they have loaded a dose and prevent double dosing or the use of 
empty device [215].  
 
 
 
 
 
 
         
 
          Figure 2. 28. Easyhaler
®
 (Orion Pharma, Kuopio, Finland) [215] 
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The Easyhaler
® 
more closely demonstrates the characteristics of an ideal inhaler than its 
competitors [215] whilst being available at a price comparable to that of a p-MDI. 
Consistency in the fine particle dose of the Easyhaler
®
 is the main clinical advantage 
compared with its competitors. Studies have shown superior consistency both versus 
other inhalers and within a random sample of the Easyhaler
® 
[217, 218]. This device 
also performs consistently irrespective of inspiration rate, which is in contrast to flow 
rate-dependent inhalers [215]. Therefore, patients can receive the same dose every time 
they used their Easyhaler
®
, providing the ability to prescribe salbutamol, beclometasone 
and, more recently, budesonide in a DPI to children and COPD patients with low 
inspiration rates. A study of 120 children using the Easyhaler
®
 measured the peak 
inspiratory flow. Only four achieved  28 L min-1, but even in patients with these low 
flow rates, use of the Easyhaler
®
 provided the required clinical response [219]. 
Equivalent therapeutic responses have been shown in various studies following the use 
of the Easyhaler
®
 versus p-MDI, or other DPIs in the market [220, 221]. 
Pharmacological equivalence to the Turbuhaler
®
 shows the possibility for changing to 
the Easyhaler
® 
[215, 222]. Furthermore, a meta-analysis of the opinions of asthmatic 
patients about different inhaler devices showed the Easyhaler
®
 to be the preferred 
device when compared with pMDI or other DPIs [215].  
 On the other hand the multiple unit-dose inhaler was first developed by 
GlaxoWellcome which introduced Diskhaler
®
 [207, 208]. It has been used for the 
delivery of both the short acting -agonist sulbutamol, as well as the long acting 
salmeterol. In addition, the steroids, beclomethasone dipropionate and fluticasone 
propionate are also available in disks. This device has a circular disk that contains a 
number of powder charges (four or eight) depending on a typical dosing schedule. The 
doses are stored in separate aluminium blister reservoirs, thus ensuring the integrity of 
the powder blend to be protected from moisture attack. On priming the device, the 
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aluminium blister is pierced and the powder charge is dropped into the dosing chamber. 
One of the advantages of the Diskhaler
®
 is the ability to see the remaining doses 
through a window on the surface. However, this device has a limited commercial 
success [207, 208] mainly because it held only a few doses per disk and also the loading 
difficulty. Further improvements in patient convenience and the ease of use were 
included into the next generation of a factory-metered doses inhaler, called the Diskus
®
 
(GlaxoWellcome, UK) in the mid-1990s. It represents a further development of the 
Diskhaler
® 
approach, with pre-metered doses sealed in blisters on a foil strip. The use of 
coiled strip rather than a disk, allows 60 doses of medication to be contained within the 
device [207, 208]. Metered dose inhalers produce high quality, and consistent dosing 
performance as well as efficient protection for the drug powder from moisture, but they 
are more expensive to the manufacturer [212, 213]. Generally multidoses reservoir 
devices are becoming more common because they have simple design, which are also 
cheaper to produce than multiple unit-dose inhalers. However some of them may show 
dose variability because of inconsistent powder dispensing or reduced moisture 
protection of the drug powder [223]. Therefore, accurate dose metering for this type of 
inhaler requires careful manipulation of the device by the patient [207].        
DPIs are generally described as breath actuated devices use the inspiratory flow as the 
energy source for dispersion and delivery of the particles into the airflow. The DPIs 
currently available have different airflow resistances that govern the flow rates, which 
might be generated from them for a given level of inspiratory effort from a patient. This 
process follows an inverse relationship; the higher the resistance, the lower the flow rate, 
the higher the level of inspiratory efforts from the patient required to deliver the dose 
out of the device. This is considered the major disadvantage of DPIs especially for the 
treatment of patients with low inhalation flow rate [207, 223, 224]. The main 
advantages and disadvantages of DPIs are summarized in Table 2.6. 
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Table 2. 6. Advantages and disadvantages of DPIs versus p-MDIs [207]. 
Advantages of dry powder inhalers Disadvantages of dry powder inhalers 
Environmental sustainability propellant 
free design 
Efficient drug delivery dependent on the 
patient‟s inspiratory flow rate and the 
device resistance  
Little or no need for synchronising the 
dose release with the patient inspiration 
Potential for problems in dose consistency  
Less potential for formulation problems Development and manufacture processes 
are more complex and expensive  
Less problems associated with the drug 
stability 
The drug is not highly protected from the 
environmental effects such as moisture 
 
 
2.6.3.3. Carrier material 
 
DPIs are often composed of fine drug particles and inert coarse carrier particles. The 
carrier particles are often used to aid the mixing of the drug particles, enable filling of 
every small doses in capsules or blisters, improve powder flow and to facilitate drug 
dispersion during inhalation [225-227].  
The adhesion between carrier and drug must be sufficient for the blend drug/carrier to 
be stable, and the adhesive forces between drug and carrier particle have to be weak 
enough to enable the release of drug from carrier during patient inhalation [227]. Then, 
the drug particles will be able to reach the lungs. Interactions between particles are 
mainly dependent on their physicochemical characteristics such as particle size, shape, 
surface morphology, contact area, and the hygroscopicity [228, 229]. 
Therefore, any factor that affects drug-carrier interaction will have an impact effect on 
the delivery and deposition of the drug. For example, increasing the surface smoothness 
of the lactose carrier particles was shown to improve the potentially respirable fraction 
of salbutamol sulphate from the Rotahaler
®
 [225-227] and this was attributed to lowered 
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adhesion forces between the drug and carrier particles with a smooth surface.  
The shape of the carrier particles as well as the carrier surface smoothness have an 
important effect in determining the dispersion and deaggregation of the drug [227]. The 
effect of particle size of the carrier on drug deposition is also reported in different 
articles [230]. Fine particles of ternary components, such as magnesium stearate and L-
leucine, were found to improve drug delivery from DPIs by reducing inter-particulate 
forces between the drug and carrier particles. More recently, the addition of fine 
particles of carrier to dry powder formulation was also shown to enhance the dispersion 
and deposition of drug particles [227]. The finer particles tend to occupy the high 
energy binding sites on the coarse carrier material, leaving lower energy sites available 
for the drug. Therefore the best dry powder performance will be achieved when the 
formulation contain both coarse and fine carrier particles at optimal proportions [225-
227]. 
At present glucose and mainly lactose are the only carriers used in DPIs. The 
advantages of monohydrate lactose are its low toxicity, wide availability and its 
relatively low price. However its reducing sugar function; which prevents its use with 
certain drugs may be considered as its main disadvantage. Several studies on 
technological properties of dry powder inhalers provide alternatives to lactose such as 
mannitol [229].  
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Chapter 3 
Development and validation of HPLC 
method for the determination of theophylline 
and other related methylxanthines and 
methyluric acids in urine samples and 
aqueous solution 
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3.1. Introduction 
Methylxanthines such as theophylline (TP) and caffeine (CA) are commonly taken by 
patients  as over-the-counter drug mixtures for pain, cold and cough. In addition, they 
are found in many plant species and food products including coffee, tea, chocolate, cola 
drinks and many other beverages. As a drug TP is a bronchodilator used in the treatment 
of acute and chronic asthma with a narrow therapeutic range (10-20 g ml-1). Similarly 
CA is also used to alleviate neonatal apnoea to relieve bronchial spasm, and in the 
therapy of asthma. The analysis of these compounds in body fluids is therefore 
important for monitoring of asthma, or neonatal apnoea, in the non-invasive assessment 
of various isoforms of cytochrome P-450 (CYP) activity [80] and also to detect the drug 
abuse in athletics [231]. 
HPLC is the most popular technique used for the determination of these compounds in 
biological samples (Table 2.1). However, many of the HPLC methods for CA or TP and 
their metabolites show interference from caffeine metabolites and especially 
paraxanthine [78]. Therefore, the number of HPLC methods, which report the 
simultaneous determination of TP, and CA and their metabolites in one run is somewhat 
limited. Thus, in this study the goal was to develop a simple and fast method for 
efficient separation of theophylline and its related compounds, which allow 
straightforward quantitative analysis of these compounds in either urine matrix or 
aqueous solutions. Two methods, which are increasingly being explored to achieve 
separation and high resolution of drugs in a short experimental period; ultra-
performance liquid chromatography (UPLC
TM
) and HPLC using monolithic columns 
[51]. UPLC uses particle-packed columns with sub-2.0 m packing materials and 
pressures up to approximately 1400 bar.  However, in this process special high quality 
equipment is obligatory to meet these requirements [16]. Monolithic packed columns, 
on the other hand allow for flow rates up to 9.9 ml min
-1
 with backpressures lower than 
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400 bar. Therefore, monolithic columns can be used with conventional HPLC 
equipment [134] and can achieve a high-speed separation without loss of column 
efficiency [232]. The monolithic column consists of one piece of either an organic 
polymer or silica with a continuous homogenous phase instead of a packed bed with 
individual particles. The column has a total porosity of over 80 % v/v, fast mass transfer 
and low-pressure resistance which enables rapid separation [147]. Packed and 
monolithic silica columns have been compared in different applications, and the results 
indicated that the porous rod provides equivalent efficiency when compared to 
microparticulate columns but the monolith generally produces faster separation [157, 
160]. 
 
3.2. Materials and Methods 
3.2.1. Instruments  
3.2.1.1. High performance liquid chromatography 
(1) Pump and auto sampler 
 Chromatographic analyses were performed by using Hewlett Packard (HP) 1050 
system; with a multiple solvent delivery system containing an autosampler with a 
variable injection loop. 
 
(2) Detectors 
Variable wavelength UV-visible detector HP 1050 series has been used in the study. All 
connections from the autosampler to column and from the column to detector were 
made from stainless steel with 0.005 i.d.  All connection tubes were made as short as 
possible to minimize extra-column band broadening. All end fittings used were 
carefully chosen to give a zero dead volume.  
(3) Integrator 
Prime Multichannel Data Station (version 4.2.0) (HPLC Technonlgies, Herts, UK) 
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(4) HPLC columns and Guard columns 
 Two Monolithic columns RP-18e 100  4.6 mm (Merck, Darmstadt, Germany) from 
two different batches (Batch 1. OB452773, Batch 2. HX754226) were used. Columns 
specifications as supplied from the manufacturer were as follow; 
Macropore size                                 2 m 
Mesopore size                                  13 nm (130 Å) 
Pore volume                                     1 ml/g 
Surface area                                     300 m
2
/g                             
Surface modification C18                 endcapped 
 Six traditionally available particulate columns were used for the comparison with the 
monolithic column. The columns details; manufacturer, dimensions, the particle size 
and the pore sizes, are listed in Table 3.1. 
 Table 3. 1. Details of the HPLC columns used in the study 
Columns Company Dimensions 
(mm) 
Particle  
size (m) 
Pore  
size (Å) 
Symmetry-C18  Waters, Milford, USA 150  4.6 3.5 100 
Hypersil BDS-C18  Shandon Scientific, 
Cheshire, UK 
150  4.6 5 100 
ACE- C18  ACT, Aberdeen, UK 150  4.6 5 100 
Nucleosil-C18  Hichrom Ltd, 
Berkshire, UK 
150  4.6 3 150 
Nucleosil-C18  Hichrom Ltd, 
Berkshire, UK 
150  4.6 5 100 
Hichrom RPB-C18 Hichrom Ltd, 
Berkshire, UK 
150  4.6 5 150 
Zorbax Eclipse XDB-C8 Agilent Technologies, 
CA, USA 
150  4.6 5 80 
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The performance of a novel stationary phase platinum TM C18 3 m column 100  4.6 
mm (Grace
®
 Davison Discovery Sciences, Lokeren, Belgium) was tested and compared 
with the monolithic column. Two different columns were tested in this study; their 
serial numbers were; 608121210, and 608121211, respectively.  
 For the protection of the analytical columns during working with urine samples 
Phenomenex C18 (4  3 mm i.d.) security guard cartridge system (Phenomenex, 
Torrance, USA) was used.  
 
3.2.1.2. Solid phase extraction (SPE) 
(1) SPE Cartridges 
SPE octadecyl (C18) disposable extraction columns, 1 ml/100mg, (J.T. Baker Inc., 
Phillipsburg, USA). 
 
(2) SPE vacuum manifolds 
Vacmaster international sorbent technology, Ltd. 
Vac-Elut analytichem international (Harbour city, CA, USA) 
 
3.2.1.3. General Laboratory Instruments 
 Utrasonic bath (Decon laboratories, Hove, UK) 
 Syringe filters 0.2 m pore size (Scientific Resources Inc., NJ, USA) for filtration of 
the samples after solid phase extraction before injection in HPLC instruments 
 Nylaflo® nylon membrane filter, 47 mm, 0.45 m pore size (Pall Gelaman Sciences, 
Michigan, USA) for filtration of the mobile phase. 
 Metler Toledo (AL) analytical balance (Leicester, UK) 
 pH meter Accumet AB10 Basic (Fisher Scientific, Leicester, UK) 
  Nitrogen-drier (Fisher Scientific, Leicester, UK) 
 ELGA ultra-pure water dispensing system (High Wycombe, UK) 
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3.2.2. Materials 
3.2.2.1. Analytes 
 Basic and acidic test compounds were used for the initial studies of the performance 
of monolithic column in comparison with different traditional packed columns. 
Analytical grades of all the studied drugs were purchased from Sigma-Aldrich Inc. (St. 
Louis, MO, USA). Structures and   pKa values of each solute are listed in Figure 3.1. 
Figure 3. 1 Structures and (pKa) of the studied acidic and basic drugs. 
 
 
 Methylxanthines, methyluric acids, and the internal standard; 8-chlorotheophylline 
used in this study were obtained from Sigma-Aldrich Inc. (St. Louis, MO, USA).  
Figure 3.2 shows the chemical structure and abbreviations of all the tested 
methylxanthines and their metabolites.  
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 Figure 3. 2. Chemical structures and abbreviations of the studied methylxanthines and 
methyluric acids. 
 
 
3.2.2.2. Pharmaceutical formulations 
 Nulein® SA tablets (3M Health Care Limited, Loughborough, England) labelled to 
contain 175 mg of theophylline BP / tablet. 
 Uniphyllin® prolonged release tablets (Napp Pharmaceuticals Ltd, Cambridge, UK) 
labelled to contain 200 mg of theophylline / tablet. 
  Methylxanthines 
 
 
 
 
 
R1 R2 R3  
CH3 H H 1-Methylxanthine (1-MX) 
H CH3 H 3-Methylxanthine (3-MX) 
CH3 CH3 H 1,3-Dimethylxanthine (Theophylline;TP) 
CH3 H CH3 1,7-Dimethylxanthine (Paraxanthine; PA) 
H CH3 CH3 3,7-Dimethylxanthine (Theobromine;TB) 
CH3 CH3 CH3 1,3,7-Trimethylxanthine (Caffeine; CA) 
Methyluric acids 
 
 
 
 
 
R1 R2 R3  
CH3 CH3 H 1,3-Dimethyluric acid (1,3-DMU) 
CH3 H CH3 1,7-Dimethyluric acid (1,7-DMU) 
CH3 CH3 CH3 1,3,7-Trimethyluric acid (1,3,7-TMU) 
 
  
Chapter 3                                                 Development and validation of HPLC method  
 84 
 Slo-Phyllin® capsules (Merck Sante s.a.s., Lyon, France) labelled to contain 60 mg of 
theophylline anhydrous / capsule. 
 
3.2.2.3. HPLC mobile phase 
 HPLC-grade acetonitrile, and methanol (Fisher Scientific, Loughborough, UK).  
 Spectrophotometric grade trifluroacetic acid (TFA) (Alderich Chemical Co. Inc., 
Steinheim, Germany). 
 Potassium dihydrogen phosphate ASC reagent  99% (Sigma-Aldrich, Inc.)  
 Ortho-phosphoric acid and sodium hydroxide (BDH, Poole, UK) 
 Analar grade sodium acetate anhydrous (BDH)  
 
 
3.2.3. Methods 
3.2.3.1 Preparation of buffer solutions 
An accurately weighed amount of the desired buffer salt was transferred into a 
volumetric flask, and then dissolved in about 60 % v/v of double distilled water before 
being made up to the exact volume. The pH of the buffer was then adjusted using 
appropriate acid or alkali. The buffer solution was then filtered through a 0.45m 
membrane filter. The pH meter was calibrated using commercially available buffers.  
 
3.2.3.2 Preparation of mobile phase 
In order to minimize the volume error that may occurs upon the addition of the organic 
solvents to aqueous solutions, they were measured separately and then mixed together. 
The mobile phase was then filtered through a 0.45m membrane filter and degassed 
using ultrasonic bath under vacuum for 10 min.  
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3.2.3.3. Preparation of the aqueous standard solution of acidic and basic drugs 
The standard stock solution of each test compound was dissolved in a methanol: water 
mixture (70: 30 v/v) at concentration 1.0 mg ml
-1
. A mixture solution contain 100 g 
ml
-1
 of each drug was prepared from the stock solution with further dilutions by the 
mobile phase.  
 
3.2.3.4. HPLC analysis of the acidic and basic mixtures 
The HPLC methods for the separation of acidic and basic test mixtures used in the 
initial study were based on those published by Wang et al [147, 233]. However, the 
mobile phase compositions were modified to adapt the studied tested compounds. The 
following are the optimized HPLC conditions used for separation of the acidic and basic 
compounds. 
 
(1) Optimized HPLC conditions for separation of acidic compounds 
Stationary Phase: Monolithic and all packed columns mentioned in Table 3.1. as 
well as the platinum column were tested 
Mobile phase: Acetonitrile: 0.1% Trifluroacetic acid (TFA) (35: 65  % v/v) 
Flow rate: 1 ml min
-1
 
Temperature: Room temperature 
Injection volume: 20 l 
UV- Detection: 220 nm 
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(2) Optimized HPLC conditions for separation of basic compounds 
Stationary Phase: Monolithic and all packed columns mentioned in Table 3.1. as 
well as the platinum column were tested 
Mobile phase:  Methanol: 25mM potassium dihydrogen phosphate buffer (pH 6) 
(80: 20 % v/v) 
Flow rate: 1 ml min
-1
 
Temperature: Room temperature 
Injection volume: 20 l 
UV- Detection: 220 nm 
 
 
3.2.3.5. Preparation of the stock solution of the internal standard 
The stock solution of the internal standard (IS); 8-chlorotheophylline was prepared at 
concentration of 1mg ml
-1
. Working standard solutions were prepared by further 
dilutions with the mobile phase or urine matrix. 
 
3.2.3.6. Collection of urine samples 
Blank urine samples were obtained from 5 healthy volunteers after 5-days on 
methylxanthines-free diets. All samples were pooled, frozen and stored at -20C until 
analysis. Standard freeze/thaw procedures were carried out.  
 
3.2.3.7. Preparation of standard solutions of methylxanthines and methyluric acids 
An accurately weighed amount of each drug was dissolved in appropriate volume of 
methanol: water (30:70 % v/v) mixture, to provide a stock solution containing 1.0 mg 
ml
-1
. Few drops of sodium hydroxide (1M) were added to some solutions for complete 
solubilization. From this stock solution, working standards were prepared by serial 
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dilutions using either the mobile phase or urine matrix. Aqueous stock and working 
solutions were stored in the fridge at temperature below 4C in well-closed containers. 
While the spiked urine samples were stored below –20 ºC in well-closed, light resistant 
containers prior to analysis.  
 
3.2.3.8. Preparation of sample solutions of theophylline formulations 
For Nulein
®
, or Uniphyllin
®
, twenty tablets were accurately weighed, finely powdered 
and mixed thoroughly. While, for Slo-Phyllin
®
 the contents of twenty capsules of were 
carefully evacuated, collected, mixed, and then accurately weighed. An accurately 
weighed quantity of the powder equivalent to the weight of one tablet or one capsule 
was dissolved in 100 ml of methanol/water (30:70 % v/v) mixture, shaken well for 5 
min, sonicated for 5 min and finally filtered using qualitative filter papers (Whatman 
International Ltd). The obtained filtrate was then used as a stock sample solution and 
further dilutions were made using the mobile phase. 
 
3.2.3.9. Solid phase extraction 
(1) Pre-treatment of the spiked urine samples 
Before treatment, spiked urine samples were filtered through 0.45 m nylon filters 
(Millipore-Whatman Ltd, Kent UK). The filtered urine samples (2 ml) were then 
acidified to pH 4 by the addition of 0.5 ml of 10 mM sodium acetate buffer.  
 
(2) Conditioning of the SPE cartridge 
Octadecyl (C18) disposable SPE cartridges with 1.0 ml reservoir (J.T. Baker) were 
conditioned with methanol (2 x 1 ml), and then water (2 x 1 ml).  
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(3) Separation of a mixture of methylxanthines and their metabolites from the   
       urine matrix 
The urine samples (2.5 ml) containing a fixed concentration of the I.S. (30 g ml-1), and 
varying concentrations of the methylxanthines and methyluric acids were loaded onto a 
RP-C18 SPE cartridge. The samples were then extracted at a flow rate of approximately 
1-1.2 ml min
-1
. The interferences of the urine matrix were removed by washing the 
cartridge with water (2 x 1 ml) after applying the sample. The SPE cartridge was then 
dried at full vacuum pressure for 5 min to remove any residual amount of water. The 
compounds of interest were then eluted by; chloroform: methanol mixture (80:20 % v/v) 
(5 x 0.5 ml). The eluate was collected and dried under a stream of nitrogen at 40C for 7 
min, and then the residue reconstituted with the mobile phase (2.5 ml). 
 
3.2.3.10. Optimized HPLC conditions used for the analysis of methylxanthines and 
methyluric acids mixture in urine matrix and for theophylline in aqueous solutions  
Stationary Phase Monolithic column RP-18e 100  4.6 mm 
Mobile phase Methanol: 10 mM KH2PO4 (pH 4) (12.5: 87.5 % v/v) 
Flow rate 1 ml min
-1
 
Temperature Room temperature 
Injection volume 20 l 
UV- Detection 274 nm 
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3.2.3.11. Validation of the developed HPLC method for the determination of 
methylxanthines and their metabolites in urine samples 
(1) Linearity, detection, and quantitation limits 
Six calibration standard solutions were prepared covering the desired concentration 
range (0.03-40 g ml-1) for 3-MX, 1-MX, TB, TP &CA, and (0.05- 40 g ml-1) for 1,3-
DMU, 1,7-DMU, PA and 1,3,7-TMU. The standards were prepared using pooled urine 
samples. All working standard solutions contained 30 g ml-1of 8-chlorotheophylline as 
internal standard. The samples were then extracted and analysed by the developed 
HPLC method.  
Calibration curves were constructed as peak area ratios (compound/internal standard) 
versus the standard concentrations and the linear relationship was determined.  
The regression analysis of the results was calculated according to the following linear 
regression equation [234];                       y = bc + a 
Where, y: peak area ratios, a: intercept, b: slope, and c:  drug concentration in g ml-1. 
The limit of detection LOD and quantitation LOQ were calculated for all of the cited 
drugs using the following equations [234];     LOD = (3.3)/S       LOQ = (10)/S  
where  = S.D. of y-intercept           S = the slope of the calibration curves 
  
(2) Recovery 
The recovery of the studied methylxanthines and their metabolites was investigated 
using urine samples spiked with three known concentrations of each drug corresponding 
to low (5 g ml-1), medium (15 g ml-1) and high (30 g ml-1) levels in the calibration 
curve. The analytical recovery was assessed (n= 6) by comparing the peak areas of the 
studied compounds after extraction from urine and those obtained from direct injections 
of equivalent quantities of pure standards.  
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(3) Precision and accuracy 
Method validation regarding intra-day precision was achieved by replicate analysis (n= 
6) of extracted urine samples spiked with standard solutions at low (5 g ml-1), medium 
(15 g ml-1) and high (30 g ml-1) levels in the calibration curve. The inter-day 
precision was conducted during routine operation of the system, over a period of five 
consecutive working days. The overall precision of the method was expressed as 
relative standard deviations (RSD). The accuracy was determined by comparing the 
calculated concentration of the extracted compounds with their true (actual) 
concentrations.  
 
(4) Batch-to-Batch reproducibility on monolithic column packing 
The reproducibility of the developed method was investigated by comparing the 
chromatographic data acquired upon working with two-monolith columns from two 
different batches (Batch 1: No. OB452773, Batch 2: No. HX754226).  
In addition, as a comparison; our newly developed and validated method was examined 
alongside other C18 packings for the separation time and efficiency required for 
resolving the compounds of interest.  
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3.2.3.12. Validation of the developed HPLC for the quantitation of theophylline in 
aqueous solutions 
The developed HPLC method was also validated for the analysis of theophylline in 
aqueous solutions; to allow the analysis of its formulations and the in-vitro 
determination of the aerodynamic behaviour of inhaled theophylline (Chapter 5).  
 
(1) Linearity, detection, and quantitation limits 
Six consecutive concentrations of the standard solution 20, 50, 80, 100, 150, and 200 g 
ml
-1
 of theophylline were prepared, by further dilutions of suitable aliquots from the 
stock solution (1 mg ml
-1
) with the mobile phase. All working standard solutions 
contained 30 g ml-1 of 8-chlorotheophylline as internal standard. Calibration curves 
were constructed as peak area ratios (compound/internal standard) versus the 
theophylline concentrations and the linear relationship was determined. The limit of 
detection LOD and quantitation LOQ were calculated.  
 
(2) Recovery 
Recovery of theophylline from its formulations (tablets or capsules) were assessed (n= 6) 
at three concentration levels (50, 100, 150 g ml-1) by comparing the peak area after 
extraction from the pharmaceutical formulations (as described in 3.2.3.8.) and that 
obtained from direct injection of equivalent quantities of pure standard.  
 
(3) Precision and accuracy 
Intra-day precision was determined by replicate analysis (n= 6) of standard solutions at 
low, medium, and high concentration levels (50, 100, 150 g ml-1). The inter-day 
precision was conducted by repeating the analysis over a period of five consecutive 
working days. The overall precision of the method was expressed as relative standard 
deviations (RSD) and the accuracy was expressed as percent to the true value.  
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3.3. Results and Discussions 
3.3.1. Optimization of HPLC method for the analysis of the mixture of 
methylxanthines and their metabolites 
For method development, optimization of the different key factors governing the 
separation to obtain the highest quality data is required. The main analytical parameters 
that required to be optimized are the stationary phase, mobile phase composition 
(organic modifier, buffer, and pH). As a starting point the procedures reported by 
Rasmussen and Brosen [71] was investigated. The chromatographic conditions in this 
article was; ODS column, 5 m, 250  4.66 mm, mobile phase consisted of methanol: 
10mM acetate buffer (pH 4) (7:93 % v/v), flow rate; 1 ml min
-1
 and UV detection at 274 
nm. These conditions were used with the monolithic column, but unresolved peaks with 
poor shape were obtained.  Therefore further trials were done for optimisation of the 
chromatographic conditions required for efficient separation of the studied compounds.  
 
3.3.1.1. Stationary phase 
3.3.1.1.1. Performance comparison between monolithic and traditional C18 columns 
for the separation of acidic and basic test mixtures 
In the initial study it was considered important to study and understand the performance 
of the monolithic column in comparison with conventional packed columns using acidic 
and basic test mixtures. The HPLC procedures was based on those reported by Wang et 
al [147, 233] as a starting point and then the mobile phase composition was modified to 
adapt the selected mixtures. The final optimised HPLC procedure for separation of the 
acidic mixture containing 100 g ml-1 of each drug was; acetonitrile: 0.1 % TFA (35: 
65 % v/v), flow rate; 1 ml min
-1
, injection volume; 20 l, and UV detection at 220nm.  
Figure 3.3 represents the separation of the acidic mixture on monolithic and other tested 
packed columns.  
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Figure 3.3. Chromatograms of the acidic compounds on monolithic (Batch1) and 
traditionally packed columns with optimal conditions: acetonitrile: 0.1 % 
TFA (35: 65 % v/v), flow rate; 1 ml min
-1
, Injection volume; 20 l, and UV 
detection at 220nm. (1) 4-Hydroxybenzoic acid, (2) Coumaric acid, (3) 
Acetylsalicylic acid, (4) Benzoic acid, (5) 2-chloro-4-nitrobenzoic acid. 
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While the final optimised procedures for determination of basic mixture containing 100 
g ml-1 of each drug was; methanol: 25mM KH2PO4 (pH 6) (80:20 %v/v), flow rate; 1 
ml min
-1
, injection volume; 20 l, and UV detection at 220 nm. Figure 3.4 shows the 
separation of the basic compounds on the tested columns under the optimised conditions.  
 
Figure 3.4. Chromatograms of the basic compounds on monolithic (Batch1) and 
traditionally packed columns with optimal conditions: Methanol: 25mM 
KH2PO4 (pH 6) (80:20 % v/v), flow rate; 1 ml min
-1
, Injection volume; 20 
l, and UV detection at 220nm. (1) Uracil, (2) Caffeine, (3) Propranolol, 
(4) Lidocaine, (5) Desipramine.   
 
Chapter 3                                                 Development and validation of HPLC method  
 95 
The performance of the test columns for acidic and basic mixtures was also evaluated 
and compared using different chromatographic parameters (Tables 3.2 and 3.3). These 
chromatographic parameters include [157, 235];  
 The capacity factor (K) which gives a measure of the retention time independent on 
the flow rate and column dimension.          K= (tR-tM)/tM 
   tM= unretained peak‟s retention time                tR= retention time of the peak of interest  
 Number of theoretical plates (N) is a measure of the efficiency or resolving power of a 
column.                                        N=5.54 (tR/w0.5)
 2
 
   tR= retention time of the peak of interest        w0.5= the peak width at half peak height 
 Peak resolution (Rs), is a measure of the separation between two peaks as well as the 
column efficiency. It is expressed as the distance between two maxima to the mean of 
the peaks width at base.                 RS= 2[(tR)B- (tR)A] /[wA+ wB]  
 Tailing factor (T 0.05) is a measure of the peak symmetry.  
T0.05= w0.05/2f 
   w0.05 = width at 5% of the peak height              f = distance between maximum and the 
leading edge of the peak  
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  Table 3. 2. Performances of monolithic and traditional packed columns for separation of the acidic mixture 
   K; capacity factor,     N; number of theoretical plates       Rs; peak resolution             T0.05; tailing factor at 5% of the peak height  
   N.B. absence of data (-) indicates that insufficient resolution was observed 
 
Analytes 
Monolith Symmetry Hypersil ACE 
K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 K N 
10-3 
Rs T0.05 K N 
103 
Rs T0.05 
4-hydroxy benzoic acid  
 
1.33 5.45 - 1.44 1.85 5.36 - 1.58 1.81 5.56 - 1.59 2.10 8.66 - 1.37 
Coumaric acid 
 
1.54 6.98 1.80 1.50 2.35 7.72 3.24 1.47 2.15 7.14 2.26 1.50 2.59 10.02 3.57 1.19 
Acetylsalicylic acid 
 
2.07 6.76 3.88 1.51 3.69 13.16 8.43 1.28 2.99 9.10 5.30 1.52 3.79 10.67 7.26 1.17 
Benzoic acid 
 
2.37 7.39 1.92 1.35 4.38 13.06 3.92 1.30 3.42 8.63 2.39 1.40 4.39 13.02 3.23 1.10 
2-chloro-4-nitrobenzoic 
acid 
3.58 7.96 6.72 1.38 7.76 13.86 13.9 1.27 5.18 10.43 8.17 1.31 7.04 14.51 11.6 1.10 
 
Analytes 
Nucleosil-3µm Nucleosil -5µm Hichrome Zorbax C8 
K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 K N 
10-3 
Rs T0.05 K N 
103 
Rs T0.05 
4-hydroxy benzoic acid 
 
2.44 10.52 - 1.34 2.35 7.09 - 1.00 1.45 0.46 - - 1.73 8.57 - 1.28 
Coumaric acid 
 
3.20 14.65 5.58 1.41 2.97 9.44 3.82 0.97 - - 0.92 - 2.15 7.32 3.18 1.31 
Acetylsalysylic acid 
 
4.36 17.10 7.64 1.20 3.77 9.19 4.45 0.88 2.13 0.97  - 3.13 10.93 6.74 1.19 
Benzoic acid 
 
5.12 15.34 4.21 1.18 4.34 9.34 2.69 0.85 - -  - 3.63 10.39 2.91 1.14 
2-chloro-4-nitrobenzoic 
acid 
8.15 13.97 11.9 1.11 6.51 9.58 8.23 0.83 2.53 -  - 5.61 11.58 9.28 1.07 
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                      Table 3. 3. Performances of monolithic and traditional packed columns for separation of the basic mixture 
 
Analytes 
Monolith Symmetry Hypersil ACE 
K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 
Uracil 
 
1.01 1.47 - 1.44 1.08 4.62 - - 1.38 - - - 1.31 3.50 - - 
Caffeine 
 
1.15 4.73 1.42 1.34 1.33 3.36 1.09 0.92 1.57 - - - 1.53 5.90 1.51 1.18 
Propranolol 
 
2.09 1.45 5.23 2.18 2.69 1.40 3.93 - 1.92 - - - 2.17 2.75 3.42 2.23 
Lidocaine 
 
2.46 11.12 3.41 1.24 3.66 3.88 1.35 - 3.13 0.69 - 1.76 3.28 7.53 1.29 0.64 
Desipramine 
 
4.32 8.39 1.89 2.14 4.54 0.55 3.31 4.87 5.38 0.27 2.07 1.74 2.88 1.34 2.15 - 
 
Analytes 
Nucleosil-3µm Nucleosil -5µm Hichrome Zorbax C8 
K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 
Uracil 
 
1.43 2.18 - 1.52 1.56 1.40 - 0.98 1.45 0.45 - - 1.07 1.71 - - 
Caffeine 
 
1.94 6.89 2.29 1.51 2.03 5.36 2.16 1.05 - - 0.92 - 1.26 6.39 1.17 1.02 
Propranolol 
 
6.09 1.01 3.93 3.78 5.78 1.77 5.26 2.33 2.13 0.97  - 1.99 2.58 4.21 2.25 
Lidocaine 
 
3.93 8.69 11.2 1.50 3.51 6.84 7.73 1.01 - -  - 2.56 8.73 2.95 - 
Desipramine 
 
17.1 4.59 5.16 - 13.3 0.66 5.26 2.94 2.53 -  - 2.75 3.57 0.94 - 
          K; capacity factor,             N; number of theoretical plates       Rs; peak resolution             T0.05; tailing factor at 5% of the peak height 
          N.B. absence of data (-) indicates that insufficient resolution was observed 
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From the abovementioned results the following points could be concluded: 
 All the tested columns (except Hichrome) were able to resolve the acidic and basic 
mixtures with variable resolution, peak symmetry, total analysis time and column 
back- pressure.   
 The total run times of the acidic mixture on Symmetry, Hypersil, ACE, Nucleosil 
3 m, Nucleosil 5 m, Hichrome, and Zorbax C8 were 6.57, 4.64, 6.03, 6.86, 5.63, 
2.54, and 4.96 min respectively.  For the monolithic column the total analytical 
runs took only 3.44 min, which is shorter than all the test columns except 
Hichrome, which did not resolve the mixture under the same conditions.   
 For the basic mixture; the total run times on Symmetry, Hypersil, ACE, Nucleosil 
3 m, Nucleosil 5 m, Hichrome, and Zorbax C8 were 4.16, 3.50, 3.21, 13.60, 
10.74, 4.79, and 2.81 min respectively. The monolithic column took 3.99 min to 
separate the mixture, which is shorter than the investigated columns with the 
exception of the ACE and Zorbax C8 columns, which show poor resolution 
between uracil / caffeine, and lidocaine / desipramine peaks. 
 Thus we can conclude that the main advantage of the monolithic column is the 
reduction of the run time while the separation efficiency is less affected compared 
to the particulate columns.  
 Furthermore, the monolithic column enables the performance of the analytical run 
under back-pressure of only about 60 bar, which was much lower than that 
produced by conventional columns (150-180 bar). This is attributed to that the fact 
that the monolithic support has a total porosity of over 80 %, which permits fast 
mass transfer and low-pressure resistance. Decreasing the backpressure extends 
the lifetime of the analytical column and also the HPLC instrument.  
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3.3.1.1. 2. Performance comparison between platinum and monolithic columns for 
the separation of acidic and basic test mixtures 
To complete the overview on the monolithic columns, its performance was compared 
with platinum column, which was considered as a novel stationary phase. This phase 
has hydrophobic and polar selectivity providing a dual mode separation medium with 
both polar and non-polar sites. The acidic and basic test mixtures mentioned in section 
3.2.2.1 were used. The optimal chromatographic conditions for separation of these 
mixtures were mentioned in section 3.2.3.4.    
(1) Columns selectivity 
Figures 3.5 shows the acidic and basic test compounds separated on monolith and 
platinum columns at the optimised conditions using flow rate of 1 ml min
-1
.  
Figure 3. 5.  Chromatograms represent separation of the acidic and basic compounds 
on monolithic and platinum columns. The acidic compounds are; (1) 4-
Hydroxybenzoic acid, (2) Coumaric acid, (3) Acetylsalicylic acid, (4) 
Benzoic acid, (5) 2-chloro-4-nitrobenzoic acid. The basic compounds are; 
(1) Uracil, (2) Caffeine, (3) Propranolol, (4) Lidocaine, (5) Desipramine.   
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From this chromatogram it can be noted that both columns were able to separate all 
compounds in both mixtures with sufficient resolution under the same chromatographic 
conditions. However, the total run times for the acidic and basic mixture using the 
monolith were 3.44, and 4.16 min., respectively, and for the platinum were 4.51, and 
10.76 min., respectively. The equivalent selectivity allows for easy transfer of existing 
methods from platinum to monolith in order to reduce the analysis time. 
 
(2) Comparison between the different chromatographic data obtained from the 
monolithic and platinum columns  
The following operating parameters for the monolithic column were compared to those 
of the platinum column for both test mixtures (Table 3.4) [157, 235]; 
 The capacity factor (K), which gives an indication of how long each component, is 
retained on the column, number of theoretical plates (N) that measures the sharpness of 
the peak and therefore the efficiency of the column. The plate height (H) another 
parameter can be used to determine the column efficiency H=L /N 
   L= Length of the column                                     N= number of theoretical plates 
They also include peak resolution (Rs), that a measure of the separation between two 
peaks in addition to the efficiency of the column, and the tailing factor (T 0.05) which a 
measure of the peak symmetry.  
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 Table 3. 4. Performances of monolithic and platinum columns for separation of acidic    
and basic test mixtures 
 
From the results presented in Table 3.4, it was observed that the total run time for the 
monolith column is shorter than that of the platinum column. The efficiency of the 
monolith with respect to the number of theoretical plates is higher than the platinum 
column for the entire acidic and basic compounds. On the other hand, the peak 
symmetry for the acidic compounds when using platinum column is better than 
monolith, which is the reverse of the results from the basic compounds separation.  
 
(3) The effect of the flow rate on the column efficiency 
The influence of the mobile phase flow rate on the performance of the monolith and 
platinum columns for the separation of acidic and basic compounds was investigated. 
The flow rate for both columns was varied in the range 0.5-2 ml min
-1
. The Van 
Deemter plots (H versus flow rate) of the tested columns for the acidic and basic 
mixtures are shown in are shown in Figures 3.6 and 3.7, respectively. These plots show 
the effect of the flow rate on the columns efficiency for separation of both mixtures.    
 
Acidic mixture 
Monolith Platinum C18 
K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 
4-hydroxy benzoic 
acid 
1.33 5.45 - 1.44 1.35 5.09 - 1.28 
Coumaric acid 1.54 6.98 1.80 1.50 1.74 5.35 3.31 1.18 
Acetyl-salicylic 
acid 
2.07 6.76 3.88 1.51 2.43 6.67 3.86 1.11 
Benzoic acid 2.37 7.39 1.92 1.35 2.78 7.08 2.13 1.06 
2-chloro-4-
nitrobenzoic acid 
3.58 7.96 6.72 1.38 4.83 7.83 8.49 1.08 
Basic mixture K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 
Uracil 1.01 1.47 - 1.44 0.61 1.39 - 1.55 
Caffeine 1.15 4.73 1.42 1.34 0.84 3.94 1.76 1.54 
Propranolol 2.09 1.45 5.23 2.18 3.78 1.39 5.23 3.57 
Lidocaine 2.46 11.1 3.41 1.24 1.89 5.41 7.89 1.46 
Desipramine 4.32 0.84 1.89 2.14 13.2 0.69 5.43 4.94 
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Figure 3. 6. Van Deemter plot of the height equivalent to a theoretical plate versus flow 
rate for monolithic (A) and platinum (B) columns for separation of acidic 
mixture. Chromatographic conditions: mobile phase was; acetonitrile: 
0.1 % TFA (35: 65 % v/v), flow rate; 1 ml min
-1
, Injection volume; 20 l, 
and UV detection at 220nm.  
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Figure 3. 7. Van Deemter plot of the height equivalent to a theoretical plate versus flow 
rate for monolithic (A) and platinum (B) columns for separation of basic 
mixture. Chromatographic conditions: mobile phase; methanol: 25mM 
KH2PO4 (pH 6) (80:20 % v/v), flow rate; 1 ml min
-1
, Injection volume; 20 
l, and UV detection at 220nm. (1) Uracil, (2) Caffeine, (3) Propranolol, 
(4) Lidocaine, (5) Desipramine.   
  
 
As can be seen, at higher flow rates there was slow loss in the resolution efficiency for 
the acidic mixture. But for the basic mixture the separation efficiency of both of them 
does not significantly decrease when the flow rate is increased. Although the efficiency 
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of the platinum column is not significantly affected by increasing the flow rate, the 
backpressure increases significantly. Therefore, the monolithic column is more 
convenient as it allows performing an analytical run under lower backpressure with a 
shorter analysis time. This is mainly due to the high porosity of the monolithic 
compared to particulate columns. Figure 3.8 illustrates the backpressure required to 
achieve a flow rate in the range 0.5-2 ml min
-1
 through monolith against particulate 
backed platinum column. It was observed that at a flow rate of 2 ml min
-1 
the 
backpressure on the monolith was of only 65-74 bar while, on the platinum column 
packed with 3m particles reached 175-220 bar. On the other hand, at a flow rate 1 ml 
min
-1
, which is the commonly used flow in the HPLC methods, the backpressure is 
about 3-folds smaller on the monolithic than on the platinum column.  
Figure 3. 8. Column backpressure as a function of the flow rate on monolithic and 
platinum columns.  
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(4) Precision and reproducibility of chromatographic data obtained from 
monolithic and platinum columns 
The intra-day and inter-day precision for the chromatographic data acquired from two 
different batches of monolith and platinum columns were determined by repeating six 
consecutive runs of the test mixture on each column within one and five working days, 
respectively. The RSDs of the retention time, resolution factor and the tailing factor 
obtained with the monolithic column varies between 0.04 - 2.47 % for both the acidic 
and basic compounds (Table 3.5). On the other hand, the precision values obtained from 
the platinum column, which ranged from 0.16 to 4.83 % for both mixtures (Table 3.6). 
This demonstrates the good precision of the chromatographic data obtained from the 
monolith which is possibly due to the better peak shape and reduced baseline noise that 
can lead to more precise integration [16]. Batch-to-Batch reproducibility is presented by 
the RSD of six injections on the two batches. The RSDs for all compounds in both 
monolithic batches were  2.50 %, while with platinum column they ranged from 0.97 
to 4.47 %. A high level of batch to batch reproducibility achieved on the monolith is in 
agreement with earlier reports [236], while poor reproducibility was observed with the 
platinum columns. 
As a conclusion, on comparison with both traditional packed and newly introduced C18 
columns, the monolith provides two important features required for method 
development; short analysis time with low backpressure. Therefore, the monolithic 
column was selected for analysis of the methylxanthines and their metabolites in urine 
samples as well as the determination of theophylline in aqueous solutions. 
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Table 3. 5. Precision and reproducibility of the chromatographic data obtained from separation of acidic and basic mixture on two different 
batches of monolithic column. 
 
 
 
Analytes 
 
 
 
RSD of the chromatographic data (n=6)  
Intra-day precision Inter-day precision Batch-to- Batch 
reproducibility 
 
Batch 1   
(OB452773) 
 
Batch 2 
(HX754226) 
 
Batch 1   
(OB452773) 
 
Batch 2 
(HX754226) 
 
tR
 
 
 
 
T0.05
 
 
 
RS
 
 
 
 
 
tR
 
 
 
 
T0.05
 
 
 
RS
 
 
 
 
 
tR
 
 
 
 
T0.05
 
 
 
RS
 
 
 
 
 
tR
 
 
 
 
T0.05
 
 
 
RS
 
 
 
 
 
tR
 
 
 
 
T0.05
 
 
 
RS
 
 
 
 
Acidic mixture                
4-hydroxy- benzoic acid 0.04 1.90 - 0.18 1.34 - 0.05 1.21 - 0.26 0.35 - 0.06 2.01 - 
Coumaric acid 0.17 1.79 1.61 0.22 1.47 1.32 0.32 1.54 1.23 1.29 2.04 2.15 0.15 1.58 1.33 
Acetyl-salicylic acid 0.12 2.18 2.14 0.23 2.31 2.05 0.11 2.01 1.33 1.69 0.66 0.75 0.54 1.64 2.31 
Benzoic acid 0.11 2.31 2.40 0.19 2.17 1.18 0.65 1.71 2.13 2.10 1.82 0.57 0.36 1.87 2.14 
2-chloro-4-nitrobenzoic acid 0.09 2.33 1.72 0.23 1.54 1.47 0.05 1.39 1.87 2.35 1.78 2.08 1.02 2.36 2.47 
Basic mixture                
Uracil 0.17 1.91 - 0.35 1.25 - 0.06 1.58 - 0.54 1.47 - 0.16 1.57 2.14 
Caffeine 0.65 2.33 1.24 0.05 1.47 2.25 0.08 1.54 2.47 0.37 1.23 2.47 0.03 1.87 2.36 
Propranolol 1.81 2.14 1.58 0.08 1.88 2.36 0.54 1.29 2.36 0.14 1.54 2.14 0.05 1.65 2.25 
Lidocaine 0.53 2.01 2.36 0.14 1.54 2.34 0.25 1.36 2.14 0.06 2.18 2.01 1.28 2.14 2.17 
Desipramine 0.69 1.58 2.41 0.87 2.25 2.01 0.36 2.36 2.25 0.14 2.04 1.98 0.87 2.43 1.65 
  
 
Chapter 3                                                                                                                                                      Development and validation of HPLC method 
 107 
Table 3. 6. Precision and reproducibility of the chromatographic data obtained from separation of acidic and basic mixture on two different    
                  batches  of platinum column.  
 
 
 
Analytes 
 
 
 
RSD of the chromatographic data (n=6)  
Intra-day precision Inter-day precision Batch-to- Batch 
reproducibility  
Batch 1   
(608121210) 
 
Batch 2 
(608121211) 
 
Batch 1 
(608121210) 
 
Batch 2 
(608121211) 
 
tR
 
 
 
 
T0.05
 
 
 
RS
 
 
 
 
 
tR
 
 
 
 
T0.05
 
 
 
RS
 
 
 
 
 
tR
 
 
 
 
T0.05
 
 
 
RS
 
 
 
 
 
tR
 
 
 
 
T0.05
 
 
 
RS
 
 
 
 
 
tR
 
 
 
 
T0.05
 
 
 
RS
 
 
 
 
Acidic mixture                
4-hydroxy- benzoic acid 0.35 4.91 - 0.98 4.83 - 2.03 1.89 - 2.03 1.54 - 0.97 4.23 - 
Coumaric acid 0.30 3.77 3.38 0.83 4.03 4.98 2.19 0.96 2.42 1.91 1.66 1.69 1.12 3.36 4.11 
Acetyl-salicylic acid 0.19 3.22 2.42 0.75 2.98 4.04 1.53 1.82 1.33 0.43 1.76 1.58 1.78 4.24 4.65 
Benzoic acid 0.16 4.29 3.33 0.68 2.64 4.14 1.60 1.48 1.62 0.46 2.39 1.98 1.68 4.11 3.95 
2-chloro-4-nitrobenzoic acid 0.24 2.21 1.73 0.62 0.96 1.17 1.43 1.45 0.31 1.37 1.37 0.22 2.46 4.11 4.25 
Basic mixture                
Uracil 0.61 4.73 - 1.54 1.60 - 0.33 4.03 - 2.22 1.97 - 1.30 3.99 - 
Caffeine 0.64 3.24 3.39 1.97 4.49 4.20 0.73 4.04 3.61 3.43 2.57 3.27 1.60 4.27 4.51 
Propranolol 0.58 4.74 4.75 1.28 3.62 3.22 2.26 2.82 4.83 1.78 1.68 0.78 2.81 3.15 4.47 
Lidocaine 0.95 2.31 2.33 0.49 2.41 1.31 2.07 3.51 4.14 1.29 4.36 3.98 2.70 3.20 1.95 
Desipramine 0.75 3.79 2.77 2.03 4.28 5.53 1.50 0.30 4.06 1.16 4.88 1.92 4.43 4.14 3.96 
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3.3.1.2. Mobile phase composition 
A number of variables relating to the mobile phase composition were studied such as 
buffer (type and concentration, pH) organic modifier (type and proportion).  
 
(1) Buffer (type, concentration) 
Acetate and phosphate buffers are commonly used in different reported articles for the 
determination of methylxanthines and methyluric acids. Therefore the effect of each of 
them as a constituent of the mobile phase on the elution of the studied compounds was 
investigated. Using 10 mM of acetate buffer (pH 4) as reported in Rasmussen and 
Brosen [71] was not ideal for efficient separation of the tested compounds on the 
monolithic column. It was observed that TB could not be separated from 1,3-DMU, and 
also the eluted peaks of PA, TP and 1,3,7TMU were not completely base line separated 
(Figure 3.9).  While, using of 10mM of phosphate buffer (pH 4) was found to show 
good separation between all the studied compounds. Therefore potassium dihydrogen 
phosphate (KH2PO4) buffer was chosen for method optimisation. 
   Figure 3.9. The effect of using acetate buffer in the mobile phase on the chromatographic 
behaviour of the studied methylxanthines and methyluric acids (20 g ml-1). (1) 
3-MX, (2) 1-MX, (3) 1,3-DMU, (4) TB, (5) 1,7-DMU, (6) PA, (7) TP, (8) 1,3,7-
TMU, (9) CA. Chromatographic conditions was; monolithic column (Batch1), 
methanol:  10 mM acetate buffer (pH 4) (12.5:87.5 % v/v), flow rate 1ml min
-1
, 
injection volume 20 l, and UV detection at 274 nm.  
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The effect of buffer concentration was studied by preparing phosphate buffer solutions 
on different molar concentrations; 10, 20, 50, 100 mM.  It was observed that changing 
the buffer concentration from 10-100 mM provides little effect on both the retention 
times and the peak resolution of the tested drug (Figure 3.10). Phosphate buffer with the 
concentration of 10 mM was chosen for further development, because this concentration 
is low enough to avoid problems associated with precipitation, when significant 
amounts of organic modifiers are used in the mobile phase. In the case of phosphate 
buffers particularly, the use of lower concentrations was advisable to minimize the 
abrasive effect on pump seals.  
Figure 3. 10. The effect of different buffer concentrations on the retention times (A) and 
peak resolution (B) of the studied methylxanthines and methyluric acids. 
Chromatographic conditions was; monolithic column (Batch1), methanol: 
KH2PO4 (pH 4) (12.5:87.5 % v/v), flow rate 1ml min
-1
, injection volume 
20 l, and UV detection at 274 nm. 
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(2) Effect of buffer pH 
The effect of pH of the selected phosphate buffer was studied, because the pH could 
alter the retention time, resolution or the shape of the eluted peaks. At pH values lower 
than 2.0 or higher than 7.5, dissolution of silica could occur and hence shorten the 
lifetime of the stationary phase. Therefore pH from 2.5-7 was tested using a phosphate 
buffer. Five separate buffered solutions were prepared and their pHs were adjusted to 
2.5, 4, 5, 6, and 7. The retention times of all the studied compounds were unaffected by 
pH changes from 4 to 6 but optimum peak resolution and shape were obtained at pH 4. 
At pH 2.5, 3-MX and 1-MX were not well resolved and this was the case with PA and 
TP, this was accompanied with increase in retention times as well as poor peak shape 
for all the compounds. While at pH 7, PA and TP are completely overlapped and a 
decrease in the retention times of all the compounds was also observed (Figures 3.11 
and 3.12). This may be attributed to that the drugs are considered as weak acids (except 
caffeine is weak base) and so their degree of ionization is increased at high pHs leading 
to decrease in the retention times [55, 237].  However, caffeine is less affected by 
changes in pH than other drugs studied that is in agreement with that reported in the 
literatures [238, 239]. Hence pH 4 was chosen as the optimal pH.  
 
 
 
 
 
 
 
Figure 3.11. The effect of mobile phase pH on the retention time of the studied 
methylxanthines and methyluric acids. Chromatographic conditions was; 
monolithic column (Batch1), methanol: 10 mM KH2PO4, flow rate 1ml 
min
-1
, injection volume 20 l, and UV detection at 274 nm.  
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Figure 3. 12. Chromatograms represent the effect of the pH of the mobile phase on the 
chromatographic behaviour of the studied methylxanthines and 
methyluric acids (20 g ml-1). (1) 3-MX, (2) 1-MX, (3) 1,3-DMU, (4) TB, 
(5) 1,7-DMU, (6) PA, (7) TP, (8) 1,3,7-TMU, (9) CA. Chromatographic 
conditions was; monolithic column (Batch1), methanol:  10 mM KH2PO4 
(12.5:87.5 % v/v), flow rate 1ml min
-1
, injection volume 20 l, and UV 
detection at 274 nm.  
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(3) Organic modifier (type and proportion) 
The retention time and peak resolution of the studied compounds were extensively 
affected by the type of organic modifier used. The effect of using acetonitrile, methanol 
or both of them as organic modifiers was investigated.  As shown in Figure 3.13 
acetonitrile has an accelerating effect on early eluted peaks and only four peaks could be 
recorded these are; PA, TP, 1,3,7-TMU, and CA. The same effect was also observed 
upon using acetonitrile /methanol mixture in different proportions. Therefore, methanol 
was selected as the ideal organic modifier in the studies. 
  
 
Figure 3. 13. The effect of acetoniltrile as an organic modifier, on the chromatographic 
behaviour of the studied methylxanthines and methyluric acids  (1) PA, (2) 
TP, (3) 1,3,7-TMU, (4) CA. Chromatographic conditions; monolithic 
column (Batch1), acetonitrile: 10 mM KH2PO4 (pH 4) (12.5:87.5 % v/v), 
flow rate 1ml min
-1
, injection volume 20 l, and UV detection at 274 nm.  
 
The effect of different proportions of methanol on the chromatographic behaviour of the 
eluted peaks was studied. Four different proportions of methanol in the mobile phase 
were tested; 10, 12.5, 15, 20 %v/v. It was observed that with reduced amounts of 
methanol in the mobile phase, the retention time of methylxanthines and their 
metabolites were extended. On the other hand, peak resolution was decreased for each 
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of the drugs studied except for PA and TP (Figure 3.14).  No sharp effect on peak 
resolution was observed when changing the methanol percentage in the mobile phase 
for PA and TP compared to other compounds. Since a reasonably long retention time is 
important to avoid the interference from urine matrix peaks, the proportion of 12.5 % 
v/v of methanol was selected. It provides both long retention time and sufficient 
resolution for the eluted peaks. As an alternative the proportion of 10 % v/v of methanol 
provides longer retention times than 12.5% v/v, but it was not selected because of the 
obtained poor peaks shape.  
 
Figure 3. 14. The effect of different proportions of methanol on the retention times (A) 
and peak resolution (B) of the studied methylxanthines and methyluric 
acids Chromatographic conditions; monolithic column (Batch1), 
methanol:  10 mM KH2PO4 (pH 4), flow rate 1ml min
-1
, injection volume 
20 l, and UV detection at 274 nm.  
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3.3.2. The optimized chromatographic conditions 
Stationary Phase Monolithic column RP-18e 100  4.6 mm 
Mobile phase Methanol: 10 mM potassium dihydrogen phosphate (pH 4) 
(12.5: 87.5 % v/v) 
Flow rate 1 ml min
-1
 
Temperature Room temperature 
Injection volume 20 l 
UV- Detection 274 nm 
 
The next objective was to use the developed method to separate and quantitate the 
methylxanthines and methyluric acids from urine matrix. 
 
3.3.3. The choice of the internal standard 
8-chlorotheophylline was a suitable internal standard in the present study. Since it was 
structurally close to theophylline and had the same UV absorption at 274 nm. Secondly, 
it had relatively longer retention time (14.06 min) when compared with other studied 
compounds, therefore it show no interference with their peaks. Furthermore, its polarity 
is quite similar to the tested drugs and thus was suitable as an internal standard in the 
SPE of spiked urine samples, and the detection conditions used. 
 
3.3.4. Optimisation of solid phase extraction procedure 
Before the quantitative analysis of methylxanthines and their metabolites in urine 
samples, they were extracted from the matrix and then pre-concentrated. The most 
common extraction techniques used for the elimination of the matrix interferences are 
liquid-liquid extraction, or solid phase extraction (SPE). SPE is now the most 
commonly used technique for sample extraction (especially of biological origins), 
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concentration, and clean up [240, 241] and it also it offers a wide sorbent selection. SPE 
prevents, many of the problems associated with liquid/liquid extraction, such as 
incomplete phase separations, low quantitative recoveries, use of expensive breakable 
specialty glassware, and disposal of large quantities of organic solvents. Extraction of 
methylxanthines and their metabolites from urine samples using SPE has been proposed 
previously [19, 80, 242, 243] but these methods did not give satisfactory recoveries for 
the compounds of interest. Therefore in this work the influence of various parameters to 
include; the cartridge type, pH adjustment of the urine samples, and different elution 
solvents, on the extraction efficiencies were examined.  
As the first stage pre-treatment of the spiked urine samples was important where the 
extraction required isolation of the hydrophilic analytes in the presence of relatively 
high levels of endogenous hydrophilic compounds typically found in the urine. To delay 
the elution of the tested compounds and so can be well separated from matrix 
interferences, the samples have to be in acidic medium thus the analytes will be in non-
ionized forms, which are strongly retained on C18 cartridge. The effect of adjustment of 
the spiked urine samples over the pH range of 2-6 by using either 10 mM sodium 
acetate buffer or 1 M HCl was investigated [71, 80, 244]. It was found that acidification 
of the urine sample to pH 4 with 0.5 ml of 10 mM sodium acetate buffer is the optimum 
for good recoveries for all the studied.  
 
(1) SPE cartridge 
As recommended in most the reported SPE procedures for the tested drugs, octadecyl 
C18 cartridge (1ml/100mg) was used in the study as it gave good reproducible recoveries 
for all compounds. RP-C18 cartridge was conditioned with methanol (2 x 1 ml), and then 
water (2 x 1 ml). Methanol wets the surface of the sorbent and penetrates bonded alkyl 
phases, allowing water to wet the silica surface efficiently.  
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(2) Elution mixture 
 As an initial step the elution mixture reported by Zydron [19], which is chloroform: 2- 
propanol (80:20 % v/v) was examined. This elution solvent gave low recoveries for all 
the studied compounds in the range of 33-71 % w/w. Methanol has been used with 
chloroform instead of propan-2-ol in the same ratio and good recoveries were obtained 
( 80 % w/w) for all the studied compounds (Figure 3.15). 
 
Figure 3. 15. The effect of using different elution mixtures on the extraction efficiencies 
of the studied methylxanthines and methyluric acids. 
 
Different ratios of the chloroform: methanol mixtures have been also tested. The 
recoveries of the tested drugs decreased upon decreasing the amount of methanol in the 
elution mixture (5, 10 % v/v) as it became insufficient for the elution of the compounds 
from the C18 cartridge.  Higher proportions of methanol (30, 40 % v/v) gave good 
recoveries but elution of some retained urine impurities was observed. Therefore, it was 
clear that 20 % v/v of methanol as the optimum amount. The Chromatograms of the 
blank urine and the extracted urine sample spiked with 40 g ml-1of studied compounds 
according to the optimized SPE method are shown in Figure 3.16. No interference from 
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any endogenous compounds in the sample matrix was observed. Peak resolution factors 
(Rs) ranged from 1.27 to 7.64 which indicating satisfactory separation of the resolved 
analytes.   
Figure 3. 16. Chromatograms of blank urine sample (A), and extracted urine sample (B) 
spiked with standard solutions of the tested methylxanthines and 
methyluric acids at 40 g ml –1 ; with the optimal conditions; monolithic 
column (Batch1), methanol:  10 mM KH2PO4 (pH 4)(12.5:87.5 % v/v), 
flow rate 1ml min
-1
, injection volume 20 l, and UV detection at 274 nm.  
(1) 3-MX, (2) 1-MX, (3) 1,3-DMU, (4) TB, (5) 1,7-DMU, (6) PA, (7) TP, 
(8) 1,3,7-TMU, (9) CA, and (10) IS (30 g ml –1). 
 
The retention times of the studied compounds under the developed chromatographic 
conditions in both aqueous solution and in the extracted urine samples are presented in 
Table 3.7. It can be seen from the data that the retention times of the compounds of 
interest in urine sample is slightly increased from that in aqueous solution. This is 
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attributed to the use of a guard column connected to the monolithic column during the 
work with biological samples leading to the increase of the actual length.  
 
          Table 3. 7. Retention times of methylxanthines and methyluric acids in  
aqueous standard solutions and urine samples (n= 6) 
 
 
 
 
 
 
 
 
3.3.5. Validation of the developed HPLC method for the determination of 
methylxanthines and methyluric acids mixture in urine samples 
(1) Linearity 
As stated in the ICH guideline [234] the linearity of an analytical procedure is its ability 
to produce test results, which are proportional to the concentration of the analytes 
within a certain concentration range. This also suggests that if there is a linear 
relationship, the test results should be evaluated by appropriate statistical methods as 
calculation of the regression line using least square equation; y = bc + a 
Where, y: peak area ratios, a: intercept, b: slope, and c:  drug concentration in g ml-1. 
Under the developed procedure, the relationship between the peak area ratios versus the 
standard concentrations was linear over the desired concentration range for all the tested 
compounds. The intercepts (a), slopes (b), correlation coefficients (R
2
), limits of 
detection (LOD), and limits of quantitation (LOQ), for all studied compounds are 
Analytes Retention times in aqueous 
solutions (min)  SD 
Retention times in urine 
samples (min)  SD 
3-MX 2.39  0.01 2.55  0.05 
1-MX 2.68  0.01 2.88  0.05 
1,3-DMU 3.04  0.02 3.31  0.03 
TB 3.35  0.02 3.63  0.04 
1,7-DMU 4.14  0.03 4.43   0.02 
PA 5.22  0.02 5.43  0.04 
TP 5.63  0.03 5.94  0.03 
1,3,7-TMU 6.59  0.09 6.95  0.05 
CA 12.02  0.11 12.45  0.05 
Chapter 3                                                 Development and validation of HPLC method 
 119 
summarized in Table 3.8. From these results it was seen that the values of correlation 
coefficients (R
2
) of the calibration curves were  0.9991 (n = 6). This proves that the 
response of the detector showed a good linearity for quantification of the 
methylxanthines and their metabolites over the studied concentration range. LODs and 
LOQs were ranged from 0.004 - 0.014 g ml-1, and 0.014 - 0.041 g ml-1, respectively, 
which indicates the good sensitivity of the analytical method. 
 Table 3. 8. Data from the regression equations for determination of the studied 
methylxanthines and their metabolites after SPE from urine samples 
 
* Average of six determinations  S.D. x 10-3.                    
 
Analytes Linear range 
(g ml-1) 
Slope* 
 
Intercept* 
 
R
2
* 
 
LOD 
(g ml-1) 
LOQ 
(g ml-1) 
3-MX 0.03- 40 0.062 
 0.46 
0.001 
 0.08 
0.9995 
 0.07 
0.005 0.014 
1-MX 0.03- 40 0.057 
 0.61 
0.003 
 0.09 
0.9996 
 0.38 
0.005 0.016 
1,3- DMU 0.05- 40 0.041 
 0.07 
0.001 
 0.13 
0.9995 
 0.21 
0.011 0.032 
TB 0.03- 40 0.057 
 0.39 
0.002 
 0.01 
0.9994 
 0.04 
0.006 0.018 
1,7- DMU 0.05- 40 0.044 
 0.55 
0.001 
 0.13 
0.9998 
 0.12 
0.009 0.029 
PA 0.05- 40 0.043 
 0.27 
0.001 
 0.13 
0.9996   
0.34 
0.010 0.030 
TP 0.03- 40 0.051 
 0.13 
0.001 
 0.11 
0.9993 
 0.05 
0.007 0.021 
1,3,7- 
TMU 
0.05- 40 0.027 
 0.09 
0.003 
 0.11 
0.9995 
 0.21 
0.014 0.041 
CA 0.03- 40 0.049 
 0.16 
0.001 
 0.11 
0.9991 
 0.05 
0.007 0.022 
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(2) Recovery 
The mean recoveries of all methylxanthines and their metabolites from the urine matrix 
for low and high spiked concentrations ranged from 82.28 to 98.73 % w/w.   
The recoveries of these compounds were found to be consistent, precise and 
reproducible as their RSDs were  2.5 % (Table 3.9).   
                Table 3. 9. Recovery of the methylxanthines and their metabolites from  
urine samples after SPE  (n = 6). 
Analytes 
*Nominal conc. 
(g/ml) 
**Recovered 
conc. (g/ml)  
 SD 
RSD 
(%) 
Recovery 
(%) 
3-MX   5.36   4.41  0.08 1.81 82.28 
 15.16 12.65  0.24 1.89 83.44 
 29.65 24.57  0.45 1.83 82.87 
1-MX   4.29   3.76  0.02 0.53 87.65 
 15.06 12.99  0.23 1.77 86.25 
 29.88 25.51  0.05 0.20 85.37 
1,3- DMU   5.40   4.78  0.01 0.29 88.52 
 14.86 13.15  0.11  0.84 88.49 
 30.24 26.86  0.24 0.89 88.82 
TB   5.06   4.52  0.10 2.21 89.33 
 15.22 13.73  0.15 1.09 90.21 
 30.11 26.94  0.34 1.26 89.47 
1,7- DMU   5.71   5.26  0.06 1.14 92.12 
 15.13 13.72  0.22 1.60 90.68 
 30.24 27.46  0.59 2.15 90.81 
PA   5.34   4.90  0.10 2.04 91.76 
 15.66 14.29  0.24 1.68 91.25 
 29.78 27.36  0.06 0.22 91.87 
TP   5.01   4.64  0.02 0.43 92.61 
 15.24 13.93  0.33  2.37 91.40 
 30.33 28.16  0.06 0.21 92.85 
1,3,7- TMU   5.11   4.78  0.11 2.30 93.54 
 14.81 14.03  0.24 1.71 94.73 
 30.02 28.41  0.55 1.94 94.64 
CA   5.01   4.93  0.10 2.03 98.40 
 15.21 14.99  0.36 2.40 98.55 
 29.88 29.50  0.11 0.37 98.73 
 
  *
Mean concentration of six injections of aqueous standard solutions. 
 
**
 Mean concentration of six injections of extracted spiked urine samples. 
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 (3) Precision and accuracy 
Precision of an analytical method describes the closeness of a series of measurements 
obtained from multiple analysis of the same homogenous sample using certain 
analytical conditions [234]. The intra-day and inter-day precision of the developed 
method were checked by replicate analysis of six separate spiked urine samples of each 
of the three concentration levels within the same day or in different days respectively. 
The RSD‟s were less than 2.6 % in all cases, indicating good precision of the proposed 
method (Table 3.10). While the accuracy is described as the closeness between the true 
value and the measured values by the proposed analytical procedures [234]. The 
accuracy of the developed method was determined by comparing the actual 
concentrations with the measured concentrations after their extraction from urine 
samples. The accuracy percentages of all compounds ranged from 82.60-98.08 %w/w.  
 
(4) Precision and reproducibility of the chromatographic data recovered from two 
different batches of monolithic columns [245]. 
The intra-day precision and inter-day precision of the chromatographic data acquired 
from two different batches of monolith columns were determined by repeating six 
consecutive runs of the test mixture on each column within one day and five working 
days respectively. The RSD measurements for all methylxanthines and their metabolites 
 2.00 % and this indicates that the developed method using monolithic columns is 
precise (Table 3.11). Batch-to-Batch reproducibility is presented by the RSD of six 
injections on the two batches. The RSD for all compounds in both columns was 2.50 
% except for 3-MX (RSD = 4.59%), TB (RSD = 3.23 %) and 1,3-DMU (RSD = 
2.94 %).  From these results it is possible to suggest that there is no difference between 
the two monolith batches in terms of the retention time (tR) or peak resolution (Rs) or in 
terms of peaks symmetry, which is expressed as the tailing factor (T 0.05) (Table 3.11).  
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Table 3. 10. Precision and accuracy for the developed HPLC method for the 
determination of the methylxanthines and methyluric acids mixture in 
urine matrix 
 
 
Actual 
conc. 
(g/ml) 
Intra-day precision 
(n= 6) 
Accuracy 
(%) 
Inter-day precision 
(n= 6) 
 
Accuracy 
(%) Measured 
conc.(g/ml) 
RSD 
(%) 
Measured 
conc. (g/ml) 
RSD 
(%) 
3-MX 5 4.16  0.03 0.79 83.28 4.18  0.06 1.51 84.90 
15 12.63  0.22 1.72 84.22 12.40  0.29 2.32 82.60 
30 25.27  0.31 1.23 84.22 25.59  0.31 1.22 85.29 
1-MX 5 4.27  0.06 1.35 85.44 4.28  0.03 0.72 85.62 
15 12.80  0.22 1.74 85.32 12.81  0.33 2.55 85.39 
30 25.82  0.36 1.41 86.06 25.73  0.35 1.36 85.58 
1,3- 
DMU 
5 4.48  0.05 1.04 89.56 4.48   0.07 1.65 89.68 
15 13.29  0.15 1.13 88.57 13.34  0.18 1.37 88.91 
30 26.62  0.14 0.53 88.72 26.64  0.27 1.00 88.78 
TB 5 4.45  0.07 1.59 89.08 4.37  0.04 0.92 87.33 
15 13.49  0.25 1.86 89.93 13.45  0.18 1.37 89.65 
30 26.71  0.23 0.85 89.04 26.74  0.12 0.45 89.12 
1,7- 
DMU 
5 4.51  0.01 0.31 90.28 4.51  0.02 0.34 90.10 
15 13.63  0.17 1.22 90.83 13.63  0.03 0.23 90.83 
30 27.02  0.14 0.53 90.06 27.06  0.06 0.23 90.20 
PA 5 4.53  0.07 1.52 90.56 4.54  0.04 0.82 90.84 
15 13.64  0.06 0.40 90.94 13.62  0.14 1.04 90.83 
30 26.75  0.11 0.42 89.18 27.17  0.25 0.93 90.56 
TP 5 4.70  0.02 0.51 93.94 4.69  0.04 0.81 93.80 
15 13.87  0.04 0.25 92.46 13.81  0.06 0.44 92.05 
30 27.65  0.18 0.65 92.17 27.62  0.31 1.14 92.08 
1,3,7- 
TMU 
5 4.77  0.01 0.21 95.72 4.78  0.01 0.23 95.52 
15 14.87  0.11 0.74 95.01 14.24  0.12 0.86 94.91 
30 28.41  0.31 1.06 94.69 28.43  0.31 1.10 94.75 
CA 5 4.92  0.02 0.37 98.44 4.90  0.03 0.63 98.08 
15 14.66  0.21 1.45 97.71 14.60  0.08 0.56 97.33 
30 29.19  0.07 0.25 97.30 29.34  0.19 1.25 97.79 
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            Table 3. 11. Precision and reproducibility of the chromatographic data obtained from separation of methylxanthines and their metabolites 
on two different batches of monolithic columns (Batch 1. OB452773, Batch 2. HX754226) 
 
 
 
Analytes 
RSD  (%) of the chromatographic data (n=6)  
Intra-day precision Inter-day precision Batch-to- Batch 
reproducibility Batch 1 Batch 2 Batch 1 Batch 2 
tR
* 
 
T0.05

 RS

 tR
* 
 
T0.05

 RS

 tR
* 
 
T0.05

 RS

 tR
* 
 
T0.05

 RS

 tR
*
 
 
T0.05

  RS

 
3-MX 1.23 0.89 - 1.24 1.02 - 1.55 0.52 - 1.63 0.33 1.63 1.59 4.59 - 
1-MX 1.02 0.70 0.88 1.23 1.36 1.35 0.90 0.66 1.82 1.28 0.84 0.47 1.57 0.42 2.27 
1,3-DMU 0.65 0.76 1.12 0.86 0.69 1.87 0.32 1.09 1.18 0.95 2.34 0.92 1.76 2.94 2.10 
TB 0.88 1.52 1.28 0.93 1.25 1.33 0.63 1.05 1.27 0.68 1.36 1.13 1.69 1.55 0.71 
1,7-DMU 1.41 1.20 1.57 1.15 1.87 0.98 0.48 1.46 1.62 0.76 2.12 1.88 1.17 1.28 1.39 
PA 1.19 1.36 1.44 1.66 0.56 0.81 0.46 1.72 1.53 1.26 1.32 1.65 1.04 1.75 2.00 
TP 0.96 1.55 1.30 2.03 0.87 1.02 0.98 1.63 1.30 1.06 1.69 1.35 0.98 0.42 0.46 
1,3,7- TMU 1.05 1.00 1.50 1.69 1.13 0.63 0.94 1.23 1.47 1.13 1.47 0.56 1.34 0.11 0.93 
CA 1.71 1.53 0.58 1.39 1.52 0.56 1.80 0.41 1.64 1.87 0.68 0.43 0.51 2.14 0.62 
                 * tR: Retention time     
 
T0.05; tailing factor at 5% of the peak height
        
RS: Resolution factor 
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3.3.6. Performance comparison between the monolithic and traditional C18 
columns for separation of methylxanthines and methyluric acids mixture 
Figures 3.17 and 3.18 show the chromatograms for all the studied methylxanthines and 
methyluric acids on the monolith and seven conventional HPLC columns. The tested 
columns were compared using relevant chromatographic parameters including; capacity 
factor (K), peak resolution (Rs), and tailing factor (T0.05) which express the peak 
symmetry (Table 3.12). Most of the tested columns were able to separate the mixture 
albeit with variable resolution peak symmetry, and total run time. From these results, it 
was observed the separation efficiency of monolith might be less than the symmetry or 
Hypersil columns even after extensive trials in optimization step. However, for all the 
tested columns at least 28 min is required for complete separation of the compounds of 
interest, while monolith needs only 14.06 min. The total run times for the Symmetry, 
Hypersil, ACE, Nucleosil 3 m, Nucleosil 5 m, Hichrome, and Zorbax C8 were 30.18, 
34.41, 49.34, 55.42, 44.13, 7.19, 28.01 min, respectively. Furthermore, lower 
backpressure (60 bar) was obtained upon working with monolith compared to other 
particulate packed columns (150-180 bar). Thus it can be concluded that the high 
permeability combined with high efficiency makes monolithic columns more 
convenient for high-speed separations especially when there is a complex mixture like 
the methylxanthines and their metabolites. 
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Figure 3. 17. The chromatograms represent the separation of extracted urine samples 
spiked with 40 g ml-1 of methylxanthines and their metabolites on 
monolithic (Batch1), Symmetry, Hypersil, and ACE columns with the 
optimal conditions; methanol: 10mM KH2PO4 (pH 4)(12.5:87.5 % v/v), 
flow rate 1ml min
-1
, injection volume 20 l, and UV detection at 274 nm. 
(1) 3-MX, (2) 1-MX, (3) 1,3-DMU, (4) TB, (5) 1,7-DMU, (6) PA, (7) TP, 
(8) 1,3,7-TMU, (9) CA, and (10) IS (30 g ml-1).   
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 Figure 3. 18. The chromatograms represent the separation of the extracted urine 
samples spiked with 40 g ml-1 of methylxanthines and their metabolites 
on Nucleosil 3m, Nucleosil 5m, Hichrome, and Zorbax columns with 
the optimal conditions; methanol: 10mM KH2PO4 (pH 4)(12.5:87.5 % 
v/v), flow rate 1ml min
-1
, injection volume 20 l, and UV detection at 274 
nm. (1) 3-MX, (2) 1-MX, (3) 1,3-DMU, (4) TB, (5) 1,7-DMU, (6) PA, (7) 
TP, (8) 1,3,7-TMU, (9) CA, and (10) IS (30 g ml-1).    
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  Table 3. 12. Performances o f monolithic and traditional C18 columns for separation of the methylxanthines and methyluric acids mixture. 
      K; capacity factor,     N; number of theoretical plates       Rs; peak resolution             T0.05; tailing factor at 5% of the peak height 
      N.B. absence of data (-) indicates that insufficient resolution was observed 
Analytes Monolith Symmetry Hypersil ACE 
K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 
3-MX 2.40 3.73 - 1.60 4.12 5.90 - 1.33 4.69 7.19 - 1.38 6.69 11.11 - 1.14 
1-MX 2.84 3.22 1.80 1.62 5.14 7.15 3.67 1.34 5.65 6.72 3.24 1.41 8.19 11.79 4.76 1.12 
1,3-DMU 3.41 3.33 1.97 - 6.53 7.30 4.32 - 7.33 7.67 4.77 1.30 10.82 16.61 7.47 1.05 
TB 3.84 2.60 1.27 - 6.90 6.13 0.97 - 8.09 7.62 1.91 1.40 11.41 10.99 1.40 0.73 
1,7-DMU 4.89 1.86 2.27 1.69 10.13 6.68 6.81 1.22 11.50 6.87 6.68 1.22 17.53 10.19 10.1 1.10 
PA 6.26 2.94 2.53 - 12.09 8.25 3.51 1.49 13.72 8.56 3.58 1.39 19.65 12.08 2.86 1.20 
TP 6.92 3.79 1.26 - 13.74 10.57 2.87 1.40 15.08 7.21 1.95 1.41 21.73 11.88 2.63 1.15 
1,3,7-TMU 8.28 4.16 2.49 1.50 17.37 10.20 5.58 1.30 20.63 7.76 6.38 1.22 29.37 12.17 7.89 1.12 
CA 15.60 2.33 7.51 - 29.21 9.33 11.9 2.16 33.89 10.08 11.1 1.99 46.09 12.24 11.9 1.42 
Analytes Nucleosil 3 m Nucleosil 5 m Hichrome Zorbax C8 
K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 
3-MX 8.56 10.87 - 0.86 7.68 7.61 - 0.80 - - - - 4.47 8.18 - 1.22 
1-MX 10.54 9.50 4.72 0.90 9.56 6.87 3.52 0.84 - - - - 5.46 8.52 3.79 1.19 
1,3-DMU 12.94 9.41 4.57 0.88 10.96 7.54 3.25 0.81 - - - - 6.27 8.61 2.75 1.12 
TB 16.72 10.19 5.92 1.05 14.38 7.87 5.10 0.86 2.32 0.32 - - 7.44 9.49 3.55 1.29 
1,7-DMU 19.86 8.48 3.91 0.83 16.44 7.49 2.74 - - - - - 10.18 7.58 6.37 1.18 
PA 27.34 10.22 7.39 - 22.07 9.44 6.41 - 3.28 0.42 1.22 - 12.41 9.05 4.14 1.19 
TP 29.49 10.88 1.87 - 23.47 8.77 1.41 0.68 4.42 0.34 1.14 - 13.72 9.94 2.27 1.14 
1,3,7-TMU 35.48 10.73 4.65 0.85 27.49 8.43 3.51 0.82 - - - - 15.83 9.41 3.29 1.07 
CA 72.89 8.06 15.9 1.25 56.67 - - - 8.59 0.23 2.27 1.34 27.78 10.18 13.0 1.41 
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3.3.7. Performance comparison between monolithic and platinum
 
columns for        
separation of methylxanthines and methyluric acids mixture. 
The performances of both platinum and monolithic columns for separation of 
theophylline and its related compounds were compared using the developed HPLC 
method mentioned in section 3.2.3.10. Figure 3.19 shows the methylxanthines and 
methyluric acids mixture, which was separated on both columns. Table 3.13 shows 
different chromatographic parameters obtained from both columns 
 Figure 3. 19. The chromatograms represent the separation of extracted urine samples 
spiked with 40 g ml-1 of methylxanthines and their metabolites on 
platinum (Batch1) (A) and monolithic (Batch1)(B) columns with the 
optimal conditions; methanol: 10mM KH2PO4 (pH 4)(12.5:87.5 % v/v), 
flow rate 1ml min
-1
, injection volume 20 l, and UV detection at 274 nm. 
(1) 3-MX, (2) 1-MX, (3) 1,3-DMU, (4) TB, (5) 1,7-DMU, (6) PA, (7) TP, 
(8) 1,3,7-TMU, (9) CA, and (10) IS (30 g ml-1).    
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Table 3. 13. Performances of monolithic and platinum C18 columns for separation of   
                    the methylxanthines and methyluric acids mixture. 
 
Platinum and monolith was able to separate the studied mixture efficiently with no 
sharp difference (2 min.) in the total analysis time with monolith 16.72, 14.03 min., 
respectively. If a choice was to be made, the peak resolution and symmetry values 
obtained from the platinum were slightly better however; the lower backpressure of the 
monolithic column was preferred. The backpressure achieved using monolith was 56 
bar while with platinum was about 170 bar.  
As a conclusion the monolithic column is a useful tool of achieving efficient separation 
under lower backpressure and shorter run time which are the most important aspects in 
method development [246]. This is also important when repeated analyses are required 
during manufacturing process at quality control laboratories. It also provides rapid 
washing and equilibrium times. Although some of the tested packed columns have an 
equivalent selectivity to the monolithic column, but they take more time to re-
equilibrate (30 min.) or to wash the stationary phase [16, 247]. These advantages should 
aid in the reduction of the total time to develop a method using a monolith compared 
with a packed column.  
 
Analytes 
Monolith Platinum C18 
K N 
103 
Rs T0.05 K N 
103 
Rs T0.05 
3-MX 2.40 3.73 - 1.60 2.61 10.28 - 1.39 
1-MX 2.84 3.22 1.80 1.62 3.42 7.89 2.06 1.11 
1,3-DMU 3.41 3.33 1.97 - 4.07 7.53 2.97 1.07 
TB 3.84 2.60 1.27 - 6.26 8.52 7.99 1.17 
1,7-DMU 4.89 1.86 2.27 1.69 7.02 1.28 3.08 1.62 
PA 6.26 2.94 2.53 - 7.81 9.32 1.44 - 
TP 6.92 3.79 1.26 - 8.35 9.43 1.60 - 
1,3,7-TMU 8.28 4.16 2.49 1.50 9.04 4.41 1.23 - 
CA 15.60 2.33 7.51 - 13.03 1.90 6.07 0.97 
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The high permeability and total porosity in the monolithic column allows the use of 
high flow rate without a significant increase in backpressure or substantial loss in the 
resolution power [248]. This will provide a time saving analysis with only minimal 
resolution loss. On the other hand with all the tested packed columns, the backpressure 
increases significantly by increasing the flow rate. This considered as the main 
disadvantage since working at high pressure limits the speed of analysis and reduces the 
lifetime of the HPLC instrument and the injector seals.  
Packed columns are filled with 3-5 m particles which can be easily block and cause 
high backpressure, especially with biological samples and thereby reduce the column 
lifetime. On the other hand, with the monolithic columns, there is a reduced need for 
tedious sample preparation, as they are very resistant to blocking (even with biological 
samples). 
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3.3.8. Validation of the developed HPLC method for the determination of 
theophylline in aqueous solution 
Figure 3.20 represents the typical chromatogram of theophylline and the internal 
standard in aqueous solution using the optimized HPLC method (section 3.2.3.10).  
 Figure 3. 20. The typical chromatogram of theophylline (50 g ml-1) and 8-
chlorotheophylline (I.S. 30 g ml-1) in aqueous solution with the 
optimal conditions; monolithic column (Batch1), methanol: 10 mM 
KH2PO4 (pH) 4 (12.5:87.5 % v/v), flow rate 1ml min
-1
, injection 
volume 20 l, and UV detection at 274 nm.  
 
(1) Linearity 
Under the optimized chromatographic conditions, the relationship between peak area 
ratios (compound/internal standard) and theophylline concentrations was linear in the 
range 20-200 g ml-1 (Figure 3.21). The mean of slopes and intercepts for five 
calibration curves (n= 6) were 0.06  0.002 and 0.19  0.001, respectively and 
correlation coefficient R
2
 = 0.9993  0.004. The limits of detection (LOD), and limits of 
quantitation (LOQ), of theophylline in aqueous solutions were 0.08 and 0.23 g ml-1, 
respectively. This enabled the determination of theophylline in different pharmaceutical 
formulations and in the assessment of the aerodynamic behaviour of theophylline 
(chapter 5).  
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Figure 3. 21. The calibration curve of theophylline aqueous standard solutions (I.S. 
concentration 30 g ml-1) with the optimal conditions; monolithic 
column (Batch1), methanol: 10 mM potassium dihydrogen phosphate pH 
4 (12.5:87.5 % v/v), flow rate 1ml min
-1
, injection volume 20 l, and UV 
detection at 274 nm.  
   
(2) Recovery from different pharmaceutical formulation  
The developed HPLC procedure was applied for the analysis of the commercially 
available dosage forms of theophylline. Results presented in Table 3.14 indicate good 
recovery (95.24-98.62 % w/w) of theophylline from the studied formulations and 
confirm the absence of interference due to common excipients. This is also confirmed 
by the RSD values at three concentration levels, which are not exceeding 2.00 %. 
               Table 3. 14. Recovery of theophylline from its pharmaceutical dosage forms  
Pharmaceutical 
formulations 
*
Nominal  
conc. (g/ml)  
 SD 
** 
Recovered  
conc. (g/ml)  
 SD 
RSD 
(%) 
Recovery 
(%) 
Nulein
® 
SA   50.32  
99.36  
149.28 
49.12  0.25 
95.40  0.69 
143.16  0.83 
0.51 
0.72 
0.58 
97.61  
96.01 
95.90  
Uniphuylline
®
  50.11  
100.03  
151.55  
49.34  0.14 
98.65  0.92 
149.46  0.35 
0.28 
0.93 
0.23 
98.47  
98.62  
98.62  
Slo-phylline
®
  49.23  
98.01  
150.26 
47.19  0.33 
94.77  0.84 
143.11  0.73 
0.69 
0.89 
0.51 
95.86  
96.69 
95.24  
                *
Mean concentration of six injections of aqueous standard solutions. 
     
**
 Mean concentration of six injections of extracted samples. 
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(3) Precision and Accuracy 
Intra-day precision of the proposed method was tested by replicate analysis of six 
separate aqueous solutions of the working standard of theophylline, at three different 
concentration levels. This study was repeated for five days to determine the inter-day 
precision. RSD % values for theophylline in all cases were ranged from 0.47-1.14 
indicating good repeatability and precision (Table 3.15). Accuracy was determined by 
comparing measured concentrations of theophylline with the actual values and 
expressed as percentage. The accuracy of the method ranged from 99.02 - 99.78 % w/w.    
Table 3. 15. Precision and accuracy of the developed HPLC method for the 
determination of theophylline in aqueous standard solutions 
 
In conclusion, the results show that the new developed method gives improved 
separation and quantitation of the methylxanthines and their metabolites in 15 min, 
with high precision, and accuracy. Moreover the solid phase extraction procedure 
described here provides an easier and solvent saving sample preparation technique 
comparing to traditional liquid-liquid extraction with high recoveries ( 80%). However, 
many reported of the HPLC methods for CA or TP and their metabolites show 
interference from caffeine metabolites and especially paraxanthine [78]. In addition 
some of these methods require complexed pre-treatment steps and long retention times 
to complete the separation of all the methylxanthines [81-83]. The developed method 
provides a mean for assessing of theophylline concentration in urine samples for 
asthmatic patients consuming methylxanthines containing food. 
Actual 
conc. (g) 
Intra-day precision and accuracy 
(n= 6) 
Inter-days precision and accuracy 
(n= 6) 
Measured conc. 
(g/ml)  S.D. 
RSD 
(%) 
Accuracy 
(%) 
Measured conc. 
(g/ml)  S.D. 
RSD 
(%) 
Accuracy 
(%) 
50 49.51  0.55 1.11 99.02 49.83  0.31 0.63 99.66 
100 99.24  0.47 0.47 99.24 99.78   0.48 0.48 99.78 
150 149.65  1.70 1.14 99.76 148.53  0.85 0.57 99.02 
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Chapter 4 
 
Crystallisation of theophylline using Solution 
Enhanced Dispersion by SCFs (SEDS) 
process and solid-state analysis of the 
products 
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4.1. Introduction 
The particle size, morphology, and configuration of the crystalline lattice can all play an 
important role in the therapeutic behaviour of substances especially for respiratory drug 
delivery. Therefore, the production of micro- and nano- particles with controlled 
characteristics is a critical step in pharmaceutical industry. Of the many procedures used, 
crystallisation using supercritical fluids (SCF) was mainly developed to overcome the 
drawbacks of the conventional techniques used for production of micro- or nano- 
particles such as spray drying, milling and re-crystallisation using liquid antisolvent 
[13]. It can provide an improved control of the particle size, a lower concentration of 
residual solvent in the product as well as the environmental advantage of reducing the 
solvent wastes [14]. Carbon dioxide (CO2) is commonly used as an SCF especially for 
pharmaceutical compounds [9] due to its mild critical conditions of temperature 
(31.1C), and pressure (73.8 bar) and its non-reactive characteristics. 
There have been different SCF techniques proposed as the Rapid expansion of 
supercritical solutions (RESS), and Precipitation from gas saturated solutions (PGSS) 
processes. However, crystallisations using supercritical CO2 (SC-CO2) as antisolvent as 
in the Aerosol solvent extraction system (ASES), and Solution enhanced dispersion by 
SCFs (SEDS) processes have been commonly used in different pharmaceutical 
applications. Their main advantages include a totally enclosed single step process, 
which require reduced amounts of organic solvent compared to traditional 
crystallisation [9]. 
Particle formation in these techniques is determined by the mass-transfer of the SCF 
into the atomised drug solution. In order to obtain small particle and minimize the 
particle agglomeration frequently observed, increased mass-transfer rates and a 
reduction in the drying time are required [127]. These have been efficiently achieved in 
SEDS process by the use of coaxial nozzle design with mixing chamber (Figure 4.1.).   
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             Figure 4. 1.  Schematic diagram of a SEDS two coaxial nozzle. 
 
This arrangement provides a means by which the drug solution interacts and mixes with 
the SCF in the mixing chamber before dispersion and then flows to the particle 
formation vessel via a restricted orifice. Thus high mass transfer rates are achieved with 
a high ratio of SCF to the solvent and the high velocity of the SCF facilities the jet 
break-up into small droplets [9].  
Theophylline (TP) a methylxanthines derivative has a bronchodilator effect but its low 
solubility in water restricts its clinical applications. The drug also has a low therapeutic 
index with a small difference between its therapeutic benefits and toxic effects. 
Therefore controlling the particle size, morphology and the crystal structure of TP 
during its production process is important to assist characteristics like bioavailability, 
functionality and stability [12].  
Several important operating parameters have been identified previously as influencing 
the re-crystallisation and product formation by SEDS process. These are temperature, 
pressure, and solution flow rate. The working temperature and pressure determine the 
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density of SC-CO2, which in turn affects the extraction rate of the solvent into the SC-
CO2 and the supersaturation state of the test compounds [249].  
The effect of these parameters on TP produced by SEDS technique was investigated in 
this study, which focused on the particle size and other important characteristics of the 
powdered products. The precipitated samples were characterized by scanning electron 
microscope (SEM), X-ray powder diffraction (XRPD), Fourier transform infrared 
spectroscopy (FT-IR), Fourier transform Raman (FT-Raman), thermogravimetric 
analysis (TGA), and differential scanning calorimetry (DSC).  
 
4.2 Material and methods 
4.2.1. Material 
  Theophylline anhydrous, minimum 99% (Sigma-Aldrich Inc, St. Louis, MO, USA).  
 HPLC grade absolute ethanol (EtOH) and dichloromethane (DCM) (Fischer Scientific, 
Loughborough, UK)  
 
4.2.2. Methods 
4.2.2.1. Preparation of the theophylline solution 
Solution of unprocessed theophylline with concentration of 1g % w/v (10 mg ml
-1
) was 
prepared in ethanol: dichloromethane mixture (50:50 % v/v) assisted by sonication for 
15 min.   
 
4.2.2.2. Precipitation of theophylline particles by SEDS process 
Figure 4.2 shows a schematic diagram of the SEDS equipment and Table 4.1 lists the 
components of the laboratory scale equipment 
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                        Figure 4. 2.  Schematic diagram represents SEDS 
 
process [250] 
 
Table 4.1. SEDS equipment components list 
Component Manufacturer 
Cooler Bath. Model: LTD6G Grant Ltd, Hertfordshire, UK 
HPLC Pumps. Models Pu 980, PU 1580 Jasco CO. Tokyo, Japan 
Column oven. Model: PU860-CO Jasco CO. Tokyo, Japan 
Back Pressure Regulator and controller.  
( Model: PU880-81) 
Jasco CO. Tokyo, Japan 
Pressure vessel 50 ml Keystone Inc, USA 
Nozzle 2 component Bradford Particle Design PLC, UK 
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4.2.2.2.1. The experimental procedure used in SEDS crystallisation 
The liquid CO2 temperature is lowered via the cooling bath and the cooling head.  The 
liquid CO2 is pumped via a pulse dampener into the temperature controlled oven at 
constant pressure regulated by a backpressure regulator (BPR). The CO2 becomes 
supercritical in the oven where the temperature and pressure conditions are above the 
critical point of CO2.  
The prepared theophylline solution (1g % w/v) and SCCO2 are pumped simultaneously 
via a specially designed coaxial nozzle into the particle formation vessel within the oven. 
The fluids premix before exiting the nozzle tip where the SC-CO2 disperses and mixes 
with the drug solution and extracts the solvent. This results in a high degree of 
supersaturation causing rapid crystallisation of the drug precipitation post the nozzle tip. 
The drug substance is retained by the filter in the particle formation vessel, while the 
solvent and SC-CO2 go to waste for collection or recirculation via the BPR.  
Finally, after completion of the precipitation process, the whole system is flushed with 
SC-CO2 to ensure that the retained drug substance is dry and solvent free. The system is 
then slowly depressurized, and the drug collected, labelled, stored at ambient 
temperature and protected from light and moisture prior to analysis. The ratio of the 
amount of the collected powder to that delivered in the drug solution is defined as the 
process yield. 
 Different temperatures, pressures and drug solution flow rate have been used in this 
study to determine the effect of these parameters on the properties of the theophylline 
particles produced.  Three runs were done for different samples prepared at different 
conditions. 
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4.2.2.3. Methods of particle analysis   
 
4.2.2.3.1. Particle size analysis 
Particle size analysis of the processed samples was made by using Photon Correlation 
Spectroscopy (PCS), using a Zetasizer
®
 Nano-S (Malvern Instruments Ltd, 
Worcestershire, UK) (0.6 nm to 6 m). Analyses provided the mean particle diameter 
(n=6) of SEDS theophylline samples.  PCS relies on measuring the fluctuations in the 
intensity of the scattered light from large and small particles that occurs because they 
are undergoing Brownian motion. By determining the diffusion rate of the tested 
particles, their sizes can be obtained [251]. Suspensions of all the processed samples 
were firstly prepared in absolute ethanol at a concentration of 500 g ml-1. About 2.00 
ml from each shaken suspensions were transferred into disposable polystyrene cuvettes 
and then loaded in the instrument for measurement. During all experiments, the 
viscosity of the suspensions (continuous phase) was taken as the viscosity of ethanol 
(1.200 cP at 25 C). 
 
4.2.2.3.2. Scanning electron microscope 
The morphology and size of unprocessed and SEDS particles were investigated using a 
Quanta 400 SEM (FEI Europe Ltd, Cambridge, UK) equipped with a low vacuum 
facility. The sample was dusted onto a graphite disk that was affixed to the sample 
holder, then viewed and photographed under varying magnifications. Higher resolution 
and depth of focusing can be achieved compared with optical microscopy.  
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4.2.2.3.3. Differential scanning calorimetry (DSC)  
DSC measures the differential heat flow required to maintain a pair of sample pans (one 
containing the sample and the other is an empty reference pan) at the same temperature 
throughout a thermally dependent process. A baseline was obtained using empty pan 
holders prior to the analyses. Any deviation from this base line determined in 
subsequent analyses relates to a thermal event. For the apparatus used in the project, 
positive deviation from the base line represents an endothermic process such as melting, 
while the negative deviations represent exothermic processes such as re-crystallisation. 
DSC is used to monitor any phase transitions after processing and storage of the 
theophylline samples, which could be related to a change in the crystal structure of the 
processed samples. DSC analysis was performed using a TA Instrument 2920 
Modulated DSC (TA instruments LTD, Sussex, UK). Samples (1-3 mg) were placed in 
the instrument in pierced crimped pans and scanned from 25-300C at a heating rate 
10C min-1. The calorimeter was calibrated using pure indium (melting point 156.6C) 
and zinc (melting point 419.5C) standards. Each SEDS sample was analysed three 
times and the melting point and latent heat of fusion  (Hf) were recorded. 
 
4.2.2.3.4. Thermal Gravimetrical analysis (TGA)     
This instrument measures thermally induced weight loss of produced materials as a 
function of applied temperature. Dynamic TGA measures the change in weight of 
sample over a temperature range at a pre-determined heating rate. TGA analysis was 
performed using TA Instrument 2920 Modulated TGA (TA instruments LTD, Sussex, 
UK). Samples were placed in an open pans attached to the microbalance and then 
heated at a uniform rate of 10C min-1over a range 25-400C. The instrument was 
calibrated with a ferromagnetic standard. Each SEDS sample was analysed three times 
and the transition temperature was recorded. 
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4.2.2.3.5. X-ray Powder Diffraction (XRPD)  
XRPD analysis of bulk-powdered samples has been used to assess any change in the 
crystalline structure of SEDS samples under different experimental conditions 
comparing to the unprocessed sample. Powder X-ray diffraction was recorded with a 
Bruker D8 diffractometer (Bruker AXS Limited, Coventry, UK). A small quantity of 
the SEDS sample was packed into the sample holder and then placed in the equipment. 
The samples were then scanned from 5-50 (2) with a 0.01 step width and a 1 second 
time count using Cu source (x-ray  = 0.154 nm), voltage 40 kv, and the filament 
emission 30 mA. The receiving slit on the instrument was 1 and the scatter slit 0.2. 
The system was calibrated using the diffraction peaks of crystalline silicone with an 
accuracy of 10
-4 (2). 
 
4.2.2.3.6. Fourier Transform Infra-Red (FT-IR) 
FT-IR has been used to monitor any structural or polymorphic changes by detecting any 
changes in molecular vibration for samples. FT-IR was performed using Perkin Elmer 
1725-x spectrophotometer (Perkin Elmer Ltd, Bucks, UK). The sample (0.005 g) was 
mixed well with dried KBr (0.35g) and then the mixture was used to form a compact 
disc and placed in the instrument. The sample disc was then scanned over wave number 
500 to 4000 cm
-1
 at 4 cm
-1
 spectral resolution and 264 spectral scans. Visual inspection 
of the spectra was used to identify any major differences between the obtained FT-IR 
spectra of the processed theophylline samples and the reference spectra for unprocessed 
theophylline [252, 253]. 
 The instrument resolution is calibrated by recording the spectrum of a polystyrene film 
approximately 35 m in thickness. The difference between the absorbances at the 
absorption minimum at 2870 cm
-1
 and the absorption maximum at 2849.5 cm
-1
 is 
greater than 0.33. The difference between the absorbances at the absorption minimum at 
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1589 cm
-1
 and the absorption maximum at 1583 cm
-1
 is greater than 0.08. Calibration of 
wavenumber is checked by reference to a polystyrene film at 14 specified wavenumbers; 
the reference values range from 3027.1  0.3 to 698.9  0.5 cm−1. 
 
4.2.2.3.7. Fourier Transform Raman Spectroscopy (FT- Raman) 
FT-Raman spectra were recorded using a Bruker IFS 66 instrument with an FRA 
106 Raman module attached (Bruker Optics Inc., Ettlingen, Germany), with 
Nd3+/YAG solid state laser operating at 1064 nm and liquid nitrogen cooled 
InGaAs detector.  Spectra were recorded at 4 cm
–1
 spectral resolution, and 200 
spectral scans were accumulated to improve signal-to-noise ratios. Laser power was 
maintained at 26 mW at the sample. The spectral wave number range was typically 
4000-80 cm
-1
. For calibration sulphur was used produced 25,000 counts at 37 mW. 
The spectra obtained for SEDS samples were compared with that of the 
unprocessed theophylline sample to detect any differences.  
 
4.3. Results and discussion 
4.3.1. Re-crystallisation process 
Pure theophylline was re-crystallised from an EtOH-DCM mixture (50: 50 % v/v) 
by the SEDS process using SC-CO2 as the antisolvent. This solvent mixture is based 
on number of reported studies for the theophylline solubility in different solvents 
[12, 254]. Where, it was reported that the addition of solvents like DCM to ethanol 
enhances the TP solubilization by a factor of 5.8 mg ml
-1 
at 36.15 C.  A 50:50 % 
v/v of EtOH-DCM mixture was found to produce dispersions of relatively low 
viscosity. This enabled processing of the solutions by SEDS without the occurrence 
of nozzle blocking [255].  
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The concentration of theophylline solution was limited by its viscosity, as highly 
concentrated solutions causing difficulties in pumping the solutions. Thus the drug 
solution with concentration of 10 mg ml
-1
 (1g % w/v) provided a balance between a 
solution suitable to be pumped at moderate backpressure values while still of 
sufficiently high concentration to allow an acceptable processing rate.  On the other 
hand solutions at lower concentrations were too diluted to produce a precipitation of 
theophylline [255]. 
 
4.3.2. The effect of changing the variable crystallisation parameters on the mean 
particle size of theophylline 
It was reported [256] that changing the crystallisation conditions can alter the 
produced mean particle size. Therefore, the effect of changing temperature, pressure, 
and solution flow rate on the mean particle size was investigated to ascertain the 
significance of varying theses crystallisation parameters in this study. The aim is to 
provide a general prediction for the mean particle size of theophylline at a given set 
of crystallisation parameters. Typically, inhalations products require sub 5 m 
particles; therefore a predictive method for approximate mean particle size could 
reduce the number of experiments before the identification of the optimised 
parameters.  
The effects of temperature and pressure in the ranges of 40-60 C and 80-125 bar, 
respectively were investigated. These selected ranges allow the operation with CO2 
as antisolvent in supercritical state.  The drug solution flow rate ranged from 0.1-0.3 
ml min
-1
,
 
while the SC-CO2 was pumped at 20 ml min
-1
. In this study nozzle tips 
with 0.5 mm internal diameter were used while others with lower diameters were 
found to be more susceptible to blockage. Table 4.2 shows the operating conditions, 
yield, and the mean particle size of the theophylline SEDS samples. 
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Table 4. 2.The experimental conditions, yield and the mean particle size of theophylline 
samples re-crystallised from EtOH-DCM mixture using the SEDS technique. 
 
From the results in Table 4.2 it can be observed that the mean particle size obtained 
from Zetasizer
®
 Nano-S and confirmed by SEM images for all the processed samples 
were in the range of 2-5 m. There is a dramatic reduction in the particle size of the 
processed samples when compared to the unprocessed theophylline sample (30-100 m). 
Figure 4.3 illustrates the SEM images of unprocessed theophylline and SEDS sample 1 
as a representative example showing the difference in particle size as well as particle 
shape.  It can also be noted from the results in Table 4.2 that the change of temperature, 
pressure and the solution flow rate over the precipitation process affect the particle size 
of the precipitated theophylline samples. 
 
 
Sample 
 
Solution 
flow rate 
(ml min
-1
) 
CO2 
flow rate 
(ml min
-1
) 
T 
(C) 
P 
(bar) 
Nozzle tip 
i.d. (mm) 
Yield 
(%) 
Mean particle 
size (m) 
(n=6) (SD) 
1 0.2 20 50 80 0.5 92 2.44 (0.29) 
2 0.2 20 50 95 0.5 75 2.69 (0.45) 
3 0.2 20 50 125 0.5 45 2.87 (0.13) 
4 0.2 20 60 80 0.5 50 1.82 (0.46) 
5 0.2 20 60 95 0.5 47.5 1.89 (0.56) 
6 0.2 20 60 125 0.5 83 2.44 (0.36) 
7 0.2 20 40 80 0.5 33 2.55 (0.47) 
8 0.2 20 40 95 0.5 50 2.89 (0.60) 
9 0.2 20 40 125 0.5 37.5 3.12 (0.04) 
10 0.3 20 50 95 0.5 90 3.11 (0.56) 
11 0.3 20 60 125 0.5 70 2.71 (0.91) 
12 0.1 20 60 125 0.5 60 2.20 (0.25) 
13 0.1 20 50 95 0.5 60 1.82 (0.31) 
14 0.3 20 60 80 0.5 60 2.46 (0.22)  
15 0.3 20 40 125 0.5 70 3.54 (0.62) 
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Figure 4. 3. SEM images of unprocessed theophylline sample (A) and SEDS sample 1. 
 
The reproducibility of the mean particle size produced by SEDS technique was 
ascertained by duplicate crystallisation runs of three samples (1, 5, and 9) as 
representative examples, on different days using freshly prepared solutions each day. 
The overall reproducibility of the process was expressed as relative standard deviation 
(RSD). Table 4.3 displays the mean particle size, SD and RSD of the selected samples. 
 Table 4. 3. Reproducibility of the mean particle size produced by SEDS technique 
 
 
 
 
 
 
As shown in Table 4.3 the RSD values for the mean particle size of theophylline  4 % 
indicating that SEDS technique can repeatably reproduce material with consistent 
particle size. This in turn allows confident interpretations to be made based on single 
crystallisation.   
Sample Mean particle size (m) SD RSD (%) 
1 2.44 0.06 2.46 
5 1.85 0.03 1.62 
9 3.15 0.10 3.17 
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4.3.2.1. Effect of temperature 
Increasing the temperature during the precipitation process led to a decrease in the 
particle size of the processed samples (Figure 4.4.). The effect of temperature can be 
also observed in the SEM images for SEDS samples 5 and 8, these samples were 
prepared at the lowest and highest temperatures investigated (Figure 4.5.). At high 
temperature the SC solution density is the lowest and therefore has expanded from the 
initial volume pumped at the pump head results in a net increase in the fluid flow 
velocity through the nozzle exit. This leads to increase in both the supersaturation and 
the nucleation rate and the formation of smaller particles [257]. Similar observations 
were reported by Subra et al [12] and by Franceschi et al [13]. They also suggested that 
at 60 C, CO2 is a SCF and as such its surface tension is insignificant compared to the 
more liquid like state at 40C and this might be contributing to produce the smaller 
particles.  
 
 
 
 
Figure 4. 4. The effect of temperature on the particle size of the processed                     
theophylline samples (Processing conditions for samples 1-9 were 
described in Table 4.2)  
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Figure 4. 5. SEM images the theophylline SEDS sample 8 (A), at T= 40 C and 
SEDS sample 5 (B), at T= 60 C.  
 
 
4.3.2.2. Effect of pressure 
An increase in the particle size was observed upon increasing the pressure at constant 
temperature (Figure 4.6). Subra and co workers [12] suggested that an increase in the 
pressure might increase the particle aggregation leading to the formation of larger 
particles. It was also reported [258] that an increase in the pressure decreases the 
diffusivity, which in turn reduces the mass transfer resulting in lower mixing efficiency 
of the SCF and solute solution. This will suppress the supersaturation and nucleation 
rate leading to larger particles. Contradictory results concerning trends of particle size 
as a function of pressure were reported in other literatures [259]. Figure 4.7 shows the 
SEM images of SEDS samples 4 and 6 at the lowest and highest pressures studied.  
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Figure 4. 6. The effect of pressure on the particle size of the processed theophylline 
samples (Processing conditions for samples 1-9 were described in 
Table 4.2)  
 
 
 
Figure 4. 7. SEM images the theophylline SEDS sample 4 (A), at P= 80 bar and SEDS 
sample 6 (B), at P= 125 bar  
 
 
4.3.2.3. Effect of drug solution flow rate 
As seen in the data presented in Table 4.2 there is an increase in the particle size of the 
processed samples upon increasing the solution flow rate (Figure 4.8.). This is primarily 
attributed to a high theophylline solution flow rate, at a constant CO2 flow rate, leading 
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to a decrease in mass transfer which in turn causes a decrease in the supersaturation 
level, and thereby the rate of nucleation resulting in larger particles. On comparing the 
experimental condition for SEDS 13 (low solution flow rate) with experimental 
condition for SEDS 15 (high solution flow rate), it can be observed that the particle size 
obtained for both samples were 1.81, and 3.04 m respectively. Figure 4.9 illustrates the 
SEM images of samples 13 and 15 showing the difference between their particle sizes.   
 
Figure 4. 8. The effect of solution flow rate on the particle size of the processed 
theophylline samples (Processing conditions for samples 1-9were 
described in Table 4.2)  
 
 
 
 
Figure 4. 9. SEM images the theophylline SEDS sample 13 (A), at drug solution 
                    flow rate= 0.1ml min
-1
 bar and SEDS sample 10 (B), at drug solution  
                  flow rate  = 0.3 ml min
-1
  
 
Chapter 4                                                            Crystallisation of theophylline by SEDS  
 151 
4.3.3. Analysis of the precipitated theophylline particles 
4.3.3.1. Morphology 
The processed samples were generally recovered as free flowing powders composed of 
agglomerated particles with a morphology of needles or flakes (Figure 4.10.). The 
unprocessed particles exhibited a different morphology compared with the processed 
samples, rod-like morphology with scaly characteristics (Figure 4.10.a). This variation 
may result from the different effect of the processing parameters on the mass transfer 
during theophylline precipitation as explained by Franceshi and co-workers [13]. 
 
Figure 4. 10. SEM images of unprocessed theophylline (A) compared with different 
SEDS samples; sample 1(B), sample 2 (C), and sample 9 (D). 
(Processing conditions for samples 1, 2, 9 were described in Table 
4.2)  
  
Chapter 4                                                            Crystallisation of theophylline by SEDS  
 152 
4.3.3.2. Thermal analysis 
All the results of the thermal analyses (transition temperature, melting point, and latent 
heat of fusion Hf) of the unprocessed and processed theophylline samples are reported 
in Table 4.4. 
       Table 4. 4. Thermal properties of unprocessed and SEDS theophylline samples 
 
Sample 
TGA DSC 
Transition temp. (C) Melting point (C)  Hf (J/g) 
Unprocessed 281.03 272.36 154.40 
1 235.07 271.82 156.80 
2 238.02 271.92 158.60 
3 238.43 271.78 156.90 
4 232.92 271.68 156.60 
5 234.08 271.58 156.80 
6 235.91 272.26 156.50 
7 236.53 271.73 158.40 
8 240.45 271.57 159.60 
9 242.11 271.49 159.60 
10 242.30 271.79 159.80 
11 237.12 272.04 158.60 
12 233.97 271.71 152.80 
13 232.15 271.95 157.40 
14 239.23 271.60 155.50 
15 239.89 272.05 160.70 
 
(1) Thermal gravimetric analysis (TGA) 
 TGA analyses were carried out on the unprocessed theophylline and all the SEDS 
samples to determine any change in the weight of each sample in relation to the change 
in the temperature. From the TGA curves, the point at which weight loss is most 
apparent (transition temperature) was determined for all the samples (Table 4.4.).  From 
these results it can be observed that the transition temperature for unprocessed 
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theophylline was 281.03C, higher than that of all the processed samples. This may be 
attributed to the facts that the particle size has a predictable effect on the TGA curve the 
smaller the particle sizes, the lower the temperature required for mass loss by melting or 
decomposition. This is because, smaller particles have larger surface areas and so more 
escape of the product gas is allowed [128]. While for larger particles, the mass loss is 
more hindered and so higher temperatures are required.  This proves that there is a 
pronounced reduction in the particle size of the processed samples compared with the 
unprocessed theophylline. Although these observations are consistent with other 
reported results [12- 14], as yet this change in the transition temperature is not fully 
understood and is worthing of further investigation. Figure 4.11 represents the thermal 
gravimetric analysis curve of the unprocessed theophylline and SEDS 5 as 
representative example. From this curve it can be observed that the transition 
temperature of SEDS sample 5 is about 46C below that of the unprocessed 
theophylline. 
 
              
 
 
 
 
 
 
 
 
 
 
Figure 4. 11. TGA curves of unprocessed theophylline compared with SEDS sample 
5 (Processing conditions for sample 5 was described in Table 4.2)  
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(2) Differential scanning calorimetry  (DSC) 
DSC was used to determine the melting point and the latent heat of fusion Hf (the 
change in the enthalpy associated with the thermal event i.e. melting) for the 
unprocessed theophylline and SEDS samples. From the results presented in Table 4.4 it 
can be noted that the melting point of the unprocessed theophylline and of all the 
processed samples are almost equivalent. The melting point of the unprocessed sample 
272.36C is in agreement with those reported in literatures, 271.15-275.15C [14, 237] 
while, the melting points of the processed samples ranged from 271.49- 272.26C.  
Figure 4.12 illustrates the DSC profile of SEDS
 
sample 5 as a representative example. 
The enthalpy change was calculated by integration of the area under the endothermic 
peaks (melting peaks) in the DSC curves of the unprocessed and SEDS samples (Table 
4.4.). The latent heat of melting for the unprocessed sample was 154.40 J/g and the 
mean of the enthalpies change for all the processed samples was 157.57 J/g. All the 
results obtained from the DSC analyses confirm that the processed samples have high 
degrees of crystallinity for all the studied processing parameters. 
Figure 4. 12. DSC profile of SEDS sample 5 (Processing conditions for sample 5 
was described in Table 4.2)  
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4.3.3.3. Crystallinity 
 
X-ray powder diffraction (XRPD) analyses were carried out for the unprocessed and 
SEDS theophylline samples. Figure 4.13 shows XRPD patterns of samples 2, 4, 6, and 8 
compared with the unprocessed samples as representative examples.  
 
Figure 4. 13. XRPD patterns of unprocessed theophylline (A) compared with SEDS 
sample 2 (B), sample 4 (c), sample 6 (D), and sample 8 (E). 
(Processing conditions for SEDS samples were described in Table 
4.2)  
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The characteristic diffraction peaks of unprocessed anhydrous theophylline (Figure 4.13 
a) occur approximately at 7, 12.6, and 14.5, which is matched with its pattern 
reported in literatures [12, 13, 260]. From Figure 4.13 it can be noted that the diffraction 
patterns of the processed samples exhibit the same characteristic peaks of the 
unprocessed theophylline but with different intensities or minor peaks displacement in 
some samples. In addition, some of the processed samples also show new peaks at 
approximately 6.8, 11.6, and 13.9. These minor variations may be due to some 
changes in the growing pattern of the particles during precipitation process that 
promotes changes of both the diffraction peaks intensities [13].  However the DSC, 
TGA, FT-IR, and FT-Raman data for these samples compared with all other processed 
materials, show that theses minor changes in some of the XRPD profiles may be 
associated with instruments error.  
 
4.3.3.4. Vibrational spectroscopic techniques  
These techniques provide excellent methods for probing solid state bonding interactions 
between molecules. 
  
(1) Fourier Transform Infra-Red (FT-IR) 
IR analyses for the unprocessed and SEDS theophylline samples were done. All the 
obtained spectra were compared with that of the unprocessed sample as well as 
reference IR spectra (Figure 4.14.) of theophylline obtained from the British 
pharmacopoeia [252] and different literatures  [237, 253, 261]. It was observed that 
there was no difference between the spectra of the processed samples and that of the 
unprocessed theophylline or the standard reference spectra. Figure 4.15 shows the 
spectra of three SEDS
 
samples compared with the spectrum of the unprocessed sample 
as representative examples.   
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      Figure 4. 14. Reference FT-IR spectrum of theophylline 
       Figure 4. 15. FT-IR spectra of unprocessed theophylline (A) compared with 
SEDS sample 2 (B), sample 4 (c), sample 6 (D), and sample 8 (E) 
(Processing conditions for SEDS samples were described in Table 4.2)  
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 The IR spectrum of theophylline shows a number of bands related to its structure. The 
band present at 3448 cm
-1
 is assigned for N-H stretch of the amine and the band at 2998 
cm
-1 
is assigned to the C-H stretching.  Two bands at 1718, 1668 cm
-1
 are assigned to 
CO stretching, while bands present at 1610 cm-1, and 1566 cm-1 are assigned to CC 
and CN stretching, respectively. Bands at 1314, 1286,1240 cm-1 are assigned to C-N 
stretching and that at 927 cm
-1
 to N-CH3 stretching [253, 261]. The IR spectra for the 
processed samples illustrate all these bands, which demonstrate that there is no 
modification in the bonding interaction between molecules and hence the structure of 
theophylline during the SEDS
 
process over all the processing conditions studied.    
 
(2) Fourier Transform Raman spectroscopy (FT-Raman) 
As a complementary study to the FTIR, FT-Raman analyses were performed on the 
unprocessed and all of the processed samples. From the comparison between the 
obtained spectra, it was observed that the spectra of the SEDS samples were closely 
resembled each other and to that of the unprocessed theophylline. Figure 4.16 shows the 
FT-Raman spectra of the unprocessed and processed samples 2, 4, 6, and 8 as 
representative examples.  
The Raman spectrum of theophylline illustrates various bands, which are related to 
chemical features such as; band at 3120 cm
-1
 being assigned to N-H group. The band 
presents at 2966 cm
-1
 is assigned for C-H group, while bands at 1706, and 1664 cm
-1
 are 
assigned to the C=O group. Bands present at 1611 and 1569 cm
-1
 are assigned to C=C, 
and C=N groups respectively. Bands at 1314, 1285, 1248 cm
-1 
are assigned to the C-N 
group with that at 949 cm
-1
 is assigned for N-CH3 group [261]. These peaks are 
illustrated in all the spectra of the processed samples and this finding confirms the 
results obtained by IR analysis, that the precipitation by SEDS technique has no effect 
on the theophylline structure under different conditions.  
Chapter 4                                                            Crystallisation of theophylline by SEDS  
 159 
 
Figure 4. 16. FT-Raman spectra of unprocessed theophylline (A) compared with 
SEDS sample 2 (B), sample 4 (C), sample 6 (D), and sample 8 (E) 
(Processing conditions for SEDS samples were described in Table 
4.2)  
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4.3.4. Theophylline monohydrate 
Hydrates of pharmaceuticals frequently exhibit differences in physicochemical 
properties such as bioavailability, stability, solubility and dissolution rate. Therefore 
knowledge of transformation of anhydrous to hydrate form is essential for the 
development of stable formulations. Incorporation of water molecule (s) in the crystal 
lattice of anhydrous form changes the dimensions, shape, symmetry and capacity of the 
unit cell. As a result the hydrate form exhibit different physical properties. As a rule in 
solubility behaviour the anhydrous form of a substance is always more soluble in water 
than the corresponding hydrates [262].  
It was reported that the aqueous solubility of anhydrous theophylline is consistently 
higher than that of theophylline monohydrate, below 60C [263]. There is a significant 
difference in the initial dissolution rate of monohydrate compare to anhydrous 
theophylline [264].  It was reported that at the same transport rate, the dissolution rate of 
the anhydrous form is greater than that of the corresponding hydrate [262]. The 
differences in the solubility and the dissolution rates of the hydrate and anhydrous forms 
may alter the bioavailability of the drug. The bioavailability of anhydrous theophylline 
is higher than that of monohydrate. This may be attributed to the difference in aqueous 
solubility and dissolution rate between them. On the other hand the crystallographic 
changes between two phases may be an important factor controlling the bioavailability 
of the formulation [262, 265].  
Trials have been carried out to assess the amount of water required to prepare 
theophylline monohydrate using the SEDS
 
technique and this was traced by XRPD, 
TGA and DSC techniques. As the gram molecular weight (M.wt) of theophylline 
monohydrate is 198.20 where the water ratio is 10 % (180.2 g of anhydrous 
theophylline and 18.0 g of water), solutions of theophylline anhydrous (1g % w/v) 
containing different amounts of water (0.1 – 0.5 ml) were prepared. The processed 
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samples were prepared at T= 40 C and P= 125 bar using 20 ml min-1 and 0.2 ml min-1 
as the flow rate of CO2 and drug solution, respectively.  
Figure 4.17 illustrates the XRPD patterns of the theophylline anhydrous (unprocessed 
and processed), and all other processed samples precipitated from drug solution 
containing different quantities of water (0.1-0.5 ml). The XRPD pattern of theophylline 
monohydrate is in agreement with the reported patterns [266]. This figure shows the 
differences in the XRPD pattern of the anhydrous theophylline (characteristics peaks at 
7, 12.6, and 14.5) and the monohydrate form (characteristics peaks at 8.8, 11.6, and 
14.8). 
Figure 4. 17. XRPD patterns of different theophylline samples; anhydrous unprocessed 
(A), anhydrous SEDS sample (B), sample with 0.1 ml water (C), sample 
with 0.2 ml water (D), sample with 0.3ml water (E), sample with 0.4 
mlwater (F), sample with 0.5 ml water (monohydrate) (G) 
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Figures 4.18, and 4.19 illustrate the DSC and TGA traces for processed theophylline 
samples from solutions containing different ratios of water, respectively. 
 
Figure 4. 18.  DSC traces of SEDS samples processed with different amounts 
                     of water; 0.1 ml (A), 0.2 ml (B), 0.3ml (C), 0.4 ml (D), and 0.5 ml (E). 
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Figure 4. 19. TGA traces of SEDS samples processed with different amounts of water;  
of water; 0.1 ml (A), 0.2 ml (B), 0.3ml (C), 0.4 ml (D), and 0.5 ml (E). 
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From the DSC traces it was observed that the melting point of the products obtained 
from drug solutions containing from 0.1-0.4 ml of water ranged from 271.70-272.39C, 
which is similar to the melting point of the precipitated theophylline anhydrous. There 
are no additional endothermic peaks over the melting peak were observed in these traces. 
On the other hand the DSC trace of the product obtained from theophylline solution 
containing 0.5 ml of water illustrates one extra endothermic peak over the melting peak 
(271.87C) at 107.70C, which represents the water loss from the hydrated theophylline 
before complete melting of the product. This confirms that the theophylline product 
accepts a molecule of water during its precipitation.  
While one transition temperature (one step) is observed at each TGA trace of the first 
four products. It was also observed that the transition temperature of these products 
increases by increasing the amount of water from 0.1 ml to 0.4 ml. These temperatures 
were 245.18, 250.48, 274.36, and 274.44 C respectively.  For the product obtained 
from the theophylline solution containing 0.5 ml of water, two transition temperatures 
(two-steps) at 96.28, and 298.91C were observed. The first temperature represents the 
temperature at which the product losses the accepted water molecule from the 
precipitation process. This demonstrates the potential of preparation of theophylline 
monohydrate using SEDS technique by the addition of appropriate amounts of water to 
the starting drug solution. 
Finally, it can be concluded that anhydrous theophylline was successfully re-crystallised 
by the SEDS process. This technique can produce smaller particles 2-5 m compared to 
the unprocessed sample (30-100 m). The structure and the crystallinity of theophylline 
products were not affected by different processing parameters.  In further study, the next 
objective is to investigate the efficiency of the produced theophylline particles for 
efficient respiratory delivery as inhalable formulations.  
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Chapter 5 
 
In-vitro evaluation of the aerodynamic 
behaviour of SEDS theophylline samples as 
inhaled dry powder formulation 
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5.1 introduction 
The in-vitro characterisation of an aerosol is a useful pre-clinic tool to predict the 
emitted dose and its aerodynamic behaviour with respect to particle size, and the fine 
particle dose (FPD) available upon inhalation. This provides indications about the in-
vivo therapeutic efficiency of the drug [267]. All the methods that are recommended by 
regulatory bodies for the determination of the in-vitro efficiency of inhaled drug are 
based on inertial impaction techniques. These techniques are able to predict the amount 
of the drug that will be deposited in the lungs by using models that mimic the 
dimensions of the human airways. In this study, the dose sampling unit and the 
Andresen Cascade Impactor were used to determine the in-vitro emitted dose and the 
deposition profiles, respectively of SEDS formulations at inhalation flows 28.3, and 60 
L min
-1
 with 4 L inhalation volume. Two types of DPIs were investigated in this study; 
Easyhaler
®
 (multidose reservoir device) and Spinhaler
®
 (single dose device).  
In this study three samples having different particle sizes (SEDS 1, 5 and 9) were 
selected out of the prepared powders by SEDS technique to be tested.  The mean 
particle size of the three samples is 2.44, 1.89, and 3.12 m, respectively. These 
samples as presented in Chapter 4 were prepared under different conditions covering all 
the studied range of temperatures (40-60) and pressures (80-125 bar). They were 
selected as representative examples for all the studied operating parameters. The aim of 
the work is to study the in-vitro aerodynamic performance of the selected SEDS
 
samples either pure or blended with lactose using commercially available DPIs. 
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5.2. Materials and methods  
5.2.1. Instruments 
5.2.1.1. Apparatus used for in-vitro assessment of dry powder inhalers (DPIs) 
(1) For the determination of the emitted dose from the DPIs 
 Empty Easyhaler® dry powder inhaler device (Orion Pharma, Orionintie, Finland) 
 Empty Spinhaler® dry powder inhaler device (Fisons, Loughborough, UK), It has been 
used with empty gelatine capsules (Parke, Davis Co., London, UK) 
 GAST 1023 Pump, 0-100 L/ min (GAST, Brook Hampton, Doncaster, UK) 
 PR 4000 flow-meter (MKS Instruments, Andover, MA, USA) 
 Dry Powder controller Model TPK (Copely Scientific Ltd, Nottingham, UK) 
 Dose sampling unit for DPIs (Copely Scientific Ltd, Nottingham, UK) 
 Glass micro-fibre filters 47mm (Whatman International Ltd, Maidstone, UK) 
 
(2) For the determination of the aerodynamic behaviour of theophylline 
formulations 
  Andersen cascade impactor (Copely Scientific, Nottingham, UK) 
  Glass micro-fibre filters 81 mm (Whatman International Ltd, Maidstone, UK) 
  Copely inhaler testing data analysis software (CITDAS) version 2.00 (Copely   
    Scientific Ltd, Nottingham, UK) 
 
5.2.1.2. General Laboratory Instruments 
  Utrasonic bath (Decon Laboratories, Hove, UK) 
  Nylaflo® nylon membrane filter, 47 mm, 0.45 m pore size (Pall Gelman Sciences, 
    Michigan, USA). 
  Spiromixer S, roller mixer (Denley Instruments Ltd, Sussex, UK) 
  Tumbler mixer (Willy A., Bachofen AG Maschinenfabrik, Basel, Swizerland)  
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5.2.2. Materials 
5.2.2.1. Pharmaceutical excipients 
-Lactose monohydrate; Respitose® SV003, sieved inhalation grade lactose with 
narrow particle size distribution (DMV-Fonterra, Veghel, Netherlands) 
 
5.2.2.2. Theophylline formulations 
 Pure SEDS 1 (prepared as shown in Chapter 4) 
 SEDS 1 (25 %) / Lactose (75 %) blend 
 SEDS 1 (50 %) / Lactose (50 %) blend 
 Pure SEDS 5 (prepared as shown in Chapter 4) 
 SEDS 5 (25 %) / Lactose (75 %) blend 
 SEDS 5 (50 %) / Lactose (50 %) blend 
 Pure SEDS 9 (prepared as shown in Chapter 4) 
 SEDS 9 (25 %) / Lactose (75 %) blend 
 SEDS 9 (50 %) / Lactose (50 %) blend 
 
5.2.3. Methods 
5.2.3.1. Preparation of theophylline blends 
Two blends from the selected SEDS samples were prepared by mixing of theophylline 
and lactose for 20 min. using Spiromixer, and Tumbler mixer (10 min each). The 
uniformity of the mixture was assessed by taking three aliquots from each blend after 
mixing and then quantitatively analysed by HPLC (Chapter 3). 
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5.2.3.2. In-vitro evaluation of the performance of theophylline SEDS samples 
Empty DPIs; Easyhaler
®
 and Spinhaler
®
 were filled with either pure SEDS samples or 
their blends with lactose. For Easyhaler
® 
its reservoir was filled with 40 mg of each 
sample or blend. While for Spinhaler
®
, each capsule was filled with 10 mg of each 
sample or blend. For the in-vitro evaluation of the performance of all these formulations, 
the dose sampling unit and Andersen Cascade Impactor were used. 
  
(1) Dose sampling unit and its operating procedure 
The total emitted dose of theophylline from either Easyhaler
®
 or Spinhaler
®
 was 
determined by sampling apparatus for dry powder inhalers (DPIs) with a critical flow 
controller model TPK. The basic methodology is described in BP [252], EP [173] and 
the USP [174]. The standard compendial methodology used an inhalation volume 4L 
and pressure drop of 4 Kpa. In this study two different inhalation flows 28.3, and 60 L 
min
-1
 were examined at an inhalation volume 4 L to study the effect of flow rate on the 
total emitted dose. The sampling unit for DPIs has a larger diameter compared to the 
one used for metered dose inhalers, to enable the collection of the dose at flows up to 
100 L min
-1
. Figure 5.1 represents a schematic diagram of the dose sampling unit used 
in the study.  
Figure 5. 1. Schematic diagram of the dose sampling unit for DPI 
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The unloaded inhaler device was inserted inside the chamber using a rubber mouthpiece 
adapter, which prevents the powder loss between the collection tube and the inhaler 
mouthpiece. A vacuum pump with sufficient capacity was used to achieve the desired 
inhalation flows. It was switched on for 20 minutes prior to each determination to attain 
a stable flow.          
A time controlled two-way solenoid valve (P2 and P3), connected between the vacuum 
pump and the flow controller valve was opened and the desired flow rate adjusted using 
the flow controller valve. The two-way solenoid valve allows measurements of 
individual values of absolute pressure on either side of the flow controller valve. The 
flows stability is ensured (sonic flow) when the absolute pressure ratio P3/P2 ≤ 0.5 
[174]. Once the flow was set using an electronic flow digital meter (MKS Instruments, 
USA), the two-way solenoid was closed. The inhaler device was then loaded with the 
theophylline dose according to the instructions in the patient information leaflet and re-
inserted in the mouthpiece adapter. The dosing time was set using the following 
equation described in the USP (2005) [174] 
T = (60 sec.  X)/ Q 
Where; T       The time required for withdrawal of 4 L of air from the inhaler 
             Q      Airflow rate 
             X      2or 4 L to be withdrawn 
Depending on the above equation the flow duration required for inhalation flows 28.3, 
and 60 L min
-1 
were; 8.5, and 4 seconds, respectively to allow an inhalation volume 4L. 
After complete delivery of the emitted dose into the sampling unit, the amount of the 
drug on the collection filter (Glass micro-fibre filters 47mm) and the sampling tube 
were carefully rinsed with 20 ml of methanol: water (30:70 % v/v) mixture containing 
30 g ml-1 of the 8-chlorotheophylline as internal standard. The obtained solution was 
placed in an ultrasonic bath for 15 min. to ensure complete solubilization of 
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theophylline and then filtered through nylon membrane filter. The emitted dose of 
theophylline was quantitatively analysed using the developed HPLC method (Chapter 3) 
and the mean, SD and RSD were calculated. Similarly ten separate single doses (n=10) 
were determined for each formulation at each flow rate (28.3 and 60 L min
-1
) using 4 L 
as the inhalation volume.  
 
(2) Determination of the aerodynamic behaviour of formulation using Andresen 
cascade impactor (ACI) 
The ACI stages, preseparator and the induction port were washed with methanol and left 
to dry at room temperature. The impactor collection plates were sprayed with silicon (in 
hexane) to prevent the particle bouncing and then allowed to dry for 1 hour at room 
temperature prior to analysis. The ACI was assembled with the throat (induction port), 
preseparator (PS), stages and the filter in the final stage. To entrain large particles 
(usually  10 m) which may be contained in the DPI, preseparator filled with 10 ml of 
methanol: water mixture (30:70 % v/v) was used [174] (Figure 5.2). 
 
Figure 5. 2.  Schematic diagram of the Andersen Cascade Impactor parts including the 
preseparator 
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The tested DPIs (Easyhaler
®
, or Spinhaler
®
) were fitted onto the induction port by the 
rubber mouthpiece adapter. The flow control valve was adjusted until the required 
steady flow measured with the calibrated flow meter is achieved through the system. 
Sonic flow is achieved by ensuring an absolute pressure ratio P3/P2 ≤ 0.5.  
Although, the EP [173] and USP [174] recommend the evaluation of the aerodynamic 
performance of the emitted dose using a flow rate that creates a pressure drop of 4 Kpa 
at a constant flow volume of 4 L across the inhaler. In this case different inhalation rates 
have been used to study the effect of inhalation flows on the deposition profile of the 
SEDS theophylline. The determinations of each formulation were performed at flow 
rates of 28.3, and 60 L min
-1
 (n = 3) with discharge times of 8.5, and 4 seconds, 
respectively to ensure an inhalation volume of 4 L.   
For the determinations at 60 L min
-1
 the stages number 0 and 7 (used at flow rate 28.3 L 
min
-1
) were replaced by stages –1 and –0. As the ACI is designated for operation at flow 
rate 28.3 L min
-1
, so upon using the higher flow rate the effective cut off diameter (ECD) 
of the stages should be recalculated using Van Oort equation [179].  
Two separate single doses were used from each formulation for each determination, 
except for the Spinhaler
®
 where only one single dose was used for each test due to the 
high emitted dose. 
After the complete sampling, the pump was turned off and the ACI was disassembled. 
The impactor components were then rinsed separately with different volumes of 
methanol: water (30:70 v/v) mixture containing 30 g ml-1 of the 8-chlorotheophylline 
as internal standard. Table 5.1 represents the washing volumes of methanol: water 
mixtures used for rinsing the ACI stages at different flow rates. 
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 Table 5.1.The effective cut-off diameters and the washing volume of ACI stages 
 
Stage  
Flow rate L min
-1
 
28.3 60 
ECD * 
(m) 
Washing volume 
(ml) 
ECD* 
(m) 
Washing volume 
(ml) 
Induction port ----- 20 ----- 20 
Preseparator ----- 20 ----- 20 
-1 ----- ----- 9.0 10 
-0 ----- ----- 5.8 10 
0 9.0 10 ----- ----- 
1 5.8 10 4.7 10 
2 4.7 10 3.3 5 
3 3.3 5 2.1 5 
4 2.1 5 1.1 5 
5 1.1 5 0.7 5 
6 0.7 5 0.4 5 
7 0.4 5 ----- ----- 
Filter 0 5 0 5 
 
      * Effective cut off Diameter Adapted from Copley Scientific 2007. 
 
 
5.2.3.3. Sample analysis using HPLC method 
The resulting solutions recovered from cascade impactor were analysed using the 
developed HPLC method (Chapter 3) for quantitative determination of the amount of 
the drug deposited on each stage in the impactor.  
 
5.2.3.4. Data analysis 
The Copley Inhaler testing data analysis software (CITDAS version 2.0) was used to 
calculate all the aerodynamic parameters for the studied SEDS theophylline 
formulations including;  
Total emitted dose (TED); was determined as the total amount of the drug deposited on 
the stages and the filter of the cascade impactor (excluding the inhaler deposition)  
Fine particle dose (FPD) as specified by CITDAS was the amount of the drug with 
aerodynamic diameter less than 5 m. 
Fine particle fraction (FPF) was calculated as FPD/emitted dose * 100% 
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The Mass median aerodynamic diameter (MMAD) was calculated from the logarithm 
of the ECD corresponding to 50% undersize particles (on probability scale).  
The Geometric standard deviation (GSD) was calculated from the following equation; 
GSD = (d84.13% / d15.87%)
^ 0.5
 [174]. 
Where d84.13%, and d15.87% are the aerodynamic particle size at 15.87% and at 84.13% 
less than the stated size, respectively for the cumulative size distribution.  
The mean and SD of the TED, FPD, FPF, MMAD, and GSD were determined for each 
formulation at two inhalation flows of 28.3, and 60 L min
-1
.  
 
5.2.3.5. Statistical analysis 
Statistical analysis of FPD, FPF, MMAD, and GSD was carried out using the SPSS 
(version 15.0) computer programme for the studied formulations at two flows 28.3 and 
60 L min
-1
. A two-way analysis of variance (ANOVA) with the application of general 
linear model univariate, was used to determine any significant differences between the 
aerodynamic behaviour of the same formulation under different flows and between 
different formulations under the same flows. The mean difference (95% confidence 
interval) was also calculated.    
 
5.3. Results and discussion 
The in-vitro testing of DPIs is an important stage in the development of a new inhalable 
formulation. The results provided gave an idea about the aerodynamic behaviour of 
theophylline prepared by SEDS technique. Furthermore, these results determine any 
differences in the emitted dose, deposition profiles, between different theophylline 
samples with different particle size. The effect of blending theophylline with inhalable 
lactose as a carrier on its deposition profile was also investigated. 
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5.3.1. Determination of the emitted dose of SEDS theophylline formulations 
recovered from Easyhaler
®
 at different inhalation flows 
Tables 5.2, 5.3, and 5.4 show the mean (n =10), SD, and RSD of the total emitted dose 
of theophylline recovered from the Easyhaler
®
 using two different inhalation flows 
(28.3, and 60 L min
-1
) for pure SEDS samples and their blends with lactose. Two blends 
were prepared in this study 50 % and 25 % blends, the first blend consists of 50 % of 
SEDS theophylline and 50 % of inhalable lactose. While, the second blend consists of 
25 % of SEDS theophylline and 75 % of lactose.   
 A summary of these data is shown in Table 5.5 and Figure 5.3. The statistical 
comparisons for the dose emission results of each formulation at different inhalation 
flows and the dose emitted from different formulations under the same inhalation flow 
were represented in Tables 5.6.  and 5.7, respectively.   
 
Table 5. 2. The emitted dose of pure theophylline SEDS samples recovered from the 
Easyhaler
®
 at different inhalation flows 
 
 
 
 
Dose 
No. 
Emitted dose (g) 
SEDS
 
1 
 
SEDS 5 SEDS 9 
 
28.3 
 L min
-1
  
 
60  
L min
-1
 
 
28.3 
 L min
-1
 
 
60  
L min
-1
   
 
28.3  
L min
-1
 
 
60  
L min
-1
 
1 184.32 213.24 186.37 215.32 173.71 211.17 
2 175.56 212.60 174.23 211.25 182.35 224.32 
3 183.01 197.35 187.01 212.37 181.21 212.30 
4 179.37 210.21 184.07 216.99 183.59 205.59 
5 178.42 216.97 180.85 220.25 192.96 211.35 
6 197.49 212.34 188.63 215.32 185.55 211.26 
7 187.24 220.78 185.42 200.21 183.32 205.55 
8 185.42 213.65 192.55 215.29 169.05 213.63 
9 181.32 212.24 184.30 182.36 180.32 215.21 
10 182.12 212.15 184.85 205.32 187.33 206.91 
Mean 183.43 212.16 184.83 212.36 181.94 211.73 
SD 6.02 5.99 4.84 5.86 6.71 5.52 
RSD 3.28 2.83 2.62 2.76 3.69 2.61 
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    Table  5. 3. The emitted dose of 50% blend of SEDS theophylline samples recovered 
                   from the Easyhaler
®
 at different inhalation flows 
 
 
Table 5. 4. The emitted dose of 25% blend of SEDS theophylline samples recovered  
                   from the Easyhaler
®
 at different inhalation flows 
 
 
 
 
 
Dose 
No. 
Emitted dose (g) 
SEDS
 
1 
 
SEDS 5 SEDS 9 
 
28.3 
 L min
-1
  
 
60  
L min
-1
 
 
28.3 
 L min
-1
 
 
60  
L min
-1
   
 
28.3  
L min
-1
 
 
60  
L min
-1
 
1 154.24 183.34 149.99 185.63 150.35 186.24 
2 149.24 172.21 154.50 181.96 139.85 184.53 
3 146.37 187.63 157.33 182.86 151.97 192.35 
4 149.55 180.55 154.19 176.17 150.64 187.66 
5 148.65 186.01 150.69 180.06 152.41 180.21 
6 149.66 182.97 138.36 185.82 148.99 181.72 
7 157.22 175.75 155.67 188.34 155.10 177.91 
8 155.65 183.32 152.76 185.46 155.30 173.35 
9 151.65 182.67 154.35 172.69 141.82 185.85 
10 152.49 182.59 154.22 186.22 157.94 186.36 
Mean 151.47 181.70 152.21 182.52 150.44 183.68 
SD 3.42 4.58 5.33 4.94 5.74 5.47 
RSD 2.26 2.52 3.50 2.71 3.81 3.13 
 
Dose 
No. 
Emitted dose (g) 
SEDS
 
1 
 
SEDS 5 SEDS 9 
 
28.3 
 L min
-1
  
 
60  
L min
-1
 
 
28.3 
 L min
-1
 
 
60  
L min
-1
   
 
28.3  
L min
-1
 
 
60  
L min
-1
 
1 140.43 150.75 136.52 155.32 136.25 156.39 
2 135.34 158.24 140.26 152.25 136.69 154.26 
3 136.64 154.76 137.89 152.37 127.26 150.64 
4 132.16 150.39 150.26 154.99 140.68 151.46 
5 138.43 156.63 140.37 150.25 141.91 158.23 
6 142.49 140.47 138.25 165.32 139.03 159.37 
7 149.99 153.68 139.69 150.21 138.65 153.32 
8 135.37 153.53 139.48 155.29 141.59 153.21 
9 137.24 162.56 140.37 152.36 139.69 155.09 
10 140.89 151.75 136.64 156.32 137.65 156.36 
Mean 138.90 153.28 139.97 154.47 137.94 154.83 
SD 4.95 5.83 3.90 4.38 4.22 2.81 
RSD 3.57 3.80 2.79 2.84 3.06 1.82 
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Table 5. 5. Summary of the mean emitted dose of SEDS samples recovered from    
                   the Easyhaler
®
 at different inhalation flows 
 
 
Formulations 
 
Dose emitted in (g) 
SEDS
 
1 SEDS 5 SEDS 9 
 
28.3  
L min
-1
 
 
60 
 L min
-1
 
 
28.3 
 L min
-1
 
 
60  
L min
-1
 
 
28.3 
 L min
-1
 
 
60 
 L min
-1
  
Pure samples  
Mean 
SD 
RSD 
183.43 
6.02 
3.28 
 
212.16 
5.99 
2.83 
 
184.83 
4.84 
2.62 
 
212.36 
5.86 
2.76 
181.94 
6.71 
3.69 
211.73 
5.52 
2.61 
50 % blend   
Mean 
SD 
RSD 
151.47 
3.42 
2.26 
181.70 
4.58 
2.52 
152.21 
5.33 
3.50 
182.52 
4.94 
2.71 
150.44 
5.74 
3.81 
183.68 
5.47 
3.13 
25% blend  
Mean 
SD 
RSD 
138.90 
4.95 
3.57 
153.28 
5.83 
3.80 
137.97 
3.90 
2.79 
154.47 
4.38 
2.84 
137.94 
4.22 
3.06 
154.83 
2.81 
1.82 
 
 
 
Figure 5. 3. Total emitted dose from the Easyhaler
®
 at inhalation flows 28.3 and 60 L 
min
-1
 for all the studied SEDS formulations (Processing conditions for 
samples 1,5, 9 were described in Table 4.2.) 
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                         Table 5. 6. Statistical comparison for the emitted dose of SEDS samples in pure form and lactose blends recovered from  
                                           the Easyhaler
®
 at inhalation flows 60 L min
-1
and 28.3 L min
-1
  
 
Formulations 
Mean difference (95% confidence Interval) 
Emitted dose from Easyhaler (g) 
SEDS
 
1 SEDS 5 SEDS 9 
 
Pure samples 
25% blend 
50% blend 
 
28.73 (22.89, 34.56)*** 
14.38 (8.24,3.20.51) *** 
30.23 (25.58, 34.88)*** 
 
27.54 (22.49, 32.88) *** 
15.50 (11.76, 19.23) *** 
30.31 (24.57, 36.06) *** 
 
28.19 (23.43, 32.95)*** 
16.89(14.06, 19.72) *** 
33.24 (26.90, 39.58) *** 
                      
                          Table 5. 7. Statistical comparison for the emitted dose of SEDS samples in pure form and in lactose blends recovered from 
                    the Easyhaler
®
 at the same inhalation flow. 
 
Formulations 
Mean difference (95% confidence Interval) 
Emitted dose from Easyhaler (g) 
SEDS
 
1 SEDS 5 SEDS 9 
 
At 28.3 L min
-1
 
 
 
31.95 (28.44, 35.46) *** 
44.53 (41.62, 48.04) *** 
12.58 (9.07, 16.09) *** 
 
 
32.62 (27.97, 37.27) *** 
44.86 (40.20, 49.51) *** 
12.23 (7.59, 16.88) *** 
 
 
31.50 (26.32, 36.68) *** 
43.99 (38.82, 49.78) *** 
12.50 (7.31, 17.68) *** 
Pure samples vs. 25% blend 
Pure samples vs. 50% blend 
25 % blend vs. 50 % blend 
At 60 L min
-1
  
 
30.44 (24.82, 36.07) *** 
58.88 (53.25, 64.50) *** 
28.43 (22.80, 34.06) *** 
 
 
29.84 (25.03, 34.66) *** 
57.90 (53.08, 62.71) *** 
28.05 (23.24, 32.86) *** 
 
 
28.05 (23.46, 32.65) *** 
56.90 (52.30, 61.49) *** 
28.84 (24.25, 33.43) *** 
Pure samples vs. 25% blend 
Pure samples vs. 50% blend 
25 % blend vs. 50 % blend 
                           ***P  0.001  
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For the determination of the total emitted dose, the pharmacopoeias recommended an 
inhalation volume of 4 L through the inhaler with inhalation flow corresponding to a 
pressure drop 4 Kpa across the inhaler. The inhalation flows equivalent to pressure drop 
of 4 Kpa across the Easyhaler
®
 is equivalent to 40.2 L min
-1 
[268]. This method is a 
quality control test when there is intra-patients or intra-device variability [269]. The 
determination of the total emitted dose at different inhalation flows provides an 
appreciation of the results obtained during normal practice. Also the main object in this 
study is to examine the effect of different inhalation flows on the total emitted doses of 
SEDS theophylline formulations. Therefore, two inhalation flows were used low (28.3 
L min
-1
) and high (60 L min
-1
).  
Data obtained from the dose emission test shows that the three samples in all the studied 
formulations provided good dose emission. The total emitted dose ranged from 138.94-
184.83 g, and from 152.68- 212.65 g upon using inhalation flows of 28.3 and 60 L 
min
-1
 respectively for all the tested samples. The results indicate good reproducibility of 
the delivered theophylline doses, as the RSDs for all samples were lower than 5 %.  
Thus sufficient homogeneity and flowability of the SEDS powder were achieved.  
As shown in Tables 5.2-5.4, generally small variations were found in the emitted dose 
between the samples within the same formulations at the same inhalation flow. But 
significant differences were observed when working with different inhalation flows. 
There was an increase in the emitted dose upon increasing the inhalation flow from 28.3 
to 60 L min
-1 
for all the studied samples. This significant difference (p 0.001) was 
confirmed by the statistical comparison between obtained data at different inhalation 
flows for all the tested samples (Table 5.6.). Although the emitted dose seemed to be 
flow rate dependant (Figure 5.3), no sharp differences observed at different inhalation 
flows. This is consistent with the reported results [218] which show that Easyhaler
®
 is 
less affected by changes in inhalation rates than other DPIs such as the Turbuhaler
®
. 
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Furthermore, the doses emitted at 28.3 L min
-1
 was found to be approximately 85% of 
that created at 60 L min
-1
 for all the tested formulations. Therefore, reasonably good 
theophylline dose can be achieved with patients who may have difficulties in generating 
high levels of inhalation flow such as children and the elderly, and this agrees with the 
reported results in different literatures [215, 270]. 
On the other hand there was a significant difference (p 0.001) between the emitted 
doses of the three samples in different formulations under the same inhalation flow 
(Table 5.7).  
The scope of this work was further extended to study the in-vitro aerodynamic 
behaviour and the lung deposition pattern of the inhaled SEDS formulations using the 
ACI. 
 
5.3.2. In-vitro aerodynamic particle size distribution of SEDS
 
theophylline         
formulations delivered from the Easyhaler
® 
at different inhalation flows  
 
5.3.2.1. Pure SEDS theophylline formulation 
Tables 5.8 and 5.9 show the particle size distribution for the pure SEDS
 
formulation 
recovered from the Easyhaler
®
 at two different inhalation flows, after actuation of two 
puffs into the ACI for each sample. They also show the total emitted dose (TED), TED 
per shot, fine particle dose (FPD), fine particle fraction (FPF), Mass median 
aerodynamic diameter (MMAD), and Geometric standard deviation (GSD) for each 
sample. 
Figures 5.4 and 5.5 represent the mean amount of theophylline deposited on each stage 
of the ACI at two inhalation flows; 28.3 and 60 L min
-1
.  
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Table 5. 8. Particle size distribution of pure SEDS theophylline samples recovered from 
the Easyhaler
®
 at 28.3 L min
-1
  
Stages Stage ECD 
(m) 
Amount in (g)  SD (n =3) 
SEDS1 SEDS 5 SEDS 9 
Throat  152.12 (1.22) 139.15 (1.01) 124.98 (3.83) 
Preseparator  183.39 (1.57) 184.74 (2.07) 218.89 (1.52) 
Stage 0 9 7.27 (0.22) 7.99 (0.20) 5.50 (0.16) 
Stage 1 5.8 4.23 (0.15) 7.33 (0.07) 2.5 (0.30) 
Stage 2 4.7 3.65 (0.51) 6.20 (0.55) 2.26 (0.10) 
Stage 3 3.3 3.28 (0.21) 8.72 (0.23) 1.99 (0.20) 
Stage 4 2.1 4.72 (0.10) 5.53 (0.25) 2.46 (0.05) 
Stage 5 1.1 2.92 (0.09) 5.11 (1.09) 1.85 (0.02) 
Stage 6 0.7 1.63 (0.11) 2.32 (0.23) 1.29 (0.21) 
Stage 7 0.43 1.53 (0.12) 1.27 (0.36) 0.73 (0.17) 
Filter 0 0.37 (0.12) 0.52 (0.25) 0.14 (0.001) 
TED (g)  365.11 (1.59) 369.07 (3.94) 362.62 (2.41) 
Number of Doses   2 2 2 
TED per shot (g)  182.56 (0.79) 184.70 (1.93) 181.31 (1.20) 
FPD (g)  7.79 (0.17) 13.00 (0.20) 4.55 (0.05) 
FPF (%)  4.27 (0.09) 7.04 (0.04) 2.51 (0.03) 
MMAD (m)  4.80 (0.01) 4.47 (0.07) 5.12 (0.14) 
GSD  3.30 (0.07) 2.71 (0.04) 3.43 (0.14) 
 
Figure 5. 4. Mean amounts (g) of pure SEDS theophylline deposited in ACI                         
stages at 28.3 L min
-1
 from the Easyhaler
®
 (Processing parameters of 
samples 1, 5, 9 were described in Table 4.2.) 
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Table 5. 9. Particle size distribution of pure SEDS theophylline samples recovered from 
the Easyhaler
®
 at 60 L min
-1
  
Stages Stage ECD 
(m) 
Amount in (g)  SD (n =3) 
SEDS1 SEDS 5 SEDS 9 
Throat  127.19 (3.36) 124.39 (0.32) 112.79 (3.97) 
Preseparator  261.15 (1.37) 245.40 (2.82) 287.81 (4.88) 
Stage -0 9 5.73 (0.11) 9.34 (0.25) 5.643 (0.05) 
Stage -1 5.8 7.17 (0.06) 8.50 (0.40) 2.88 (0.07) 
Stage 1 4.7 4.97 (0.04) 6.54 (0.31) 3.54 (0.13) 
Stage 2 3.3 4.82 (0.05) 8.41 (0.33) 3.11 (0.06) 
Stage 3 2.1 5.42 (0.08) 9.49 (0.22) 3.11 (0.02) 
Stage 4 1.1 3.90 (0.08) 6.78 (0.04) 1.22 (0.03) 
Stage 5 0.7 2.16 (0.09) 2.27(0.057) 1.57 (0.05) 
Stage 6 0.43 1.54 (0.02) 1.88 (0.01) 1.03 (0.03) 
Filter 0 0.37 (0.10) 1.20 (0.08) 0.32 (0.002) 
TED (g)  424.36 (4.65) 424.194 (2.45) 423.03 (0.99) 
Number of Doses   2 2 2 
TED per shot (g)  212.18 (2.32) 212.10 (1.23) 211.52 (0.48) 
FPD (g)  9.88 (0.02) 16.12 (0.31) 5.70 (0.05) 
FPF (%)  4.70 (0.06) 7.60 (0.16) 2.70 (0.02) 
MMAD (m)  4.62 (0.01) 4.17 (0.05) 4.95 (0.02) 
GSD  3.13 (0.03) 2.67 (0.02) 3.29 (0.05) 
 
       
Figure 5. 5. Mean amounts (g) of pure SEDS theophylline deposited in ACI                         
stages at 60 L min
-1
 from the Easyhaler
®
. (Processing parameters of 
samples 1, 5, 9 were described in Table 4.2.) 
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Data obtained from the ACI show that for a pure SEDS sample, the largest deposits 
were in the throat and the preseparator and only small amounts were recovered from the 
ACI stages and the filter. This may be attributed to the fact that pure powder particles 
without any carrier are stuck together and needed high inhalation flow to be de-
aggregated into fine particles. Therefore, these adhered particles are too large to be 
carried by the air stream to the lower stages of the ACI. The TED was quite similar for 
the three samples but there was a significant difference between them in other 
aerodynamic characteristics under the same inhalation flows (Table 5.10).  
Table 5. 10. Statistical comparison for the ACI results of different pure SEDS 
theophylline samples recovered from the Easyhaler
®
 at the same 
inhalation flows. 
 
 
 
Mean difference (95% confidence Interval) 
SEDS 1 
vs 
SEDS 5 
SEDS 1 
vs 
SEDS 9 
SEDS 5 
vs 
SEDS 9 
At 28.3 L min
-1
    
FPD (g) -5.21 
(-5.61, -4.86)
***
 
3.24 
(2.84, 3.64)
***
 
8.45 
(8.05, 8.85)
***
 
FPF (%) -2.77 
(-2.92, -2.62)
***
 
1.76 
(1.61, 1.91)
***
 
4.53 
(1.61, 1.91)
***
 
MMAD (m) 
 
0.33 
(0.17, 0.49)
 **
 
-0.32 
(-0.48, -0.16)
 *
 
-0.29 
(-0.45, -0.15)
 *
 
GSD 0.54 
(0.45, 0.64)
 ***
 
 
-0.24 
(-0.34, -0.14)
 **
 
 
-0.78 
(-0.88, -0.69)
***
 
 
At 60 L min
-1
    
FPD (g) -6.21 
(-6.66, -5.83)
***
 
4.14 
(3.76, 4.59)
***
 
10.42 
(10.0, 10.83)
***
 
FPF (%) -2.96 
(-3.15,-2.76)
***
 
1.95 
(1.75,2.14)
***
 
4.90 
(4.71, 5.09)
***
 
MMAD (m) 0.46 
(0.25, 0.67)
**
 
-0.48 
(-0.69, -.27)
**
 
-0.95 
(-1.16, -0.74)
***
 
GSD 0.46 
(0.31, 0.61)
**
 
-0.29 
(-0.45, -0.15)
*
 
-0.76 
(-0.91, -0.61)
***
 
           *P 0.01    **P 0.005   ***P  0.001 
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The highest FPD and FPF were obtained from the SEDS 5; 13.00 g, 7.04 %, 
respectively. The lowest FPD and FPF were obtained from SEDS 9; 4.55 g, 2.51 %, 
respectively. On the other hand SEDS 5 shows the lowest MMAD and GSD, 4.47 m, 
2.71, respectively.  This is in agreement with SEM images and particle size analysis 
results discussed in Chapter 4. The particle size of SEDS samples 1, 5, 9 was 2.44, 1.89, 
and 3.12 m, respectively. Therefore SEDS 5 with the lowest particle size (small rod-
shape) shows better aerodynamic characteristics than sample 1 and 9 (long needles). 
The results also indicate an increase in the FPD and FPF as the flow increases from 28.3 
to 60 L min
-1
. It was also observed that the MMAD and GSD decrease as the flow 
increases. There was a statistically significant difference in FPD, FPF, MMAD and 
GSD for all the studied samples at different inhalation flows (Table 5.11).  To enhance 
the FPD and FPF for pure formulation, theophylline was blended with different 
proportions of inhalable lactose (DMV-Fonterra) and the aerodynamic behaviour of 
these new formulations was tested. Lactose is the commonly used as a carrier as it can 
accomplish many of the ideal requirements. It is readily available in an acceptable 
pharmaceutical grade, chemically and physically stable and inert to the drug substances. 
Furthermore, it is readily cleared from the airway without any harmful effect on the 
respiratory tract [227, 230]. Lactose is available in two basic isomeric forms namely - 
and -lactose or as an amorphous form. -lactose exists as monohydrate and anhydrous 
forms. -lactose monohydrate is thermodynamically stable form and is commonly used 
as a carrier in DPIs. The physical properties of lactose such as particle size, shape and 
surface texture have been shown to affect the dispersion and deaggregation of adhered 
drugs [225-227]. 
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Table 5. 11. Statistical comparison for the ACI results of different pure SEDS 
theophylline samples recovered from the Easyhaler
® 
at inhalation flows 
60 L min
-1
 and  28.3 L min
-1
. 
 Mean difference (95% confidence Interval) 
SEDS 1 SEDS 5 SEDS 9 
FPD (g) 
 
 
 
FPF (%) 
 
 
 
MMAD (m) 
 
 
GSD 
 
 
2.13 
(1.84, 2.43)*** 
 
 
0.42 
(0.24, 0.59)** 
 
-0.16 
(-0.18, -0.15)** 
 
 
-0.21 
(-0.37, -0.05)* 
 
 
3.01 
(2.44,3.57)** 
 
0.53 
(0.21, 0.86)** 
 
 
 
 
 
 
 
 
 
 
-0.31 
(-0.46, -0.16)* 
 
 
 
 
 
 
 
-0.07 
(-0.12, -0.01)* 
1.17 
(1.04, 1.29)*** 
 
0.19 
(0.11, 0.26)** 
 
-0.21 
(-0.41, -0.01)* 
 
 
-0.21 
(-0.32, -0.09)* 
 
 
      *P 0.01    **P 0.005   ***P  0.001 
 
5.3.2.2. SEDS
 
theophylline and lactose blends 
Tables 5.12-5.15 show the particle size distribution of theophylline blends (25 %  and 
50 % blends) delivered from Easyhaler
®
 at two different inhalation flows (28.3 and 60 L 
min
-1
), after actuation of two puffs into the ACI. They also illustrate TED, TED per shot, 
FPD, FPF, MMAD, and GSD for each sample. Figures 5.6 - 5.9 represent the mean 
amount of theophylline deposited on each stage of the ACI at two inhalation flows. A 
summary of the ACI data for all SEDS theophylline formulations recovered from 
Easyhaler
®
 is shown in Table 5.16. 
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Table 5. 12. Particle size distribution of 50% blend of SEDS theophylline from the 
Easyhaler
®
 at 28.3 L min
-1
  
Stages Stage ECD 
(m) 
Amount in (g)  SD (n =3) 
SEDS 1 SEDS 5 SEDS 9 
Throat  81.56  (2.43) 71.57 (2.43) 98.72 (1.50) 
Preseparator  110.77 (0.18) 90.12 (1.27) 151.91 (2.98) 
Stage 0 9 19.77 (1.30) 22.43 (0.20) 13.50 (0.39) 
Stage 1 5.8 15.61 (0.12) 17.61 (0.12) 7.30 (0.04) 
Stage 2 4.7 17.52 (0.27) 18.25 (0.20) 6.41 (0.51) 
Stage 3 3.3 19.15 (0.16) 27.14 (0.15) 7.56 (0.37) 
Stage 4 2.1 19.65 (0.30) 27.65 (0.30) 7.15  (0.12) 
Stage 5 1.1 10.08 (0.06) 16.08 (0.06) 4.24 (0.07) 
Stage 6 0.7 5.82 (0.66) 7.72 (0.21) 2.59 (0.06) 
Stage 7 0.43 3.24 (0.25) 3.57 (0.33) 2.14 (0.16) 
Filter 0 1.26 (0.06) 1.26 (0.06) 0.66 (0.15) 
TED (g)  304.42 (3.11) 303.39 (3.40) 302.17 (1.85) 
Number of Doses   2 2 2 
TED per shot (g)  152.22 (1.56) 151.70 (1.70) 151.08 (0.93) 
FPD (g)  32.43 (0.59) 44.84 (0.14) 13.31 (0.17) 
FPF (%)  21.31 (0.31) 29.56 (0.30) 8.68 (0.07) 
MMAD (m)  4.43 (0.03) 3.99 (0.02) 4.93 (0.06) 
GSD  2.62 (0.04) 2.36 (0.02) 2.91 (0.02) 
 
 
 
Figure 5. 6. Mean amounts (g) of 50% blend of SEDS theophylline deposited in ACI 
stages at 28.3 L min
-1
 from the Easyhaler
®
.(Processing parameters of 
samples 1, 5, 9 were described in Table 4.2.) 
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Table 5. 13. Particle size distribution of 50% blend of SEDS theophylline recovered 
from the Easyhaler
®
 at 60 L min
-1
  
Stages Stage ECD 
(m) 
Amount in (g)  SD (n =3) 
SEDS1 SEDS 5 SEDS 9 
Throat  91.62 (2.24) 71.63 (2.24) 109.63 (1.19) 
Preseparator  123.60 (3.79) 118.60 (0.89) 170.73 (0.51) 
Stage -0 9 24.63 (1.23) 26.13 (0.20) 21.01 (0.77) 
Stage -1 5.8 23.98 (0.35) 20.65 (0.26) 12.31 (0.09) 
Stage 1 4.7 20.63 (0.07) 23.63 (0.07) 10.62 (0.33) 
Stage 2 3.3 24.06 (0.67) 29.39 (0.19) 12.43 (0.26) 
Stage 3 2.1 25.22 (0.23) 29.22 (0.23) 12.48 (0.43) 
Stage 4 1.1 18.30 (0.81) 27.63 (0.25) 7.24 (0.09) 
Stage 5 0.7 7.45 (0.29) 10.45 (0.29) 5.24 (0.01) 
Stage 6 0.43 3.50 (0.19) 3.50 (0.189) 2.43 (0.21) 
Filter 0 1.38 (0.32) 2.38 (0.32) 0.36 (0.14) 
TED (g)  364.35 (1.58) 363.18 (2.48) 364.47 (1.53) 
Number of Doses   2 2 2 
TED per shot (g)  182.18 (0.79) 181.59 (1.24) 182.24 (0.76) 
FPD (g)  43.34 (0.96) 55.29 (0.42) 21.69 (0.26) 
FPF (%)  23.79 (0.60) 30.45 (0.22) 11.90 (0.09) 
MMAD (m)  4.34 (0.32) 3.87 (0.02) 4.88 (0.04) 
GSD  2.55 (0.03) 2.29  (0.01) 2.75 (0.08) 
 
 
    
Figure 5. 7. Mean amounts (g) of 50% blend of SEDS theophylline deposited in ACI 
stages at 60 L min
-1
 from the Easyhaler
®
. (Processing parameters of 
samples 1, 5, 9 were described in Table 4.2.) 
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Table 5. 14. Particle size distribution of 25% blend of SEDS theophylline recovered 
from the Easyhaler
®
 at 28.3 L min
-1
  
Stages Stage ECD 
(m) 
Amount in (g)  SD (n =3) 
SEDS 1 SEDS 5 SEDS 9 
Throat  61.21 (0.94) 51.04  (1.13) 81.64 (4.16) 
Preseparator  53.91 (1.03) 41.72 (0.80) 103.54 (2.89) 
Stage 0 9 26.26 (0.06) 27.91 (0.07) 20.25 (0.18) 
Stage 1 5.8 22.48 (0.44) 23.28 (0.08) 15.55 (0.36) 
Stage 2 4.7 28.14 (0.08) 27.28 (0.16) 12.66 (0.30) 
Stage 3 3.3 27.47 (0.58) 28.30 (0.23) 12.86 (0.31) 
Stage 4 2.1 27.79 (0.73) 28.36 (0.29) 13.44  (0.30) 
Stage 5 1.1 18.28 (0.07) 26.48 (0.43) 12.56 (0.25) 
Stage 6 0.7 10.19 (0.06) 15.18 (0.07) 2.76 (0.05) 
Stage 7 0.43 3.28 (0.08) 6.73 (0.103) 1.86 (0.02) 
Filter 0 1.23 (0.084) 2.53 (0.042) 0.84 (0.04) 
TED (g)  280.25 (0.38) 278.80 (2.85) 277.97 (2.68) 
Number of Doses   2 2 2 
TED per shot (g)  140.13 (0.44) 139.40 (1.42) 139.02 (1.37) 
FPD (g)  48.65 (0.56) 58.37 (0.50) 24.12 (0.24) 
FPF (%)  34.72 (0.35) 41.87 (0.10) 17.34 (0.33) 
MMAD (m)  4.36 (0.03) 3.92 (0.02) 4.86 (0.05) 
GSD  2.57 (0.03) 2.25 (0.002) 2.66 (0.01) 
 
 
 
Figure 5. 8. Mean amounts (g) of 25% blend of SEDS theophylline deposited in ACI                    
stages at 28.3 L min
-1
 from the Easyhaler
®
(Processing parameters of 
samples 1, 5, 9 were described in Table 4.2.) 
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Table 5. 15. Particle size distribution of 25% blend of SEDS theophylline recovered 
from the Easyhaler
®
 at 60 L min
-1
  
Stages Stage ECD 
(m) 
Amount in (g)  SD (n =3) 
SEDS1 SEDS 5 SEDS 9 
Throat  31.72 (1.29) 27.32 (1.81) 80.76 (4.32) 
Preseparator  80.96 (0.80) 79.28 (2.23) 114.66 (4.16) 
Stage -0 9 30.36 (0.23) 22.61 (0.36) 20.36 (0.30) 
Stage -1 5.8 27.58 (0.41) 25.52 (0.23) 17.61 (0.39) 
Stage 1 4.7 29.09 (0.68) 27.38 (0.27) 16.63 (0.19) 
Stage 2 3.3 31.83 (1.06) 30.52 (0.14) 14.24 (0.35) 
Stage 3 2.1 31.52 (0.15) 33.82 (0.16) 15.75 (0.26) 
Stage 4 1.1 28.35 (0.03) 28.44 (0.21) 15.70 (0.11) 
Stage 5 0.7 9.555 (0.03) 15.45 (0.15) 3.85 (0.04) 
Stage 6 0.43 3.25 (0.13) 8.37 (0.31) 0.75 (0.08) 
Filter 0 1.66 (0.34) 4.55 (0.53) 0.18 (1.15) 
TED (g)  305.88 (2.13) 303.26 (1.18) 300.49 (0.32) 
Number of Doses   2 2 2 
TED per shot (g)  152.94 (1.07) 150.544 (0.59) 151.03 (0.26) 
FPD (g)  57.88 (0.64) 65.20 (0.24) 27.76 (0.25) 
FPF (%)  37.84 (0.33) 42.99 (0.22) 18.48 (0.18) 
MMAD (m)  4.22 (0.03) 3.61 (0.03) 4.83 (0.03) 
GSD  2.51  (0.01) 2.11 (0.01) 2.59 (0.02) 
 
 
Figure 5. 9. Mean amounts (g) of 25% blend of SEDS theophylline deposited in                       
ACI stages at 60 L min
-1
from the Easyhaler
®
(Processing parameters of 
samples 1, 5, 9 were described in Table 4.2.) 
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Table 5. 16. Summary of ACI results for all SEDS formulations recovered from Easyhaler
®
 at inhalation flows of 28.3 and 60 L min
-1
 
 
 
 
 
Formulations 
Pure samples  50 % blend 25 % blend 
 
SEDS 1 
 
SEDS 5 
 
SEDS 9 
 
SEDS 1 
 
SEDS 5 
 
SEDS 9 
 
SEDS 1 
 
SEDS 5 
 
SEDS 9 
At 28.3 L min
-1
          
FPD (g) 
FPF (%) 
MMAD (µm) 
GSD 
7.79 (0.17) 
4.27 (0.09) 
4.80 (0.01) 
3.30 (0.07) 
13.00 (0.20) 
7.04 (0.04) 
4.47 (0.07) 
2.71 (0.04) 
4.55 (0.05) 
2.51 (0.03) 
5.12 (0.14) 
3.43 (0.14) 
32.43 (0.59) 
21.31 (0.31) 
4.43 (0.03) 
2.62 (0.04) 
44.84 (0.14) 
29.56 (0.30) 
3.99 (0.02) 
2.36 (0.02) 
13.31 (0.17) 
8.86 (0.07) 
4.93 (0.06) 
2.91 (0.02) 
48.65 (0.56) 
34.72 (0.35) 
4.36 (0.03) 
2.57 (0.03) 
58.37 (0.50) 
41.87 (0.10) 
3.92 (0.02) 
2.25 (0.002) 
24.12 (0.24) 
17.34 (0.33) 
4.86 (0.05) 
2.66 (0.01) 
At 60 L min
-1
  
FPD (g) 
FPF (%) 
MMAD (µm) 
GSD 
9.88 (0.02) 
4.74 (0.06) 
4.62 (0.01) 
3.13 (0.03) 
16.12 (0.31) 
7.60 (0.16) 
4.17 (0.05) 
2.67 (0.02) 
5.70 (0.05) 
2.70 (0.02) 
4.95 (0.02) 
3.29 (0.05) 
43.34 (0.96) 
23.97 (0.60) 
4.34 (0.32) 
2.55 (0.03) 
55.29 (0.42) 
30.45 (0.22) 
3.87 (0.02) 
2.29 (0.01) 
21.69 (0.26) 
11.90 (0.09) 
4.88 (0.04) 
2.75 (0.08) 
57.88 (0.64) 
37.84 (0.64) 
4.22 (0.03) 
2.51 (0.01) 
65.20 (0.24) 
42.99 (0.22) 
3.61 (0.03) 
2.11 (0.01) 
27.76 (0.25) 
18.48 (0.18) 
4.83 (0.03) 
2.59 (0.02) 
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The particle size of the inhaled drug is responsible for fine particle dispersion. Usami et 
al [113] reported that the particle size influences the extent, distribution and site of the 
inhaled drug deposition within the airways. The ACI results for theophylline blends 
demonstrate the importance of the particle size on the aerodynamic behaviour and 
deposition profile of its inhaled particles. As SEDS 5, which has the smallest particle 
size (1.89 m), provides higher FPD, FPF and lower MMAD and GSD compared with 
SEDS 9 with larger particle size (3.12 m). Therefore this study proves that the smaller 
the particles the greater the total lung deposition for all the tested formulations (Figures 
5.10, 5.11). These significance differences in FPD, FPF, MMAD and GSD between the 
three samples in each blend were presented in Table 5.17.   
Figure 5. 10. Fine particle dose (A), and fine particle fraction (B) of SEDS theophylline     
samples recovered from the Easyhaler
®
 at inhalation flows of 28.3, and 60 L min
-1
.   
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Figure 5. 11. MMAD (A), and GSD (B) of SEDS theophylline samples recovered from  
                     the Easyhaler
®
 at inhalation flows of 28.3, and 60 L min
-1
.  
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Table 5. 17. Statistical comparison for ACI results of different SEDS theophylline
 
blends recovered from Easyhaler
®
 at the same  
                    inhalation flow  
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
                         *P 0.01    **P 0.005   ***P 0.001 
 
Formulations 
Mean difference (95% confidence Interval) 
FPD (g) FPF (%) MMAD (m) GSD 
At 28.3 L min
-1
 
 
50 % blend  (50 % theophylline + 50 % lactose) 
SEDS 1 vs. SEDS 5 
SEDS 1 vs. SEDS 9 
SEDS 5 vs. SEDS 9 
-6.64 (-7.10, -6.18)
***
 
25.05 (24.59, 25.51)
***
 
31.69 (31.23, 32.15)
***
 
-3.74 (-4.19, -3.29)
***
 
17.14 (16.69, 17.59)
***
 
20.88 (20.43, 21.33)
***
 
0.41 (0.30, 0.52)
***
 
-0.53 (-0.63, -0.42)
***
 
-0.94 (-1.04, -0.83)
***
 
0.264 (0.18, 0.35)
 **
 
-0.29 (-0.37, -0.21)
**
 
-0.55 (-0.63, -0.47)
***
 
At 60 L min
-1
  
-7.71 (-8.48, -6.94)
***
 
25.88 (25.12, 26.65)
***
 
33.59 (32.83, 34.37)
***
 
 
-4.24 (-4.69, -3.79)
***
 
14.31 (13.86, 14.75)
***
 
18.55 (18.09, 18.99)
***
 
 
0.39 (0.34, 0.45
)*** 
-0.61 (-0.67, -0.56)
***
 
-1.01 (-1.06, -0.95)
***
 
 
0.35 (0.32, 0.38)
***
 
-0.16 (-0.19, -0.13)
***
 
-0.51 (-0.54, -0.48)
***
 
SEDS 1 vs. SEDS 5 
SEDS 1 vs. SEDS 9 
SEDS 5 vs. SEDS 9 
At 28.3 L min
-1
 
 
 
25 % blend (25 % theophylline + 75% lactose) 
 
SEDS 1 vs. SEDS 5 
SEDS 1 vs. SEDS 9 
SEDS
 
5 vs. SEDS 9 
-9.72 (-10.57, -8.87)
***
 
24.54 (23.69, 25.39)
***
 
34.26 (33.41, 35.11)
***
 
-7.15 (-7.89, -6.413)
 ***
 
17.38 (16.64, 18.12)
***
 
24.53 (23.79, 25.27)
***
 
0.45 (0.39, 0.50)
***
 
-0.50 (-0.56, -0.44)
***
 
-0.95 (-1.01, -0.89)
***
 
0.32 (0.29, 0.35)
***
 
-0.09 (-0.12, -0.55)
 **
 
-0.40 (-0.43, -0.37)
***
 
At 60 L min
-1
  
-7.65 (-8.54,-6.76)
***
 
30.12 (29.23, 31.015)
***
 
37.77 (36.88, 38.67)
***
 
 
-5.16 (-5.54, -4.77)
***
 
19.37 (18.99, 19.75)
***
 
24.52 (24.14, 24.91)
***
 
 
0.55 (0.38, 0.72)
**
 
-0.67 (0.83, 0.49)
***
 
1.22 (-1.38, -1.05)
***
 
 
0.41 (0.38, 0.45)
***
 
-0.07 (-0.10, -0.04)
**
 
-0.42 (-0.51, -0.45)
***
 
SEDS 1 vs. SEDS 5 
SEDS 1 vs. SEDS 9 
SEDS 5 vs. SEDS 9 
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The inhalation flows had an effect on the FPD, and FPF, as the respirable amount 
increased by increasing the flow rate. This might be due to increase in the breakdown of 
small particles into fine particles as the flow increase.  The results of MMAD and GSD 
showed that they are decreased as the flow was increased. This may be due to the 
increase in the release of their carrier particles at higher flow rates [271]. For a patient 
achieving high inhalation flows it would be expected that lung deposition would be 
increased and theoretically more dose would be concentrated in the central zone of the 
lung and hence the FPD increases. However, the effect of inhalation flow is less 
pronounced on either the emitted dose or the respirable fraction recovered from 
Easyhaler
®
 than on other DPIs as the Turbuhaler
®
. It was reported by Koskela et al [270] 
that even a reasonably low peak inspiratory flow rate through the Easyhaler produces an 
improvement in lung function. This is considered as an advantage of the Easyhaler
®
 
especially for asthmatic patients, children, and elderly patients have problems achieving 
high inhalation flows as 60 L min
-1
. The significance differences between FPD, FPF, 
MMAD, and GSD under different inhalation flows for all the studied samples for each 
blend rate were reported in Table 5.18.  
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          Table 5. 18.  Statistical comparison for the ACI results of SEDS theophylline blends recovered from the Easyhaler
®
 at inhalation flows of  
                               60 L min
-1
and 28.3 L min
-1
                                    
 
             
 
 
 
 
 
 
                * P 0.05    **P 0.01   ***P  0.001 
 
Formulations 
Mean difference (95% confidence Interval) 
FPD (g) FPF (%) MMAD (m) GSD 
50% blend  
SEDS 1 
SEDS 5 
SEDS 9 
9.40 (8.92, 9.89)*** 
10.43 (9.47, 11.40)*** 
8.57 (7.65, 9.49)** 
0.75 (0.29, 1.22)* 
0.89 (0.05, 1.74)* 
3.13 (2.85, 3.59)** 
-0.14 (-0.21, 0.06)* 
-0.11 (-0.18, -0.05)* 
-0.11 (-0.22, -0.003)* 
-0.05 (-0.07, -0.03)*** 
-0.19 (-0.31, -0.07)** 
-0.22 (-0.36, -0.07)* 
25% blend  
SEDS 1 
SEDS
 
5 
SEDS 9 
9.08 (7.38,10.77)*** 
6.91 (5.761, 8.06)*** 
3.66 (2.88, 4.45)** 
3.08 (2.03, 4.13)** 
1.12 (0.573, 1.66)** 
1.16 (0.33, 1.99)* 
-0.29 (-0.52, -0.08)* 
-0.32 (-0.36, -0.27)*** 
-0.11(-0.19, -0.03)* 
-0.06 (-0.12, -0.001)* 
-0.14 (-0.16, -0.13)*** 
-0.07 (-0.12, -0.02)* 
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From the obtained results it was noticed that, most of the pure theophylline formulation 
dose was retained in the throat and preseparator. Inhalable formulation showing 
significantly less clinical effects when the amount of the drug retained in the throat and 
preseparator increased [113]. Blending of theophylline with lactose as a carrier in 
different proportions decreases its deposition in the throat and preseparator and so 
increases the amounts of theophylline held by air stream down to the ACI stages (Figure 
5.12). 
 
Figure 5.12. Mean amount of different SEDS theophylline formulations deposited in 
throat and preseparator at inhalation flows of 28.3L min
-1
(A) and 60 L min
-1
(B) 
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The carrier aids the flow and dispersion properties of pure SEDS theophylline powder, 
which is somewhat cohesive due to its small particle size. Therefore, this can potentially 
improve the deaggregation of the particles into fine particles and so the respirable 
fraction [272]. The particle size of the carrier has an important effect on the drug 
delivery from the DPI. Studies using different grades of lactose for inhalation have 
shown that the fine lactose particles added to inhalation formulations produced a more 
efficient delivery of the drug than the other grades of lactose [230]. Therefore fine 
inhalable lactose (Raspitose
®
 SV003) was used in this study. Consequentially, FPD and 
FPF for the 25 % blend are higher than the 50 % blend, which in turn shows better 
aerodynamic performance than the pure formulation. The FPD and FPF of theophylline 
blends are about 3 times higher than those of pure formulations (Figures 5.13). When 
statically tested, there was significant difference (p 0.001) in the FPD and FPF 
between the tested formulations (Tables 5.19, 5.20). It was also observed that the 
MMAD and GSD for theophylline blends were smaller than those of pure formulations 
(Figure 5.14). When the mean difference (95% confidence interval) between pairs of 
formulations was compared, significant differences in MMAD and GSD were noticed 
(Tables 5.19, 5.20). The 25 % blend showed not only the lowest MMAD (3.61-4.86) 
m but also a more uniform particle size distribution with the smallest GSD (2.11-2.66) 
compared with 50 % blend or pure formulation.  
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Figure 5.13. Fine particle dose (A) and fine particle fraction (B) of different SEDS 
theophylline formulations recovered from the Easyhaler
®
 at inhalation 
flows of 28.3 and 60 L min
-1
.   
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Figure 5.14. MMAD (A) and GSD (B) of different SEDS theophylline formulations 
recovered from the Easyhaler
®
 at inhalation flows of 28.3 and 60 L min
-1
 
 
 
 
 
 
 
  
 
 
Chapter 5                                                                                                                                                            in-vitro evaluation of inhaled theophylline 
 200 
 
            Table 5. 19. Statistical comparison for the ACI results of different SEDS theophylline formulations recovered from the Easyhaler
®
 at inhalation 
                              flow of 28.3 L min
-1
 
        *P 0.01    **P 0.005   ***P  0.001 
 
Formulations 
Mean difference (95% confidence Interval) 
FPD (g) FPF (%) MMAD (m) GSD 
SEDS 1  
pure vs. 25% blend 
pure vs. 50% blend 
25% blend vs. 50% blend 
-40.87 (-41.44, -40.29)*** 
-30.38 (-30.95,-29.81)*** 
10.48 (9.91, 11.05)*** 
-30.45 (-30.99, -29.91)*** 
-21.33 (-21.88, -20.79)*** 
9.123 (8.578, 9.67)*** 
0.45 (0.38, 0.53)*** 
0.37 (-0.29, -0.44)*** 
-0.09 (-0.16, -0.01)* 
0.75 (0.65, 0.85)*** 
0.65 (-0.55, -0.75)*** 
-0.10 (-0.20, -0.001)* 
SEDS 5  
pure vs. 25% blend 
pure vs. 50% blend 
25% blend vs. 50% blend 
-45.37 (-4621, -44.52)*** 
-31.81 (-32.66, -30.97)*** 
13.55 (12.71, 14.39)*** 
-34.83 (-35.25, -34.41)*** 
-22.52 (-22.94, -22.10)*** 
12.31 (11.89, 12.73)*** 
0.61 (0.50, 0.73)*** 
0.47  (0.35, 0.58)*** 
-0.15(-0.26, -0.04)* 
0.44 (0.35, 0.54)*** 
0.33 (0.24, 0.426)** 
-0.11 (-0.20, -0.014)* 
SEDS 9  
pure vs. 25% blend 
pure vs. 50% blend 
25% blend vs. 50% blend 
-19.56 (-19.92, -19.19)*** 
-8.57 (-8.93, -8.21)*** 
10.99 (10.63, 11.35)*** 
-14.83 (-15.28, -14.38)*** 
-6.17 (-6.62, -5.73)*** 
8.66 (8.21, 9.11)*** 
0.17 (0.032, 0.31)* 
0.31 (0.172, 0.45)** 
-0.14 (-0.28, -0.003)* 
0.78 (0.61, 0.94)*** 
0.52 (0.35, 0.68)** 
-0.26 (-0.42, -0.09)* 
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           Table 5. 20. Statistical comparison for the ACI results of different SEDS theophylline formulations recovered from the Easyhaler
®
 at inhalation 
                                flow of 60 L min
-1
  
             *P 0.01    **P 0.005   ***P  0.001 
 
Formulations 
Mean difference (95% confidence Interval) 
FPD (g) FPF (%) MMAD (m) GSD 
SEDS 1  
pure vs. 25% blend 
pure vs. 50% blend 
25% blend vs. 50% blend 
-48.00 (-48.84, -47.16)*** 
-37.69 (-38.53, -36.86)*** 
10.31 (9.47, 11.15)*** 
-33.19 (-33.76, -32.62)*** 
-21.55 (-22.12, -20.98)*** 
11.64 (11.07, 12.21)*** 
0.54 (0.41, 0.67)*** 
0.37 (-0.24, -0.49)** 
-0.17 (-0.29, -0.05)* 
0.61 (0.55, 0.67)*** 
0.40 (0.44, 0.55)*** 
-0.12 (-0.18, -0.06)** 
SEDS 5  
pure vs. 25% blend 
pure vs. 50% blend 
25% blend vs. 50% blend 
-49.08 (-49.95,-48.21)*** 
-39.17 (-40.04, -38.30)*** 
9.910 (9.044, 10.78)*** 
-35.39 (-35.88, -34.92)*** 
-22.85 (-23.33, -22.36)*** 
12.55 (12.07, 13.03)*** 
0.56 (0.49, 0.82)*** 
0.29  (0.23, 0.36)*** 
-0.26 (-0.32, -0.20)*** 
0.56 (0.54, 0.59)*** 
0.38 (0.36, 0.40)*** 
-0.18 (-0.20, -0.16)*** 
SEDS 9  
pure vs. 25% blend 
pure vs. 50% blend 
25% blend vs. 50% blend 
-22.05 (-22.62, -21.98)*** 
-15.98 (-16.56, -15.41)*** 
6.07 (5.49, 6.64)*** 
-15.78 (-16.09, -15.46)*** 
-9.20 (-9.52, -8.89)*** 
6.57 (6.26, 6.89)*** 
0.14 (0.0.08, 0.19)** 
0.07 (0.01, 0.12)** 
-0.73 (-0.13, -0.02)* 
0.71 (0.56, 0.85)*** 
0.54 (0.39, 0.69)*** 
-0.17 (-0.31, -0.02)* 
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Finally it can be concluded that the 25 % blends for all the studied samples were the 
best formulation regarding the FPD, FPF as well as the MMAD and GSD. Therefore the 
next step was to investigate the aerodynamic behaviour of 25% blend upon using single 
dose DPI as Spinhaler
®
 at two different inhalation flows 28.3, and 60 L min
-1
. 
 
5.3.3. Spinhaler
® 
5.3.3.1. Determination of the emitted dose of SEDS theophylline formulations 
                 from Spinhaler
®
 at different inhalation flows 
Table 5.21 shows the mean (n =10), SD, and RSD of the emitted dose of 25 % blend of 
SEDS theophylline recovered from Spinhaler
®
 using two different inhalation flows; 
28.3, and 60 L min
-1
.  
 Table 5. 21. The emitted dose of 25% blend of SEDS theophylline recovered from the 
Spinhaler
®
at different inhalation flows 
 
 
 
 
 
 
 
 
 
 
 
Results presented in Table 5.21 showed that the emitted dose from the three samples 
were quite similar. The total emitted dose increased by increasing the inhalation flow 
from 28.3 to 60 L min
-1
 (Figure 5.15). 
 
Dose 
No. 
Emitted dose (mg) 
SEDS
 
1 
 
SEDS 5 SEDS 9 
 
28.3 
 L min
-1
  
 
60  
L min
-1
 
 
28.3 
 L min
-1
 
 
60  
L min
-1
   
 
28.3  
L min
-1
 
 
60  
L min
-1
 
1 0.99 1.48 0.94 1.36 0.99 1.37 
2 0.97 1.27 0.98 1.45 0.97 1.44 
3 0.96 1.34 0.99 1.40 1.09 1.26 
4 1.10 1.30 1.04 1.40 1.12 1.35 
5 0.97 1.29 1.06 1.34 0.94 1.39 
6 0.94 1.29 1.11 1.32 1.00 1.32 
7 1.05 1.33 0.99 1.29 0.99 1.44 
8 1.10 1.35 0.98 1.34 0.96 1.43 
9 0.96 1.32 1.00 1.23 0.98 1.35 
10 1.00 1.43 0.99 1.39 0.91 1.39 
Mean 1.00 1.34 1.01 1.35 1.00 1.37 
SD 0.06 0.07 0.05 0.06 0.06 0.06 
RSD 5.98 5.22 4.75 4.67 6.43 4.38 
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Figure 5. 15. Total emitted dose of 25% blend of SEDS
 
theophylline recovered from 
Spinhaler
®
 at inhalation flows of 28.3 and 60 L min
-1
 (Processing 
parameters of samples 1, 5, 9 were described in Table 4.2.) 
 
 
Boer et al [273] reported that the capsule discharge rate depends on the flow properties 
of the drug and the rotation speed of the capsule. Therefore, the emitted dose from 
Spinhaler
®
 depends on the inspiratory flow rate. Although the total emitted dose is flow 
dependant, the Spinhaler
®
 as a low resistance device the inspiratory flows  60 L min-1 
are typically achieved by more than 90 % of asthmatic patients [274]. The difference in 
the total emitted dose at different inhalation flows was statistically significant (p 0.001) 
(Table 5.22).  
Table 5. 22. Statistical comparison for the emitted dose of 25% blend of SEDS samples 
recovered from Spinhaler
®
 at inhalation flows of 60 L min
-1
 and 28.3 L min
-1
  
 
Samples 
Mean difference (95% confidence Interval) 
Emitted dose from Spinhaler
®
 (mg) 
 
SEDS1 
SEDS 5 
SEDS 9 
0.34 (0.28, 0.40)*** 
0.34 (0.28, 0.41) *** 
0.38 (0.30, 0.46)*** 
         ***P  0.001 
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5.3.3.2. In-vitro aerodynamic particle size distribution of 25% blend of SEDS
    
                       
theophylline delivered from Spinhaler
® 
at different inhalation flows  
Tables 5.23, 5.24 and Figures 5.16, 5.17 show the particle size distribution 25% blend 
of SEDS theophylline
 
from Spinhaler
®
 at two different inhalation flows, after actuation 
of one puff into the ACI for each sample.  
Table 5. 23. Particle size distribution of 25% blend of SEDS theophylline recovered 
from Spinhaler
®
 at 28.3 L min
-1
  
Stages Stage ECD 
(m) 
Amount in (mg)  SD  10-1 (n =3) 
SEDS1 SEDS 5 SEDS 9 
Throat  0.40 (0.61) 0.29 (0.15) 0.64 (0.21) 
Preseparator  0.39 (0.21) 0.43 (0.22) 0.21 (0.25) 
Stage 0 9 0.04 (0.03) 0.03 (0.02) 0.04 (0.03) 
Stage 1 5.8 0.03 (0.62) 0.05 (0.11) 0.02 (0.01) 
Stage 2 4.7 0.02 (0.24) 0.04 (0.01) 0.01 (0.33) 
Stage 3 3.3 0.04 (0.71) 0.05 (0.02) 0.02 (0.01) 
Stage 4 2.1 0.04 (0.22) 0.05 (0.03) 0.03 (0.24) 
Stage 5 1.1 0.02 (0.22) 0.06 (0.11) 0.02 (0.03) 
Stage 6 0.7 0.01 (0.01) 0.03 (0.01) 0.004 (0.15) 
Stage 7 0.43 0.002 (0.02) 0.04 (0.01) 0.001 (0.45) 
Filter 0 0.001 (0.11) 0.002 (0.12) 0.0002 (0.11) 
TED (mg)  0.992 (0.21) 1.03 (0.21) 1.00 (0.24) 
FPD (mg)  0.11 (0.42) 0.20 (0.42) 0.08 (0.01) 
FPF (%)  11.43 (3.12) 19.69 (6.60) 5.36 (2.71) 
MMAD (m)  4.22 (0.41) 3.74 (0.93) 4.73 (0.27) 
GSD  2.28 (0.41) 2.02 (0.42) 2.38 (0.45) 
Figure 5. 16. Mean amounts (mg) of 25% blend of SEDS
 
theophylline deposited in ACI 
stages at 28.3 L min
-1
 from the Spinhaler
®
(Processing parameters of 
samples 1, 5, 9 were described in Table 4.2.) 
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Table 5. 24. Particle size distribution of 25% blend of SEDS theophylline recovered 
from the Spinhaler
®
 at 60 L min
-1
  
Stages Stage ECD 
(m) 
Amount in (mg)  SD  10-1  (n =3) 
SEDS1 SEDS 5 SEDS 9 
Throat  0.46 (0.22) 0.39 (0.22) 0.72 (0.14) 
Preseparator  0.51 (0.13) 0.53 (0.53) 0.34 (0.32) 
Stage -0 9 0.06 (0.20) 0.02 (0.02) 0.06 (0.15) 
Stage -1 5.8 0.05 (0.03) 0.03 (0.11) 0.03 (0.15) 
Stage 1 4.7 0.06 (0.71) 0.06 (0.21) 0.03 (0.01) 
Stage 2 3.3 0.06 (0.55) 0.10 (0.13) 0.04 (0.23) 
Stage 3 2.1 0.07 (0.34) 0.11 (0.14) 0.05 (0.11) 
Stage 4 1.1 0.06 (0.11) 0.07 (0.25) 0.04 (0.12) 
Stage 5 0.7 0.02 (0.16) 0.01 (0.02) 0.01 (0.23) 
Stage 6 0.43 0.01 (0.03) 0.01 (0.03) 0.001 (0.01) 
Filter 0 0.001 (0.31) 0.004 (0.24) 0.0001 (0.22) 
TED (mg)  1.37 (0.11) 1.33 (0.43) 1.32 (0.11) 
FPD (mg)  0.24 (0.12) 0.32 (0.14) 0.15 (0.11) 
FPF (%)  17.68 (4.91) 23.67 (1.11) 11.45 (4.63) 
MMAD (m)  4.14 (0.33) 3.51 (0.62) 4.38 (0.83) 
GSD  2.11 (0.55) 1.67 (0.81) 2.30 (0.1)1 
 
 
 
 
Figure 5. 17. Mean amounts (mg) of 25% blend of SEDS theophylline deposited in                       
ACI stages at 60 L min
-1
from the Spinhaler
®
(Processing parameters of 
samples 1, 5, 9 were described in Table 4.2.) 
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In agreement with Easyhaler
®
, the ACI results recovered from Spinhaler
®
 showed that 
SEDS 5 produced the highest FPD and FPF at each flow rate compared with SEDS 1 
and 9. SEDS 5 also exhibited the smallest and uniform particle size powder with 
MMAD and GSD of 3.62 m and 1.85, respectively. Significant differences in FPD, 
FPF, MMAD, and GSD were found between pairs of samples when tested statistically 
(Table 5.25).    
Table 5. 25. Statistical comparison for the ACI results of 25% blend of different SEDS 
theophylline samples recovered from the Spinhaler
®
 at the same 
inhalation flow. 
 
 
 
Mean difference (95% confidence Interval) 
SEDS 1 
vs 
SEDS 5 
SEDS 1 
vs 
SEDS 9 
SEDS 5 
vs 
SEDS 9 
At 28.3 L min
-1
    
FPD (mg) 
 
-0.09 
(-0.09, -0.08)
***
 
0.04 
(0.03, 0.05)
***
 
0.13 
(0.12, 0.14)
***
 
FPF (%) -8.26 
(-8.90, -7.62)
***
 
3.76 
(3.12, 4.40)
***
 
12.02 
(11.38, 12.60)
***
 
MMAD (m) 0.47 
(0.36, 0.59)
 ***
 
-0.51 
(-0.63, -0.40)
 ***
 
-0.99 
(-1.11, -0.87)
 ***
 
GSD 
 
 
0.26 
(0.19, 0.34)
**
 
 
 
-0.09 
(-0.17, -0.02)
*
 
 
-0.36 
(0.43, 0.28)
***
 
 
At 60 L min
-1
    
FPD (mg) -0.73 
(-0.94, -0.53)
**
 
0.09 
(0.07, 0.11)
***
 
0.16 
(0.14, 0.19)
***
 
FPF (%) 
 
-5.99 
(-7.06, -4.92)
***
 
6.23 
(5.16, 7.30)
***
 
12.22 
(11.15, 13.29)
***
 
MMAD (m) 0.79 
(0.63, 0.94)
***
 
-0.24 
(-0.40, -0.08)
*
 
-1.02 
(-1.18, -0.87)
***
 
GSD 
 
 
0.44 
(0.33, 0.55)
***
 
 
-0.19 
(-0.30, -0.09)
**
 
 
-0.63 
(-0.74, -0.53)
***
 
 
           *P 0.05    **P 0.01   ***P  0.001 
Chapter 5                                                       in-vitro evaluation of inhaled theophylline 
 207 
It was also noticed that the FPF and FPD increased by increasing the flow rate from 
28.3 to 60 L min
-1
 this might be attributed to the increase the break down of the 
particles into more fine ones. But the fraction of fine particles delivered to the lower 
respiratory tract may not increase to the same extent as the amount released from the 
inhaler [274]. At higher flows the oropharyngeal deposition increased (Figure 5.18) 
resulting in a decrease in the amount of particles deposited in the regions of the lung 
appropriate to the inhaled drug effects. It was also observed that there are differences in 
MMAD and GSD obtained when using the different inhalation flows. MMAD 
decreased by about 0.1-0.3 m upon increasing the inhalation flow to 60 L min-1. These 
results are consistent with data obtained by Nichols et al [275] who found that using 
different inhalation flows produced different particle size distribution due to the use of 
different particle size cut-off at different inhalation flows. On the other hand, a decrease 
in GSD was determined at higher inhalation flows indicating the increase in the particle 
size uniformity. The differences in all these aerodynamic parameters were statistically 
analysed and presented in Table 5.26. 
Figure 5. 18. Mean amount (mg) deposited of SEDS theophylline in throat and 
preseparator from the Spinhaler
®
 at different inhalation flows. 
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Table 5. 26. Statistical comparison for the ACI results of 25% blend of SEDS 
theophylline samples recovered from the Spinhaler
® 
at inhalation flows 
of 60 L min
-1
and 28.3 L min
-1
. 
 Mean difference (95% confidence Interval) 
SEDS 1 SEDS 5 SEDS 9 
FPD (mg) 
 
0.13 
(0.11, 0.15)** 
0.11 
(0.09, 0.13)** 
0.08 
(0.06, 0.09)** 
FPF (%) 6.25 
(4.35, 8.15)** 
3.98 
(2.68, 5.28)** 
3.76 
(2.59, 4.94)** 
MMAD (m) -0.11 
(-0.20, -0.02)* 
-0.39 
(-0.77, -0.01)* 
-0.35 
(-0.59, -0.12)* 
GSD -0.22 
(-0.43, -0.01)* 
-0.33 
(-0.54, -0.12)* 
-0.08 
(-0.12, -0.04)* 
*P 0.05    **P 0.01    
 
 
It was also noticed that the single-dose capsule inhaler exhibited a higher total emitted 
dose compared with the Easyhaler
®
 (1.01 mg, 0.14 mg, respectively) at 28.3 L min
-1
 and 
(1.34 mg, 0.15 mg, respectively) at 60 L min
-1
. However, Spinhaler
®
 delivered a lower 
average FPF (percentage of the emitted dose) compared with Easyhaler
® 
at different 
inhalation flows 12.14 %, 32.21 %, respectively. MMAD and GSD recovered from 
Spinhaler
®
 were lower than those recovered by Easyhaler
®
 for 25 % blend of 
theophylline. The differences in in-vitro deposition from different DPIs at the same 
inspiratory flows are primarily the result of different inhaler designs [273] as well as the 
drug formulation. As the same formulation (25 % blend) was used, the differences in 
the aerodynamic behaviour of theophylline recovered from Spinhaler
®
 and Easyhaler
®
 
may be attributed to the design differences such as the internal resistance. Spinhaler
®
 
has much lower internal resistance than that of Easyhaler
®
; 0.05, 0.16 cm H2O
0.5
/L/min, 
respectively [274]. In addition to the powder flowability in a single unit containing 10 
mg of the formulation might be higher than that of large amounts (40 mg) of the powder 
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placed in a reservoir.  Table 5.27 illustrates the significant differences between FPD, 
FPF, MMAD and GSD recovered from Spinhaler
®
 compared with Easyhaler
®
. The 
main disadvantage of the Spinhaler
®
 is poor consistency of the emitted dose compared 
with Easyhaler
®
. Also it must be loaded before use, which is considered a difficulty 
especially for patients with an asthmatic attack or elderly patients.  
 
Table 5. 27. Statistical comparison for the ACI results of 25% blend of different SEDS 
theophylline samples recovered from Spinhaler
® 
and Easyhaler
®
 at the 
same inhalation flow  
 
Samples 
Mean difference (95% confidence Interval) 
FPD (mg) FPF (%) MMAD (m) GSD 
SEDS 1  
At 60 L min
-1
 
 
At 28.3 L min
-1
 
0.19 
(0.17, 0.20)
***
 
0.07 
(0.06, 0.07)
**
 
-20.17 
(-21.38, -18.95)
***
 
-23.29 
(-23.86,-22.73)
***
 
-0.09 
(-0.12,-0.05)
**
 
-0.15 
(-0.18,-0.12)
**
 
-0.35 
(-0.67,-0.02)
*
 
-0.29 
(-0.40,-0.18)
**
 
SEDS 5  
At 60 L min
-1
 
 
At 28.3 L min
-1
 
0.25 
(0.22, 0.28)
**
 
0.15 
(0.13, 0.16)
***
 
-19.33 
(-20.15, -18.51)
***
 
-22.18 
(-23.90, -20.47)
***
 
-0.34 
(-0.49,-0.20)
**
 
-0.21 
(-0.27,-0.16)
**
 
-0.44 
(-0.66,-0.22)
*
 
-0.23 
(-0.33,-0.14)
**
 
SEDS 9  
At 60 L min
-1
 
 
At 28.3 L min
-1
 
0.12 
(0.11, 0.14)
**
 
0.05 
(0.05, 0.06)
***
 
-7.01 
(-8.44,-5.58)
**
 
-9.67 
(-10.60,-8.74)
***
 
-0.45 
(0.30, 0.59)
**
 
-0.13 
(0.02, 0.25)
*
 
-0.29 
(-0.34,-0.24)
**
 
-0.28 
(-0.30,-0.26)
***
 
* P 0.05    **P 0.01   ***P  0.001 
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As a general conclusion, this chapter demonstrated the in-vitro aerodynamic behaviour 
of SEDS theophylline as inhaled drug using multidose reservoir and single dose DPIs. 
The results show the effect of the particle size on the drug deposition profile within the 
airways, where samples with small particle size show the highest fine particle dose. The 
results also highlighted the enhancement of in-vitro performance of inhaled 
theophylline by using inhalation grade lactose as a carrier. From the data obtained it can 
be predicted that at higher flow rate, the fine particle fraction is high and so lung 
deposition is increased. The effect of different inhalation flows on the emitted dose and 
fine particle fraction delivered from Easyhaler
®
 is lower than on those delivered from 
Spinhaler
®
. The theophylline deposition in throat and preseparator is decreased upon 
increasing the inhalation flows with Easyhaler 
®
, while reverse trend happened with 
Spinhaler
®
.   
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This thesis is considered the first study on the suitability of using theophylline as 
inhalable dry powder formulation.  The need for developing such a formulation 
originated from senior medics in hospitals who are still prescribing theophylline as a 
low cost therapeutic option for treatment of chronic asthma. However, the serious side 
effects associated with the available dosage forms hinder its use as first line for 
treatment of asthma.  
The new inhalation products of theophylline allow much reduction in its therapeutic 
dose compare to the oral dosage forms (as shown in the dose emission study in Chapter 
5) and therefore decrease the undesirable side effects associated with available dosage 
and enhance the patient‟s compliance. These new formulations show promising in-vitro 
aerodynamic behaviour, which considered as a starting point in the improvement of the 
commercial use of theophylline by asthmatic patients.  The in-vitro efficiency of 
inhalable theophylline formulations was tested using the standard compendial 
methodology for testing at different inspiration flows to provide an appreciation to the 
results obtained during normal practice. As the particle size and shape have an 
important effect on the deposition profile of the inhaled drug, these formulations were 
prepared by SCF technology (Solution Enhanced Dispersions by Supercritical fluid 
(SEDS) which considered as one of the most efficient techniques for the production of 
discrete particles. SEDS technique by the aid of its coaxial nozzle allows more 
proficient control to the particle size and other physicochemical properties of produced 
particles comparing with other reported methods [12-14].  The output from all the in-
vitro testing was analyzed by a developed fast and sensitive HPLC method using 
monolith C18 column that is considered as a new approach for reduction of the analysis 
time without loss of the resolution power. The analysis time is considered as an 
important concern in the in-vitro evaluation of the inhalation products due to the large 
numbers of samples have to be analyzed. Although there is a number of HPLC methods, 
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which report the simultaneous determination of methylxanthines and their metabolites 
in one run, these methods could not achieve both a reasonably short run time with a 
satisfied resolution as the HPLC method developed in this study.  
 
The following points summarize the objectives and the main key findings of the thesis. 
 
1- To develop a fast HPLC method for separation and quantitation of theophylline 
and its related compounds in aqueous and urine samples.  
Key findings: 
1.1. A novel, fast and efficient HPLC assay can be readily used in any laboratory for a 
quantitative determination of theophylline and its related compounds in urine 
samples in less than 15 min was developed and validated.   
1.2. The developed method provides a mean for the assessing of theophylline 
concentration in urine samples for asthmatic patients consuming methylxanthines- 
containing food without confliction between metabolites peaks. 
1.3. A simple solid phase extraction (SPE) technique using Baker octadecyl (C18) 
disposable cartridge was optimised to isolate theophylline and its related 
compounds from urine followed by HPLC analysis. The urinary analysis was 
performed in accordance with ICH guidelines for validation of bioanalytical 
samples. The studied mixture was separated on monolithic column RP-18e (100  
4.6 mm) at room temperature using UV detection at 274 nm. The optimised 
mobile phase consisted of methanol: 10 mM KH2PO4 (pH 4) (12.5: 87.5 % v/v).  
The mean extraction recoveries achieved for all the methylxanthines and their 
metabolites from the urine matrix ranged from 82.28 to 98.73 % w/w.    
1.4. The recoveries of these compounds were found to be consistent, precise and 
reproducible as their RSDs were  2.5 %.  
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1.5. The values of the correlation coefficients (R2) of the calibration curves for the 
extracted compounds from the spiked urine were  0.9991 (n = 6), which proves 
that the response of the detector showed a good linearity over the studied 
concentration range. LODs and LOQs were ranged from 0.004 - 0.014 g ml-1, 
and 0.014 - 0.041 g ml-1, respectively, indicating the good sensitivity of the 
developed analytical method.  
1.6. The inter- and intra-day precision of the developed method show RSDs  2.6 %, 
while the accuracy percentages of all compounds were ranged from 82.60 to 
98.08 %w/w. On the other hand, good precision and reproducibility were 
observed upon working on different batches of monolith column.  
1.7. The developed method was also validated to analyze theophylline in aqueous 
solution to evaluate the dose emission properties and the aerodynamic behaviour 
of its inhaled particles. The standard calibration curve for theophylline in aqueous 
samples was linear (y = 0.19x + 0.06, R
2
 = 0.9993) over the studied concentration 
range 20-200 g ml-1. LOD and LOQ of theophylline were 0.08 and 0.23 g ml-1, 
respectively.  
1.8. The developed HPLC procedure was applied for the analysis of the commercially 
available dosage forms of theophylline. Good extraction recovery of theophylline 
from the studied formulations was obtained (95.24-98.62 % w/w) with RSDs  
2 % confirms the absence of interference due to common excipients.  
1.9. The performance the monolithic column was compared with traditional and newly 
introduced (Platinum
TM
) C18 columns initially for separation of acidic and basic 
test mixtures and finally for the methylxanthines and methyluric acids mixture.  
1.10. The obtained results show that the separation efficiency of the monolith for the 
methylxanthines and methyluric acid mixture was less than the symmetry, 
Chapter 6                                                                                             General conclusion 
 215 
Hypersil or platinum columns even after extensive trials in the optimization step. 
However, for all the tested columns at least 28 min (except platinum 16.72 min) 
was required for complete separation of the compounds of interest, while only 
14.06 min was required with the monolithic column. 
1.11. Furthermore, lower backpressure (60 bar) was obtained upon working with the 
monolith which was far less than the other particulate packed columns (150-180 
bar).  
1.12. As a general conclusion the monolithic column is a useful tool of achieving 
efficient separation under lower backpressure and shorter analysis time.  
1.13. The monolith also provides rapid washing and equilibrium times while some of 
the tested packed columns take more time (about 30 min.). These advantages 
should aid in the reduction of the total time to develop a method using monolith 
compared with packed columns.  
1.14. The high permeability and total porosity in the monolithic column allows the use 
of high flow rate without a significant increase in backpressure or substantial loss 
in the resolution power. This provides time saving analysis with minimal 
resolution loss. 
1.15. Packed columns which are filled with 3-5 m particles can be easily blocked, 
especially with biological samples thereby reducing the column lifetime. On the 
other hand, with monolithic columns, there is reduced need for tedious sample 
preparation, as they are very resistant to blocking (even with biological samples). 
 
2- To produce different batches of anhydrous theophylline particles using Solution 
Enhanced dispersion by Supercritical Fluids (SEDS) process under different 
crystallization parameters.  
Key finding 
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2.1. SEDS process has been successfully applied to crystallize anhydrous theophylline.  
2.2. Fifteen theophylline samples were prepared under different crystallisation 
parameters. The SEDS process has enabled the production of small crystalline 
particles 2-5 m (needles or flakes) compared to the unprocessed sample 30-100 
m (rod-like).  
 
3- To determine the effect of different practical parameters on the physicochemical 
properties of the produced SEDS theophylline samples mainly the particle size. 
Key findings 
3.1. The particle size of SEDS theophylline is significantly influenced by different 
crystallisation parameters including; temperature, pressure and solution flow rate.  
3.2.  Increasing the temperature during the precipitation process led to a decrease in 
the particle size of the processed samples. An increase in the particle size was 
observed upon increasing the pressure as well as the solution flow rate. 
3.3. The process has also demonstrated good reproducibility for the produced particle 
size on repeated crystallisation. 
 
4- To study the solid-state chemistry of the prepared SEDS theophylline samples 
using different analytical techniques. 
Key finding 
4.1. Different analytical tools were used in this study for the determination of the 
solid-state chemistry the SEDS theophylline samples and for assessing any 
changes at different crystallisation parameters; including scanning electron 
microscope, Differential scanning calorimetry  (DSC), thermal gravimetric 
analysis (TGA), x-ray powder diffraction (XRPD), Fourier Transform Infra-Red 
(FT-IR), and Fourier Transform Raman spectroscopy (FT-Raman). 
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4.2. The TGA results show that the transition temperature for the unprocessed 
theophylline was 281.03C, higher than that of all the processed samples. This 
may be attributed to that the SEDS samples exhibiting smaller size thus lower 
temperatures are required for mass loss by melting or decomposition. 
4.3. Results obtained from the DSC analyses confirm that the processed samples have 
high degrees of crystallinity under all the studied processing parameters. 
4.4. Minor variations were observed between the XRPD patterns of the processed and 
unprocessed samples.  
4.5. The IR spectra for the processed samples illustrate all the characteristic peaks of 
the unprocessed theophylline indicating that there is no modification in the 
bonding interaction between molecules and hence the structure of theophylline 
during the SEDS
 
process over all the processing conditions. This finding was 
confirmed by the results obtained from FT-Raman analyses.   
4.6. Therefore, it could be concluded that, the structure and the crystallinity of SEDS 
theophylline products compared with unprocessed samples were not affected by 
the crystallisation process under different practical parameters. 
4.7. This study also demonstrates the potential of preparation of theophylline 
monohydrate using SEDS technique by the addition of appropriate amounts of 
water (0.5 ml) to the starting drug solution and this was traced by XRPD, TGA 
and DSC techniques.   
 
5- To evaluate the in-vitro efficiency of the different particle-sized batches of SEDS 
samples as inhaled dry powder formulation using Easyhaler
®
 and Spinhaler
®
 by 
dose sampling unit and Andersen Cascade Impactor. 
Key finding 
5.1. The in-vitro efficiency of the SEDS theophylline samples as inhaled dry powder 
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formulation was investigated using two inhalation flows of 28.3, and 60 L min
-1
.  
5.2. The dose sampling unit and the Andresen Cascade Impactor (ACI) were used for 
the determination of the in-vitro emitted dose and the deposition profiles, 
respectively of SEDS formulations.  
5.3. The total emitted dose for the three tested samples within the same formulation 
and the same inhalation flow were quite similar. However it varied significantly 
(p 0.001) in different formulations and different flows; 182.86, 151.67, 138.52 
g at 28.3 L min-1 and 211.93, 182.00, 151.50, at 60 L min-1 for the pure 
formulation, 50 %, and 25 % blends, respectively.  
5.4. The dose emission results indicate good reproducibility of the delivered 
theophylline doses, as the RSDs for all samples were lower than 5 %.   
5.5. The doses emitted at 28.3 L min-1 were found to be approximately 85 % of that 
provided at 60 L min
-1
 for all the tested formulations. Therefore, reasonably good 
theophylline dose can be achieved with patients who may have difficulties in 
generating high levels of inhalation flow such as children and the elderly. 
5.6. The ACI results recovered from Easyhaler® prove the importance of the particle 
size on the aerodynamic behaviour and deposition profile of inhaled theophylline 
particles. The sample with the smallest particle size (SEDS 5) provides better 
respirable fraction and lower mass median aerodynamic diameter (MMAD) than 
samples with lager particle size (SEDS 9).  
5.7. The fine particle dose (FPD), fine particle fraction (FPF) and the mass median 
aerodynamic diameter (MMAD) were found to be affected by the change in the 
inhalation flows.  
5.8. The results also highlight the enhancement of in-vitro performance of inhaled 
theophylline by using inhalation grade lactose as a carrier.  The results indicted 
that statistically (p0.001) the theophylline blends produce better respirable 
Chapter 6                                                                                             General conclusion 
 219 
fractions (about 3 times higher) than pure formulations. 
5.9.  The 25 % blend (25 % theophylline and 75 % inhalable lactose) showed not only 
the highest FPD (24.12-65.20 g), and FPF (17.34-42.99 %) but also the smallest 
MMAD (3.61-4.86 m) compared with 50 % blend or pure formulation.  
5.10. The performance of the 25 % blend was also tested using the Spinhaler® as 
another type of dry powder inhalers (single dose device). 
5.11.  The total emitted dose recovered from the Spinhaler® for the three samples were 
quite similar 1.01, 1.34 mg at 28.3 and 60 L min
-1
 and it seemed to be flow 
dependant.  
5.12. In agreement with the results recovered from the Easyhaler®, SEDS 5 (with the 
smallest particle size) produced the highest FPD and FPF at each flow rate 
compared with other tested samples. SEDS 5 also exhibited the smallest and the 
most uniform particle size powder with MMAD and GSD of 3.62 m and 1.85, 
respectively.  
5.13. The total emitted dose and the respirable fraction recovered from the Spinhaler® is 
more affected by changes in the inhalation flows than the Easyhaler
®
.  
5.14. It was also noticed that the Spinhaler® exhibited a higher total emitted dose 
compared with the Easyhaler
®
 (1.01 mg, 0.14 mg, respectively) at 28.3 L min
-1
 
and (1.34 mg, 0.15 mg, respectively) at 60 L min
-1
. However it delivered a lower 
average FPF; 12.14 %, 32.21 %, respectively (percentage of the emitted dose), 
compared with the Easyhaler
® 
at the same inhalation flows. Furthermore, the 
Spinhaler provides lower MMAD and GSD than those recovered by the 
Easyhaler
®.
 
5.15. The theophylline deposition in throat and preseparator is decreased upon 
increasing the inhalation flows with the Easyhaler
®
, while reverse trend happened 
with the Spinhaler
®
.   
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5.16.  These differences in the in-vitro deposition of the 25 % blend in different DPIs at 
the same inspiratory flows using the same formulation are primarily the result of 
different inhaler designs. 
5.17. Generally, this study gave an overview for the in-vitro behaviour of theophylline 
prepared by SEDS process as a newly developed inhaled dry powder formulation 
by the aid of different pharmaceutical analytical tools. 
 
6.1. Future work 
This study has shown the in-vitro dose emission and lung deposition of SEDS 
theophylline at different inhalation flows using two types of dry powder inhaler; 
multidose reservoir and single dose devices. The obtained results show good 
aerodynamic performance of the new inhaled formulations. Therefore it will be useful 
to extend this work to determine the in-vivo performance of inhaled SEDS theophylline 
using the urinary excretion to determine the relative amounts of the drug delivered to 
the lungs following an inhalation.  The collected urine samples could be analyzed using 
the developed fast HPLC method for separation and quantitation of theophylline and its 
related compounds. The in-vitro studies were performed on small scale however the in-
vivo studies needs the preparation of larger amounts of theophylline under GMP 
conditions to assure the reproducibility.  
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